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The targeting of subcellular organelles offers an enhanced therapeutic effect for 
both small molecules and biologics. The main theme of this research is to use subcellular 
targeting to elicit or enhance a therapeutic effect, which leads to the hypothesis that 
targeting specific organelles in a cell will lead to better drug delivery and improvements 
in disease therapy. In this study, we focused on targeting the mitochondria, nucleus, and 
proteasome. A small molecule, vitamin E, was targeted to the mitochondria by 
conjugating it with a triphenylphosphonium cation (forming MitoE) taking advantage of 
the mitochondrial transmembrane potential. MitoE was concentrated in the myocardial 
mitochondrial of treated mice. It also reduced oxidative stress in hyperglycemic 
endothelial cells. In addition, the adiponectin protein was used to reduce the oxidative 
stress in the mitochondria via cAMP/PKA pathway. A new formulation containing 
adiponectin was developed using a biodegradable triblock copolymer, which forms a 
hydrogel at body temperature. The goal was to maintain a controlled release of 
adiponectin from the hydrogel while preserving its antioxidant activity.  
The mitochondria were also targeted to deliver the tumor suppressor p53 to 
induce apoptosis in breast cancer cells via binding to Bcl-XL. p53 was targeted to the 
outer surface of the mitochondria via fusing to the mitochondrial signal (MTS) from Bcl-
XL (XL). It was also inserted into the outer membrane, inner membrane, and matrix by 
fusing the MTSs from TOM20 (TOM), cytochrome c oxidase (CCO), and ornithine 
	   iv	  
transcarbamylase (OTC), respectively. The p53-XL construct was the most promising in 
inducing apoptosis through the p53/Bcl-XL pathway.  
In addition to the mitochondria, proteasomal targeting was explored taking 
advantage of the p53/MDM2 degradation pathway. The designed construct contained a 
nuclear export signal (NES), a nuclear localization signal (NLS), a ligand binding domain 
(LBD), and p53. The construct targeted the cytoplasm in the absence of ligand and 
translocated to the proteasome upon ligand induction. This proteasomal protein switch 
offers novel treatment therapies for diseases caused by cytoplasmic oncogenic/aberrant 
proteins.  
In summary, this dissertation offers a better understanding on subcellular delivery. 
The focus on targeting subcellular organelles takes therapeutic delivery to the next level, 
and may lead to improvements in disease therapy. 
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BACKGROUND AND SIGNIFICANCE 
 
Summary 
Subcellular targeting has been a challenge for delivering therapeutics whether 
they are small molecules or biologics. Drugs and proteins have different effects 
depending on their subcellular localization. For instance, Bcr-Abl acts as an oncogenic 
protein in chronic myelogenous leukemia (CML) when in the cytoplasm while it induces 
apoptosis when delivered to the nucleus (1).  Incorrect localization of proteins destined 
for different organelles can lead to disease (2). The main theme of this research is to use 
subcellular targeting to elicit or enhance a therapeutic effect, which leads to the 
hypothesis that targeting specific organelles in a cell will lead to better drug delivery and 
improvements in disease therapy. 
 This introductory chapter will provide an overview of the thesis in brief followed 
by Chapter 2, a review on therapeutic delivery of drugs to subcellular compartments 
(mitochondria, nucleus, proteasome, endoplasmic reticulum, peroxisome, Golgi apparatus, 
and nucleolus). Targeting a specific organelle can be achieved by chemical or biological 
means. The next level of therapeutic delivery will include specific targeting to organelles 
by imitating nature with an efficiency required to mitigate specific pathologies. Some of 
the methods reviewed to target specific organelles were further investigated by delivering 
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therapeutics to the subcellular compartments. Two disease targets are investigated: 
cardiovascular disease and breast cancer (Figure 1.1). The next four chapters discuss 
delivery of a drug agent to a particular subcellular compartment for disease treatment 
(Figure 1.2). Chapter 3 focuses on delivery of a therapeutic protein (adiponectin) to 
reduce reactive oxygen species (ROS) in the mitochondria for treatment of diabetes; 
Chapter 4 focuses on the delivery of a small molecule antioxidant to the mitochondria for 
treatment of cardiovascular disease; Chapter 5 describes delivery of p53 to the 
mitochondria for cancer therapy, and Chapter 6 discusses nuclear/proteasomal targeting 
of p53 directly and with a protein switch developed in our laboratory (3, 4).  Finally, 
Chapter 7 provides conclusions and future directions. 
The introduction chapter follows the organization in the chart in Figure 1.1. Part 
A discusses the reduction of the oxidative stress in cardiovascular disease including an 
introduction to (A1) oxidative stress in the hearts of diabetic patients, (A2) adiponectin, 
(A3) antioxidants, (A4) diabetic mitochondria, and (A5) biodegradable polymers for drug 
delivery. Part B discusses inducing apoptosis in breast cancer including a background on 
(B1) p53 protein, (B2) mitochondria in cancer cells, (B3) nuclear targeting, (B4) 
proteasomal targeting, and (B5) gene therapy. 
 
Background 
Reducing Oxidative Stress in Cardiovascular Models 
Cardiovascular diseases encompassing disorders of the heart and blood vessels 











Figure 1.2. A cell overview of the subcellular targets of the different therapeutics in this 
thesis. Chapter 2 covers the various approaches in targeting the different organelles. 
Chapter 3 focuses on the delivery of adiponectin protein through its receptors (AdR1 and 
AdR2) to reduce ROS in the mitochondria via a cAMP-dependent protein kinase (PKA) 
pathway. Chapter 4 discusses the delivery of small molecules such as vitamin E (R) to the 
mitochondria to reduce the oxidative stress by conjugation to a cation 
(triphenylphosphonium). Chapter 5 investigates the gene therapy of p53 fused to 
mitochondrial targeting signals (MTS) for cancer therapy. Chapter 6 examines the 
proteasomal targeting of p53 protein switch upon ligand addition.  
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heart disease, hypertension, cerebrovascular disease, heart failure, peripheral vascular 
disease, congenital heart disease, and rheumatic heart disease (5). Subcellular targeting is 
crucial in reducing oxidative stress in diabetic patients, who have a high risk for 
atherosclerosis and congestive heart failure (6). Increases in fatty acid flux augment the 
formation of reactive oxidative species (ROS) in the mitochondria causing a reduction in 
adenosine triphosphate (ATP) synthesis by activating uncoupling proteins (7). Uncoupled 
mitochondria contribute to lowering myocardial energy, which causes myocardial 
dysfunction (8). The vascular function is ROS modulated either by direct oxidative 
damage or by activating cellular signaling pathways (9). ROS can also modulate vascular 
function through endothelial dysfunction, decreased nitric oxide (NO) bioavailability, 
impaired contractility, and platelet aggregation (10-13). In addition, oxidative stress 
diminishes insulin signaling through cellular serine/threonine pathways (14). More 
specifically, the insulin receptor substrate-1 gets phosphorylated under oxidative stress, 
which could be improved by antioxidant agents (14-16). Moreover, some ROS serve as 
important signaling molecules that regulate several physiological mechanisms, such as 
vascular tone, growth, and remodeling (10). In the cell, there is a delicate balance 
between ROS production and destruction (17). 
Decreasing the oxidative stress in the mitochondria has been a therapeutic target 
to increase myocardial activity. Antioxidants have been used to decrease ROS levels in 
cells (18, 19). However, an additional approach to relieving oxidative stress within 
mitochondria is to augment subcellular concentrations of antioxidants by selectively 
targeting them to the mitochondria (20-22). In addition to antioxidants, proteins such as 
 6 
adiponectin, which is an anti-diabetic protein, have an impact on reducing oxidative 
stress (23).  
Indeed, antioxidants and adiponectin could be used therapeutically to reduce 
oxidative stress in the hearts of diabetic patients. To avoid using high doses of such 
therapeutic agents, sustained delivery of the substances locally to the heart can be 
achieved by directly injecting the myocardium with biodegradable triblock copolymer 
containing the drug. The sustained delivery could also be achieved when the polymer 
formulation is delivered subcutaneously (24-26). The biodegradable triblock copolymer 
allows the delivery of insoluble, unstable or expensive substances at high local 
concentrations. This is the topic of Chapter 3 of this thesis. In addition, antioxidants 
could be conjugated to cations to increase their mitochondrial targeting, where ROS is 
being produced and metabolized (Chapter 4). 
 
Oxidative Stress in the Hearts of Diabetic Patients 
Diabetic patients have a higher risk of dying of a heart attack or a stroke than non-
diabetic patients. There is an increase in fatty acid flux in patients with diabetes, which 
increases the delivery of reducing equivalents to the respiratory chain. In mitochondria, 
the electron transport chain passes electrons from the reducing equivalents (flavin 
adenine dinucleotide, FADH2, and nicotinamide adenine dinucleotide, NADH) to oxygen 
(Figure 1.3). This results in the pumping of protons from the matrix to intermembrane 
space via NADH dehydrogenase, cytochrome c reductase, and cytochrome c oxidase. As 
a result, an electrochemical gradient is established, which activates ATP synthase to 
pump protons back to the matrix and activates ADP to ATP. In the mitochondrial 
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Figure 1.3. Electron transfer chain in mitochondria affected by increase in ROS due to 
hyperglycemia. Hyperglycemia increases the delivery of reducing equivalents to the 
respiratory chain. In mitochondria, the electron transport chain passes electrons from the 
reducing equivalents (FADH2 and NADH) to oxygen. The protons are then pumped from 
the matrix to intermembrane space via NADH dehydrogenase (NADH DH), cytochrome 
c reductase (Cyt c R), and cytochrome c oxidase (Cyt c O). The resulting electrochemical 
gradient activates ATP synthase (ATP S) to pump protons back to the matrix and forms 
ATP. This process also forms superoxide radicals, which activate the proton leak 
uncoupling protein (PLC). PLC pumps protons back into the matrix without forming 
ATP. 
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respiratory chain, oxygen is partially reduced to form superoxide radicals. ROS activate 
the proton leak uncoupling proteins, which pump protons back into the matrix without 
forming ATP (Figure 1.3). ROS are also generated via TCA cycle enzymes (27), NADPH 
oxidase (28), xanthine dehydrogenase/oxidase (29), mitochondrial monoamine oxidase 
(29), superoxide dismutase (30), peroxisomal acyl-CoA oxidases (31), and 
myeloperoxidases (32). ROS are also formed from endogenous enzymatic and non-
enzymatic reactions or from external stimuli (UV and high-energy irradiation) and 
chemicals (air pollutants) (29). Superoxides are also converted to other ROS such as 
hydroxyl radicals, which can cause damage to cells and tissues. The cell produces a range 
of superoxides such as hydrogen peroxide (H2O2), hydroxyl radical (OH.), hypochlorous 
acid (HOCl), superoxide anion radical (O2.-), and singlet oxygen (1O2) (29).  
Increase in ROS production is associated with diabetes, hypercholesterolemia, 
aging, hypertension, and mechanical injury (10). There are different mechanistic 
pathways to increase ROS production. NADPH oxidase enzymes (Nox enzymes) are a 
major source of ROS in endothelial cells. The activation of Nox involves activation of the 
tyrosine kinase c-Src (33). Nox enzymes also activate xanthine oxidase (XO), which uses 
oxygen as an electron acceptor from NAD+ to form oxygen radicals and hydrogen 
peroxide (34, 35). Another mechanism of ROS generation is uncoupled endothelial nitric 
oxide synthase (eNOS). eNOS usually reduces nitrite anion (NO2-) to nitric oxide (NO), 
which acts as a protective compound to the heart and obstructs the mitochondrial electron 
transfer (36, 37). However, the uncoupling of eNOS or in the absence of L-arginine, 
eNOS stops transferring electrons to L-arginine and starts transferring electrons to 
oxygen molecules forming oxygen radicals (38, 39). Nitric oxide is also produced via the 
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activation of the fuel sensor, AMP-activated protein kinase (AMPK), which is 
responsible for the ameliorative effect on mitochondrial function and biogenesis (40, 41). 
This work provides a possible solution to reduce myocardial oxidative stress by exploring 




In human subjects, studies have shown the influence of adipose tissue on obesity, 
insulin resistance, and cardiovascular disease. Adipose tissue functions as an endocrine 
organ by secreting leptin, tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-10, 
plasminogen activator inhibitor type 1, retinol binding protein-4, and adiponectin (44, 45). 
All secreted proteins are directly involved in disorders linked to diabetes. It has been 
shown that adiponectin levels are reduced in patients with obesity and cardiovascular 
disease (46, 47). Clinical studies have linked low adiponectin concentration to insulin 
resistance (48-51), hypertension (52), dyslipidemia (53), and coronary artery disease (54-
57).   
Adiponectin is present in the plasma, ranging between 3 to 30 µg/ml (46, 58). 
There is a negative correlation between adiponectin levels and body mass index, which 
means its secretion is decreased with accumulated fat (46). Adiponectin expression is 
induced by the nuclear receptor, PPARγ (peroxisome proliferator-activated receptor 
gamma), which binds to the PPARγ response element in the promoter region of the 
adiponectin gene (59). Interestingly γ- and α-tocopherol enhance the expression of 
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PPARγ (60-63). Treatment with α-tocopherol shows elevated levels of adiponectin 
(protein and mRNA) in both adipose tissue and circulation (64, 65). 
Adiponectin receptors (AdipoR1 and AdipoR2) are found in liver and muscle 
tissue, respectively (66). Adiponectin increases fatty acid oxidation in skeletal muscle 
and reduces glucose production in the liver (67). Adiponectin improves hyperglycemia 
when bound to its receptors (68). This binding increases the intracellular calcium levels, 
which activates the protein kinases necessary for the processing of glucose (69). 
Eventually, this process enhances skeletal muscle glucose uptake. 
Adiponectin exists in trimer, hexamer, and high-molecular weight (HMW) forms 
(70, 71). The protein contains a collagen-repeat domain at the amino terminus and a 
globular domain at the carboxy terminus. Because it is thought that the globular domain 
(gAdp) is the active form of adiponectin, gAdp has been more widely used than the full-
length form (fAdp). Adiponectin plays an important role in angiogenesis (72, 73), 
endothelial function (74), glucose regulation (75, 76), and fatty acid catabolism (75, 77). 
The protein improves insulin control (78), blood glucose (79), and triglyceride levels (80). 
It has been reported that adiponectin increases nitric oxide production through AMP-
activated protein kinase (AMPK) and phosphorylation of eNOS (81, 82). Adiponectin 
also blocks the generation of ROS (38), which could be one of the major factors why 
patients with obesity and diabetes, who have low concentrations of adiponectin, develop 
ROS overproduction. Chapter 3 will further explore the activity and delivery of 





The production of oxidative stress and reduced antioxidant reserve are related to 
congestive heart failure (83). Cellular ROS is countered by endogenous antioxidants such 
as vitamin C, vitamin E, superoxide dismutase (SOD), and glutathione peroxidase (84). 
Halliwell (85) defines an antioxidant as “any substance that, when present at low 
concentrations compared to those of an oxidizable substrate, significantly delays or 
prevents oxidation of that substrate.” The cell contains oxidizable substrates such as 
proteins, lipids, carbohydrates, and DNA. Antioxidants either detoxify the free radicals 
by scavenging them or prevent their formation by eradicating their precursors (29). 
Antioxidants could be divided into different categories: vitamins (e.g., α-tocopherol, 
ascorbic acid, β-carotene), inorganic compounds (e.g., selenium), synthetic compounds 
(e.g., butylated hydroxyanisole), and plant derived polyphenols (29). 
Superoxide dismutase (SOD) is an example of a naturally occurring antioxidant 
that scavenges ROS and converts them to less reactive species. Mn (III) tetrakis (4-
benzoic acid) porphyrin chloride (MnTBAP) is a cell permeable catalytic SOD mimetic 
and peroxynitrite scavenger. MnTBAP has been shown to reduce mitochondrial ROS in 
vitro (86, 87). It was also reported that MnTBAP reduces mitochondrial ROS 
overproduction and improves markers of oxidative injury in the liver of obese (ob/ob) 
mice (88). On the other hand, vitamin C, a water-soluble antioxidant, scavenges ROS and 
free radicals and protects low-density lipoprotein against oxidation, reduces oxidized 
glutathione, and functions as a co-antioxidant to vitamin E (89, 90). Vitamin C also 
enhances nitric oxide production and endothelial cell proliferation (91, 92). Some studies 
have shown that adequate intake of vitamin C can lower the risk of heart disease (93, 94).  
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Another naturally occurring antioxidant, further discussed in Chapter 4, is vitamin 
E, a fat-soluble antioxidant with eight naturally occurring vitamer forms. The most 
common forms are the γ- and α-tocopherols. The latter has also shown activity in 
expressing certain genes involved in cell cycle regulation, inflammation, cell signaling, 
and lipid uptake (95). Vitamin E has a positive effect on insulin sensitivity and the 
prevention of type-2 diabetes (96-98) due to its antioxidant capacity (99, 100). Alpha-
tocopherol is a chain-breaking antioxidant, where it interrupts the formation of lipid-
derived oxygen- and carbon-centered free radicals (29). These radicals are formed via a 
chain reaction: initiation, propagation, and termination. Alpha-tocopherol has also shown 
activity in expressing certain genes involved in cell cycle regulation, inflammation, cell 
signaling, and lipid uptake (95). 
It has been reported that naturally occurring antioxidants such as vitamin C and 
vitamin E are reduced in diabetics (101, 102). However, supplementing these vitamins in 
diabetic populations has been ineffective or inconclusive. In general, clinical trials with 
antioxidants have failed to show any significant clinical benefit. There is a possibility that 
this failure is due to the lack of antioxidant accumulation in the mitochondria, the proper 
target for scavenging ROS (29). Meanwhile, administering high doses of antioxidants 
such as vitamin E may be harmful or act as pro-oxidant (103). Chapter 4 will provide an 
alternative pathway to reduce ROS by antioxidant targeting of the mitochondria. Using 
modified antioxidants to specifically target the mitochondria should allow use of smaller 





The mitochondria play roles in cellular energy metabolism, apoptosis, Ca2+ 
homeostasis, and cell signaling (104-107). Because of these roles, the mitochondria have 
been under investigation for therapeutic targeting (19-21, 108). Mitochondrial 
dysfunction plays a central role in the development and progression of tumors (109-111). 
In addition to its production of ATP, the mitochondria have several functions that are 
tissue specific (112). Myocardial mitochondria are involved in the generation of energy, 
the regulation of apoptosis, and the generation and detoxification of ROS. Mitochondrial 
dysfunction initiates apoptosis and necrosis resulting in organ failure. Disrupting the 
mitochondrial Ca2+, ATP, or ROS metabolism plays a role in different diseases such as 
diabetes, obesity, heart failure, stroke, aging, cancer, and neurodegenerative diseases 
(113).  The mitochondria utilize 90% of consumed oxygen for ATP synthesis and 
oxidative phosphorylation. This process in the electron transfer chain is responsible for 
ROS production (Figure 1.3). The cell has its own antioxidant defenses such as 
glutathione, catalase, and superoxide dismutase to prevent oxidative stress (114-118). 
Maintaining this ROS/antioxidant ratio is imperative for cell signaling (29). Any 
imbalance between ROS generation and destruction is associated with chronic disease 
(119). Since the mitochondria produces and metabolizes ROS, targeting antioxidants to 
the mitochondria has been a focus of interest (120). This is achieved by conjugating an 
antioxidant to a lipophilic cation. The positive charge enables mitochondrial 
accumulation 100-1000 times higher due to the high inner mitochondrial membrane 





Figure 1.4. Increased mitochondrial targeting of small molecules. The delivery of small 
molecules such as vitamin E (R) to the mitochondria to reduce the oxidative stress by 
conjugation to a cation (triphenylphosphonium). This conjugation increases the 
mitochondrial targeting by 100-500 fold due to the -150 to -180 mV mitochondrial 
transmembrane potential. 
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Mitochondria contain outer and inner membranes composed of phospholipid 
bilayers and proteins. This results in five distinct compartments: the outer membrane, the 
intermembrane space, the inner membrane, the cristae space and the matrix. Small 
molecules can permeate mitochondrial outer membrane but not the inner membrane (123). 
There are two ways for mitochondrial targeting of large molecules and small molecules 
especially to the matrix: one based on the high negative potential in the matrix, and 
another based on import through translocases in the outer and inner membranes. Small 
molecules can diffuse through pores formed by the spanning β-barrel protein in the 
mitochondrial outer membrane. Electrons are transferred to O2 in the mitochondrial 
respiratory chain. This leads to a proton gradient that drives the production of ATP via 
the ATP synthase. Consequently, a -150 to -180 mV mitochondrial transmembrane 
potential is generated. Lipophilic cations, such as rhodamine, and triphenylphosphonium 
(TPP), increase accumulation inside mitochondria due to the high negative charge in the 
mitochondrial matrix (Figure 1.4) (122, 124, 125). They initially accumulate 5-10 fold in 
the cytoplasm due to the -30 to -60 mV plasma membrane potential. Then they permeate 
the mitochondrial lipid bilayers and accumulate 100-500 fold in the matrix due to the -
150 to -180 mV mitochondrial transmembrane potential (126).  
 
A. 5. Local Controlled Delivery of Drugs Using Biodegradable Polymer 
Drugs including antioxidants, modified antioxidants, and anti-diabetic proteins, 
can be administered directly to the myocardium or subcutaneously by using an injectable 
biodegradable triblock copolymer delivery system without surgery (24, 127, 128). The 
biodegradable triblock copolymer allows the delivery of insoluble, unstable or expensive 
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substances at high local concentrations, due to the combination of hydrophilic poly 
(ethylene glycol) (PEG) or the B-block and hydrophobic poly (lactide-co-glycolide) 
(PLGA) or the A-block (26). The triblock is either arranged as BAB or ABA. The 
polymer takes advantage of the hydrophilic and hydrophobic blocks. The hydrophobic 
interactions are increased at high temperatures forming physical crosslinks resulting in 
the formation of the gel state (129). The hydrophilic block is responsible for the 
degradation rate and matrix permeability. The gelation temperature is controlled by the 
PEG/PLGA ratio, glycolide/lactide ratio, and the molecular weight. In addition, this 
formulation does not affect the activity of the loaded proteins as in the case of PLGA 
microspheres. Proteins lose activity when exposed to organic solvent/water interface 
during microsphere preparation (130, 131).  
Administering drugs using biodegradable triblock copolymer allows sustained 
drug release (several weeks) of therapeutic substances subcutaneously or directly to the 
heart without the potential of deleterious systemic effects (132-134). The polymer is also 
biocompatible and biodegradable, designed to be unreactive with the surrounding 
environment and prevents the need for retrieval of the implant. Furthermore, the polymer 
biodegrades, releasing the drug in a controlled manner then disappears from the injection 
site in a timely fashion. The polymer is in the liquid form at low temperatures and 
spontaneously gels at body temperature (37°C) (25, 135). Local controlled delivery will 
reduce the total dose of antioxidant and hence prevent the possibility of pro-oxidant 
activity that may occur with administering high doses. This approach was tested on 
delivering adiponectin, further discussed in Chapter 3. 
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Inducing Apoptosis in Breast Cancer 
Mitochondrial targeting can also be utilized for gene therapy of breast cancer. 
Breast cancer starts in the tissue of the breast either in the lobules (lobular carcinoma) or 
the ducts (ductal carcinoma).  When the cancer spreads into other breast tissues, it is 
defined as invasive. In addition, if the breast cancer is sensitive to the hormone estrogen, 
causing it to grow, it is defined as estrogen receptor-positive cancer and marked with 
estrogen receptors on the surface of their cells. Despite the fact that breast cancer 
mortality is falling in the Western world as a result in advances in treatment, it remains 
the most common cancer and the second leading cause of cancer death among women 
owing to the high and increasing incidence (136).  According to the American Cancer 
Society, the lifetime risk of a woman developing breast cancer is 13% or almost one in 
eight.  Patients with noninvasive cancers have a good treatment prognosis and have a 
high survival rate.  However, invasive cancer moves into the lymphatic system and 
metastasizes to regional lymph nodes, which help it spread to different tissues.  A breast-
conserving surgical approach benefits some patients, while others receive neoadjuvant 
(presurgery) chemotherapy or hormone therapy to downstage large tumors, thus 
potentially allowing conservative surgery (136, 137).  Moreover, adjuvant therapy 
(chemotherapy given after surgery) is used to eradicate micrometasteses, to improve 
survival rate and to delay tumor recurrence (138).  Anthracycline (doxorubicin or 
epirubicin) and taxane-based agents have been the standard chemotherapy for breast 
cancer (139, 140).  However, many patients with progressive disease are resistant to these 
treatment options. Response to chemotherapy is used as a prognostic factor (141-143).  
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Advanced breast cancer has a cure rate of less than 5%, so the usual treatment 
goal is prolongation of survival or improvement of quality of life (144, 145).  
Furthermore, only women with estrogen receptor-positive and node-negative tumors (not 
spread to the lymph nodes) receive hormone therapy (such as the antagonist tamoxifen, 
Nolvadex®) with no extra benefit from chemotherapy (146, 147).  Chemotherapeutic 
agents have well-known serious side effects, and anti-hormone therapy can lead to 
uterine cancer (in the case of tamoxifen) (138).  Additionally some patients can be 
administered trastuzumab (Herceptin®) only if their tumors overexpress the HER-2 
receptor (Human epidermal growth factor receptor 2), limiting its general use.  Currently, 
some breast cancers do not have combination therapies that address their particular 
molecular status.  These facts make p53 an attractive target due to its tumor suppressor 
ability and its ability to act independently as an apoptotic factor in any cell type.  In fact, 
patients with mutations in p53 are advised to have annual screening for breast cancer 
because most current anti-cancer agents are more efficacious when p53 is not mutated 
(148).  It is considered the worst prognosis if p53 is inactivated (149).  Knowledge of key 
molecular changes such as p53 cytoplasmic mislocalization (or mutation) in cancer cells 
will facilitate further advances in treatment of breast cancer by developing strategies that 
involve p53. 
An excellent target for p53 therapy is inflammatory breast carcinoma, an 
aggressive and deadly form of breast cancer (150) which has mislocalized or mutated p53 
(151) and therefore should readily respond to this type of therapy.  Cell lines with 
mislocalized or mutated p53 will serve as the starting point for these studies.  While this 
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application focuses on breast cancer, this approach is applicable to all types of cancers 
involving p53 mislocalization, nuclear exclusion, mutation, or inactivation.   
Mitochondrial targeting of p53 is further discussed in this section. The targeting is 
investigated by fusing the p53 protein with different mitochondrial signals (MTSs) to 
achieve an improved in activity. In addition, mutations in the p53 nuclear localization 
signal (NLS) were introduced to reduce nuclear targeting and hence increase the protein’s 
availability in the cytoplasm to target the mitochondria. A p53 “protein switch” was also 
used to exploit our emerging technology where ligand induction leads to nuclear 
accumulation of the target protein (152). Taking advantage of both the protein switch and 
the p53/MDM2 degradation pathway, a proteasomal protein switch was developed. 
Proteasomal switch can be used to target aberrant proteins in the cytoplasm and send 
them for degradation upon ligand addition. 
 
The p53 Protein 
The p53 protein plays a pivotal role in suppression of most cancers (153-156).  
Half of all tumors have mutant p53 (157), while inactivity of p53 defines the majority of 
the remaining cancer cases (158).  Additionally, the apoptotic pathways of p53 have now 
been clearly delineated.  Nuclear accumulation of p53 is essential for its transcriptional 
activities leading to induction of proteins involved in both the intrinsic and extrinsic 
apoptotic pathways (158-160).  Also, p53 triggers a nontranscriptionally mediated 
intrinsic apoptotic response if delivered to the mitochondria (161, 162).  Indeed, p53 has 
emerged as a “master switch” for cancer prevention (154) and is being actively pursued 
as the ultimate cancer therapeutic target.  
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Tumor suppressor p53, a 393 amino acid residue is encoded by the TP53 gene, 
located at 17p13 (reviewed in (163)). The protein can be divided into three regions 
(Figure 1.5): an acidic N-terminal region (codons 1-101), a DNA binding domain (DBD, 
codons 102-292), and a basic C-terminal region (codons 293-393). The acidic N-terminal 
region contains a transactivation acidic domain (codons 1-42), a MDM2 binding domain 
(MBD, codons 17-28), and a proline-rich domain (PRD, codons 63-97). The basic C-
terminal region contains three NLSs (codons 305-322 most active NLS), a 
tetramerization domain (TD, codons 323-3356), and a negative regulatory region (codons 
363-393). p53 functions as a transcription factor in many cases, regulating expression of 
genes involved in apoptosis, cell-cycle arrest, senescence, DNA repair, cell survival, and 
genomic stability, among others (163-165). Therefore it is difficult to predict its response 
to chemotherapy in cancer patients (166). Under normal growth conditions, p53 is rapidly 
degraded (167). In reaction to the p53 response, many autoregulatory feedback loops are 
triggered.  Of the ten positive or negative feedback loops, six act through the MDM2 
(mouse double minute 2) protein to regulate p53 activity (reviewed in (168)).  MDM2 is 
the main cellular antagonist of p53, and is responsible for nuclear exclusion and 
proteasomal degradation of p53 (169).  Disruption of the p53-MDM2 complex has 
become an important cancer therapeutic target (170). Upon stress, p53 is activated as a 
transcription factor by posttranslational modifications through stress signals such as DNA 
damage, UV, carcinogens, nitric oxide, heat or cold shock, or hypoxia (171). These 
modifications increase the half-life of the protein from 6-20 min to hours resulting in a 3- 
to 10- fold concentration increase. In addition, they enhance the ability of p53 to bind to 






Figure 1.5. The full-length p53. The 393 amino acids of p53 are divided into amino 
terminus, DNA binding domain (DBD), and C-terminal region. The amino terminus 
contains the MDM2 binding domain (MBD) and proline-rich domain (PRD). The C-
terminal region contains three nuclear localization signals (NLSs), a nuclear export signal 
(NES), and a tetramerization domain (TD). 
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signaling, p53 rapidly accumulates in the nucleus, which is essential for regulating cell 
cycle arrest, DNA repair, and apoptosis (159, 160).  In general, posttranslational 
modifications (ubiquitination, phosphorylation, methylation, sumoylation, neddylation, 
glycosylation and acetylation) are known to regulate p53 activity in terms of stability and 
function (reviewed in (172-174)).  Although p53 is tightly regulated by these 
modifications, the fact remains that gene therapy with p53 has been successful (175-177), 
thus circumventing the need to deliberately include these highly complex (and often 
unresolved) issues in gene therapy of p53. Tetramerization of p53 through its TD is also 
crucial for its transcriptional activity, protein-protein interactions, and degradation (178).   
Apoptosis through p53 occurs via two distinct signaling pathways (154): the 
extrinsic pathway through death receptors and the intrinsic pathway through the 
mitochondria (Figure 1.6).  The extrinsic pathway of p53-mediated apoptosis occurs via 
induction of Fas, DR5, and PERP genes.  These encode 3 transmembrane “death 
receptors” that belong to the tumor necrosis factor receptor family.  After Fas binding to 
Fas-L (ligand) (179), DR5 binding to TRAIL (ligand) (180), or activation of PERP 
(ligand unknown) (181, 182), these proteins induce caspase-8 mediated apoptosis.  The 
intrinsic pathway of p53-mediated apoptosis centers around the Bcl-2 family of proteins, 
which contain both pro- and anti-apoptotic members.  Pro-apoptotic members include 
Bax, Noxa, and PUMA (154).  The genes encoding these proteins are targets for p53 
transcriptional activation/induction.  Bax, Noxa, and PUMA all act at the mitochondria to 
activate apoptosis (reviewed in (183-185)).  A link between the extrinsic and intrinsic 





Figure 1.6. The extrinsic and intrinsic apoptosis pathways.  Caspases 8 and 9 are initiator 
caspases, while caspases 3, 6, and 7 are effector caspases.  Extrinsic pathway- p53 
induces genes encoding three transmembrane proteins: Fas, DR5, and PERP; activation 
of any leads to caspase-8 activation and triggering of apoptosis.  Intrinsic pathway- p53 
targets a key subset of the Bcl-2 family of genes including Bax, Noxa, and PUMA.  
These proteins participate in the release of cytochrome c from the mitochondria, which in 
turn with APAF-1 (a p53 regulated gene) activate caspase-9, triggering apoptosis.  
Cytochrome c, APAF-1, and caspase-9 form the apoptosome.  
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member of the Bcl-2 family that is cleaved and activated by caspase-8.  Cleaved Bid 
undergoes myristoylation, and then acts at the mitochondria to induce apoptosis.  p53 
itself also acts directly at the mitochondria to induce a rapid apoptotic response that 
occurs prior to p53 target gene activation. Via its DNA binding domain, p53 interacts 
with Bcl-XL (an anti-apoptotic) and Bcl-2 to promote permeabilization of the outer 
mitochondrial membrane (161, 162).  Clearly p53 plays an important role in preventing 
cancers from arising in a cell population by activating apoptotic pathways. 
Somatic TP53 missense mutations occur in at least 50% of all cancers, while 
inactivity of p53 is in the majority of the remaining cancer cases (158, 188, 189). In 
cancer cells, overexpressed mutant p53 (with mutations mainly in DBD) abolishes its 
transcription factor activity (189-191). Mutant p53 proteins are generally more stable 
because of the inability of MDM2 to be induced and therefore mutant p53 accumulates in 
the nucleus of tumor cells (190). The protein also becomes inactivated through different 
mechanisms, some of which are through elevation of p53 inhibitor MDM2 and silencing 
of key p53 co-activators such as ARF (192). Moreover, p53 is prevented from 
functioning as a suppressor through abnormal cytoplasmic sequestration and inhibition of 
its access to the nucleus, suggesting that the sequestration of p53 in the cytoplasm may 
represent a nonmutational mechanism of p53 inactivation (151, 193, 194).  
Mislocalization of p53 occurs in 37% of breast cancer (151) while p53 mutations occur in 
30% of breast cancer (195-197). Parc (p53-associated Parkin-like cytoplasmic protein) 
plays an important role in binding to the C-terminus of p53 in the cytoplasm and prevents 
transport into the nucleus (198). Studies have shown that mutant p53 is associated with 
resistance to chemotherapy (199, 200). Indeed, an exogenous C-terminal p53 peptide was 
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able to induce nuclear accumulation of endogenous p53 by competition for binding to 
Parc (201). These studies provide compelling evidence that regulating the shuttling of 
p53 between the cytoplasm and the nucleus or the mitochondria offers a controlled 
therapeutic approach to re-direct the mislocalized proteins to their correct cellular 
compartment. 
Localization of p53 to the mitochondria can also induce apoptosis via an 
extranuclear death function of p53 (162, 202), reflecting p53-induced apoptosis in the 
absence of transactivation of genes or protein synthesis (203, 204). A small but highly 
reproducible fraction of p53 translocates to the mitochondria at the onset of p53-
dependent apoptosis. The majority of mitochondrial p53 is found in the membranous 
compartment while a fraction of p53 is in a complex with the mitochondrial import motor 
hsp70 (162). Apoptosis ensues after critical changes in the mitochondria occur including 
collapse of the inner transmembrane potential, disruption of electron transport and ATP 
production, oxidative stress, permeability transition pore opening, and mitochondrial 
swelling with outer membrane rupture. When the outer mitochondrial membrane 
undergoes permeabilization, cytochrome c is released from the intramembranous space 
into the cytosol triggering apoptosis via the apoptosome (Figure 1.6) (105, 205, 206). In 
cancer cells, inducing the mitochondrial outer membrane permeabilization constitutes a 
therapeutic goal (207). Translocation of p53 to the mitochondria triggers the release of 
cytochrome c and procaspase-3 activation by forming inhibitory complexes with anti-
apoptotic Bcl-XL and Bcl-2 proteins through its DBD (residues 239-248) and inducing 
oligomerization of the BH123 effector protein Bak (161, 202, 208).  Such events precede 
the nuclear translocation of p53 and its target gene activation (161, 209).  When p53 is 
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targeted to the mitochondria at high levels, it induces apoptosis as efficiently as nuclear 
p53 by itself without requiring additional DNA damage. In cancer cells with endogenous 
missense mutants of p53, these mutants are not able to bind to Bcl-2 proteins due to 
mutation in the DBD, demonstrating the importance of DBD in mitochondrial apoptosis 
(208). Additionally during hydrogen peroxide-induced apoptosis, the protective effect of 
the small hsp αB-crystallin is due to its ability to bind to p53, sequester it in the 
cytoplasm, and prevent translocation to the mitochondria (210-212). These last two 
examples underscore the importance of directing functional p53 to the mitochondria for 
certain apoptotic events. The TD of p53, on the other hand, is not essential for 
mitochondrial function, since targeting a truncated version of p53 (residues 1-305) 
without the TD to the mitochondria can still induce apoptosis (162).  
Mitochondrial targeting of p53 can be achieved by adding a MTS specific for the 
outer membrane. To further enhance mitochondrial localization, the strong NLS in p53 
(213) can also be inactivated. The mitochondrial targeting of p53 is further explored in 
Chapter 5. 
 
Mitochondria in Cancer Cells 
Mitochondria are crucial in regulating the intrinsic apoptotic pathway in response 
to DNA damage, growth factor withdrawal, hypoxia, or oncogene deregulation (214, 
215). The intrinsic pathway is initiated by outer mitochondrial membrane 
permeabilization, which facilitates the release of potent death factors from the 
intramembranous space into the cytosol (206). These factors including cytochrome c can 
activate the caspases responsible for apoptosis. Mitochondrial dysfunction plays a central 
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role in the development and progression of tumors (109-111). It could initiate apoptosis 
and necrosis resulting in organ failure. 
Large molecules cross the outer and inner membranes through the TOM complex 
(translocase of the outer membrane) and the TIM complex (translocase of the inner 
membrane), respectively. The TOM complex contains two groups of receptor subunits; a 
group that recognizes proteins destined for import (Tom70 and Tom20), and a group that 
assists the transfer of the protein into the intramembranous space (Tom40, Tom22, Tom7, 
Tom6, and Tom5) (216-221). Proteins translocate the inner membrane via TIM22, which 
targets the inner membrane, and TIM23, which targets the matrix (218, 221). A protein 
needs to have a mitochondrial targeting signal (MTS) in order for it to be recognized by 
either the TOM or TIM complexes. MTSs are usually positively charged N-terminal 
cleavable peptides (15-40 residues in length). The signal forms an amphipathic α-helix, 
which is proteolyticaly cleaved by a mitochondrial peptidase in the matrix (217, 222).  
p53 primarily targets the Bcl2 (B-cell leukemia/lymphoma-2) family proteins in 
the mitochondria and either enhance their pro-death function or inhibit their survival 
function. These proteins can be grouped into pro- or anti- apoptotic subfamilies, 
depending on their modular content of BH1 (Bcl2 homology), BH2, BH3, and BH4 
domains (223). They can be classified into three classes: BH1234 (such as Bcl-XL and 
Bcl2), BH123 (such as Bax and Bak), and BH3 only (such as Bad, tBid, and Puma) 
(Figure 1.7). The first class (BH1234) contains anti-apoptotic proteins, which stabilize 
the mitochondrial outer membrane via binding to and inhibiting the pro-apoptotic 
members of the second class (BH123) via their hydrophobic BH123 binding pocket (224). 






Figure 1.7. The Bcl2 family proteins are grouped according to their modular content of 
Bcl2 homology (BH). There are BH1234 (anti-apoptotic proteins), BH123 (pro-apoptotic 
proteins), and BH3 only (activators and enablers). 
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into two subgroups: activators (such as tBid) and enablers (such as Puma) (225). tBid 
activates Bax and Bak by binding to them and inducing their oligomerization (225). 
Puma promotes mitochondrial outer membrane permeabilization via binding to and 
deactivating Bcl-XL and Bcl2 and hence freeing Bak and Bax (224). p53 acts similar to 
Puma in inducing apoptosis when targeted to the mitochondria (202).  It has also been 
reported that p53 increases the binding between Puma and Bcl-XL by changing the BH3 
binding region of Bcl-XL (223). p53 also acts similar to tBid by activating and binding 
directly to Bak and Bax to induce their oligomerization (226-228).  
 
Targeting the Nucleus 
In 1962, it was demonstrated that nucleocytoplasmic exchange occurs via pores 
embedded in the nuclear envelope (229). These 125 MDa nuclear pore complexes (NPCs) 
manage protein trafficking, both active and passive transport in and out of the nucleus, 
accommodating ~1000 translocation events per second (230-232). They have a tripartite 
structure: eight cytoplasmic filaments, a central transport, and a nuclear basket, 
constructed from approximately 100 nucleoporins (specific proteins that make up the 
NPC) (233-236). The long cytoplasmic filaments (cytoplasmic fibrils) projecting into the 
cytoplasm interact with karyopherins (family of transport receptors) and deflect non-
shuttling proteins (237-240). The central transport is a cylindrical intramembrane 
transporter (central aqueous channel) anchored to the nuclear membrane via eight spokes. 
Smaller molecules (less than ~40 kDa) transport via passive diffusion due to its 9 nm 
diameter (241-243), whereas larger molecules (>40 kDa and up to 60 MDa) are 
transported via amino acid signals, which are recognized by specific import and export 
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receptors (244-248). The nuclear basket consists of eight long fibrils projecting into the 
nucleoplasm, which are connected distally by a ring.  
Proteins containing nuclear localization signals (NLSs) are recognized by import 
receptors. Classical NLSs are monopartite with a single stretch of amino acids similar to 
the NLS found in SV-40 large tumor antigen (PKKKRKV; critical residues underlined) 
(249). Bipartite (two short amino acid sequences with a spacer in between) NLSs have 
also been recognized in proteins like nucleoplasmin (KRPAATKKAGQAKKKKLDK) 
(250). NLSs in proteins are recognized and imported into the nucleus by the importin α/β 
heterodimer. Importin α has the NLS binding site while importin β mediates the 
translocation of the importin α-NLS cargo complex into the nucleus through the NPC 
(244, 251). The cargo is freed in the nucleoplasm upon RanGTP binding to importin β, 
which along to importin α are recycled back to the cytoplasm [reviewed in (236)]. 
Conversely, the leucine-rich nuclear export signals (NESs) in the presence of RanGTP 
are recognized by the classical export receptor CRM1, which mediates the translocation 
to the cytoplasm (252). In the cytoplasm, RanGAP catalyzes the hydrolysis of a 
phosphate bond in the RanGTP dissociating the complex and freeing the cargo. Classical 
NESs are usually 8-11 amino acids in length with hydrophobic residues, leucines in 
particular. Commonly, NES is LX(1-3)LX(2-3)LXJ (where L is leucine, X is a spacer and J 
is leucine, valine or isoleucine) (253-255). 
Our lab has also designed a ligand inducible protein switch to control targeting of 
therapeutic proteins to the nucleus. Tagging EGFP with a strong NES, a ligand-inducible 
NLS (256), and a dexamethasone-specific ligand binding domain (LBD) (257) facilitate 
its bi-directional trafficking capability. The LBD is taken from a nuclear receptor, the 
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glucocorticoid receptor (GR). LBDs cause nuclear translocation of full-length receptors 
according to the dose of ligand (253, 258). Upon ligand binding, these nuclear receptors 
undergo a conformational change allowing the NLS to be exposed causing nuclear 
localization (259). The GR LBD used in our studies contains a point mutation (C656G) 
that makes it 10 times more sensitive to the agonist dexamethasone (Dex) (258). Our lab 
has previously shown that enhanced green fluorescent protein (EGFP)-tagged protein 
switch translocates from the cytoplasm to the nucleus in a dose-dependent manner (4, 
152).  The protein switch can be engineered with a dimerization domain of a protein of 
interest which will allow it to “capture” cytoplasmically mislocalized endogenous protein 
(236).  This protein switch-mislocalized protein complex can then be directed (by 
addition of ligand) to its correct compartment, the nucleus.   
The elegance of the protein switch is that it imitates proteins found in nature.  
Many proteins in signal transduction pathways are capable of binding to protein partners 
in the cell, moving them to a new location and/or altering their function.  For example, 
the p14/19 ARF protein is capable of binding to MDM2, resulting in decreased 
degradation of p53 by MDM2 (260).  p14/19 ARF, with its nucleolar targeting signal, is 
also capable of re-directing the p14/19 ARF-MDM2 complex to the nucleolus (168, 261).  
Like nature, the protein switch was designed to regulate cellular proteins by changing 
their location and hence their function.  The protein switch has the advantage of being 
regulated by externally added ligand (4, 152, 236). 
An alternative proteasomal protein switch that utilizes MDM2 mediated 
degradation of p53 was discovered in the course of these studies. MDM2 binds to p53 




Proteins marked with a death signal, a chain of polyubiquitin, are targeted to the 
proteasome for degradation (262). The proteins are further degraded into amino acids, 
which are then used in synthesizing new proteins. Proteasomes are found in both the 
nucleus and cytoplasm.  The proteasome consists of the 20S proteasomal core and two 
19S regulatory caps. The caps contain multiple ATPase active sites and ubiquitin binding 
sites. Proteasomal targeting has been studied to either inhibit the proteasome for 
inflammatory disease and cancer, or activate it for neurodegenerative diseases (263, 264).  
The ubiquitin-proteasome system is crucial for proteasomal degradation of 
proteins (265). The proteasome recognizes ubiquitinated proteins for degradation. An 
ubiquitin-activating enzyme (E1) first hydrolyzes ATP and is linked to an ubiquitin 
molecule via a thioester bond. Next, the ubiquitin molecule is transferred to an ubiquitin-
ligating enzyme (E2). In the last step, an ubiquitin ligase (E3) binds to a specific protein 
(substrate) and helps the transfer of ubiquitin from E2 to a lysine residue in the target 
protein. E3 binding to the substrate is considered the rate-limiting step in protein 
degradation (263). The polyubiquitin chains marks the protein for proteasomal 
degradation.  
The ubiquitin transfer from E2 to the targeted protein can occur in two ways: via 
the RING (really interesting new gene) domain of E3s or via the HECT (homologous to 
the E6-AP carboxy terminus) domain of E3s (266). MDM2 containing the RING domain 
is the ubiquitin ligase (E3) responsible for binding to and ubiquitinating p53 accompanied 
by Ubc5, E2 ubiquitin conjugating enzyme (267). The main lysine residues in p53 that 
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are ubiquitinated by MDM2 are found on the carboxy terminus, K370, K372, K373, 
K381, K381, and K386 (268). 
 
Gene Therapy 
For the induction of apoptosis in breast cancer, constructs encoding p53 have 
been used in gene therapy. Generally, gene therapy is the insertion of a gene (a well-
defined DNA sequence) into cells’ nuclei to produce specific therapeutic proteins to 
correct a cellular dysfunction or to provide a new cellular function (269).  If a specific 
gene contains a defect, the corresponding expressed protein usually loses its normal 
function. Once the key protein(s) and mechanisms involved are identified in a disease, 
gene therapy could be used as a treatment therapy. Identifying genes and proteins 
involved in diseases has been greatly improved due to the Human Genome Project and 
the Hap Map Project (270). Clinical trials using gene therapy have been focusing on 
certain diseases such as cancer, cardiovascular disease, inherited monogenic disease, and 
infectious disease (mainly HIV). The largest target for gene therapy clinical trials is 
cancer, which is a more complex disease involving mutations in a number of genes (271, 
272). Since gene therapy is not designed to deliver a vast amount of different genes, 
certain critical proteins involved in signaling cascades are targeted. The first clinically 
approved gene therapy product, approved only in China, was the delivery of the tumor 
suppressor p53 via an adenovirus under the brand name GendicineTM. This drug was 
approved by China’s State Food and Drug Administration (SFDA) in 2004 for head and 
neck squamous cell cancer (273-275). It also showed promising results in liver cancer, 
lung cancer, and other advanced liver tumors (274). It is noteworthy that GendicineTM 
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was approved by the SFDA on the basis of tumor shrinkage and not on the basis of 
lifetime extension of treated patients as required are by the U.S. FDA and the European 
Medicine Agency (EMA) (270). 
Gene therapy using wt p53 has had some successes for many types of cancers, 
including lung, ovarian, glioma, etc. (175-177, 276-283).  More recently, attempts to use 
p53 targeted to the mitochondria have also shown promise (207, 284).  Nuclear and 
mitochondrial p53 have been shown in one study to be equipotent (162), but have 
different mechanisms of action for apoptosis. Our mitochondrial p53 showed enhanced 
mitochondrial targeting (and is designed to cause apoptosis) due to rationally designed 
alterations/additions to the gene to be delivered (Chapter 5). While the actual delivery of 
these gene-therapeutics is not the focus of this work, ultimately these constructs could be 
delivered virally or nonvirally as genetically encoded products. 
 
Statement of Objectives 
The long-term objectives of this project are to harness different methods of 
targeting multiple organelles in a cell to lead to better drug delivery and improvement in 
disease therapy. This study describes the optimization of protein (adiponectin) delivery to 
activate certain mechanisms in the mitochondria, the designing of a small molecule 
(MitoE) to specifically target the mitochondria, and utilization of gene therapy to control 
the targeting of proteins (such as p53) to the mitochondria, nucleus and proteasome.  
Two disease models were investigated to explore the different subcellular 
targeting of therapeutics. For cardiovascular disease, controlled delivery of adiponectin 
and mitochondrial targeting of vitamin E were tested to reduce the oxidative stress in 
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endothelial cells. Adiponectin reduced the oxidative stress via cAMP pathway while 
maintaining its activity after it was released from the biodegradable triblock copolymer 
(Chapter 3). In addition, vitamin E conjugated to TPP showed recovery of endothelial 
dysfunction by reducing ROS after its accumulation in the mitochondria (Chapter 4).  For 
breast cancer, p53 was targeted to the mitochondria (Chapter 5), nucleus and proteasome 
(Chapter 6). Mitochondrial and nuclear targeting were achieved by fusing MTS and NLS 
respectively. However, proteasomal targeting was accomplished via fusing protein switch 
to p53 followed by ligand addition. Nuclear and mitochondrial p53 are responsible for 
inducing apoptosis in breast cancer cells whereas proteasomal targeting is still under 
investigation for possible targeting of oncogenic proteins. These approaches lead to the 
hypothesis that targeting specific organelles in a cell will lead to better drug delivery and 
improvements in disease therapy. In this study four major hypotheses were proposed, 
with corresponding aims, as follows: 
Hypothesis 1: Cardiac mitochondrial oxidative stress can be reversed by local controlled 
delivery of adiponectin using a triblock copolymer. 
Aim: To examine the effect of the released adiponectin on mitochondrial ROS and 
perform mechanistic studies. 
Hypothesis 2: Specific mitochondrial targeting of vitamin E can reduce ROS production 
in the cardiac mitochondria. 
Aim: To conjugate vitamin E to TPP to increase mitochondrial targeting and determine 
the ability of modified antioxidants to reduce mitochondrial ROS. 
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Hypothesis 3: Fusing MTS to p53 will increase its mitochondrial targeting and apoptotic 
potential. 
Aim: To prove that a nuclear-localization deficient version of p53 engineered with an 
improved mitochondrial targeting signal will trigger apoptosis via the intrinsic apoptotic 
pathway. 
Hypothesis 4: A p53-protein switch will localize to the proteasome upon ligand addition. 
Aim: To create localization controllable protein construct to the proteasome that could be 
used as a protein switch for degrading oncogenic proteins.  
These hypotheses and specific aims have been discussed sequentially in Chapters 
3-6. Chapter 2 discusses the different approaches for subcellular delivery. The results in 
the studies described in Chapters 2 and 3 have been published in peer-reviewed journals 
(123, 23). Chapter 5 has been submitted to Molecular Pharmaceutics while Chapter 4 is 
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CONTROLLING SUBCELLULAR DELIVERY 
TO OPTIMIZE THERAPEUTIC EFFECT 
 
Abstract 
This chapter focuses on drug targeting to specific cellular organelles for 
therapeutic purposes.  Drugs can be delivered to all major organelles of the cell (cytosol, 
endosome/lysosome, nucleus, nucleolus, mitochondria, endoplasmic reticulum, Golgi 
apparatus, peroxisomes, and proteasomes) where they exert specific effects in those 
particular subcellular compartments.  Delivery can be achieved by chemical (e.g., 
polymeric) or biological (e.g., signal sequences) means.  Unidirectional targeting to 
individual organelles has proven to be immensely successful for drug therapy.  Newer 
technologies that accommodate multiple signals (protein switch, virus-like delivery 
systems) mimic nature and allow for a more sophisticated approach to drug delivery.  
Harnessing different methods of targeting multiple organelles in a cell will lead to better 
drug delivery and improvements in disease therapy. 
 
Reprinted by permission from Therapeutic Delivery 1: 169-93 (2010). 
Mossalam M., Dixon A.S., Lim C.S. 
M.M. wrote the outline and sections on mitochondria, endoplasmic reticulum, and 
peroxisome. A.S.D. wrote sections on nucleus, nucleolus and Golgi apparatus. C.S.L. 





The 1975 discovery of the “Signal Hypothesis” led Gunter Blobel to win a Nobel 
Prize (1-3).  Blobel predicted “zip codes” were responsible for targeting certain proteins 
to subcellular compartments such as the cytoplasm, nucleus, nucleolus, mitochondria, 
endoplasmic reticulum, Golgi, and peroxisomes (Figure 2.1).  The intracellular delivery 
of a pharmaceutical agent can have a dramatic impact on its therapeutic efficacy.  Indeed, 
precise compartmentalization of certain drugs is necessary for their biological effect.  For 
example, agents intended for gene therapy must be eventually delivered to the nucleus in 
order for the therapeutic protein to be expressed.  Some drugs such as RNA interference, 
must target the cytosol in order to block the cells’ mRNA.  In other cases, pro-apoptotic 
drugs can be selectively targeted to the mitochondria where they exert their actions. 
Our previous work has shown that an oncogene can be targeted to a different 
cellular compartment to completely alter its function.  The causative agent of chronic 
myelogenous leukemia, Bcr-Abl, is normally found in the cytoplasm where it acts as an 
oncoprotein.  However, when targeted to the nucleus (by attaching four nuclear 
localization signals) it acts as an apoptotic factor (4).  In this case, targeting a protein to a 
single organelle can be used to elicit a desired effect such as apoptosis.  Further work in 
our laboratory focuses on controlled localization of proteins to alter function.  We have 
described our “protein switch” technology that allows controlled translocation from the 
cytoplasm to the nucleus upon addition of ligand (5-7).  One of the main goals of our 
research is to imitate the function of proteins found in nature.  Many proteins in signal 
transduction pathways are localized to one compartment initially, bind to protein partners 





Figure 2.1.  Drug targeting to cellular organelles.  Text on arrows indicate consensus 
targeting sequence (if available), example of targeting signal, or mode of targeting. 
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to an alteration in function.  Ultimately we seek not only targeting of a specific organelle 
but also a further level of sophistication, where multiple signals can be used to target 
multiple organelles.  Indeed, the ability to precisely target drugs to different organelles is 
changing the way therapeutics are developed.  This paper will focus on therapeutic 
targeting to specific cellular organelles (Figure 2.1).  Each organelle will be briefly 
described, followed by methods to reach and target the organelle for therapy.  Finally, 
future perspectives for therapeutic delivery will be discussed. 
 
Cytosolic Delivery 
Typically, drugs targeting cellular organelles have to be initially delivered to the 
cytosol, which in some cases is the site of action, where drugs (such as glucocorticoids, 
proteins, or siRNA) bind to their receptors or act on other targets.  There are three main 
barriers, which must be overcome to facilitate cytosolic delivery: i.) evading detection by 
the reticuloendothelial system (RES), ii). interaction with the cell membrane and 
internalization; and iii.) intracellular trafficking and endosomal escape.   
 
Evading RES Detection 
In order for cytosolic delivery to occur when the drug is delivered into the 
bloodstream, the drug first has to evade detection by the RES prior to interacting with cell 
membranes.  The endothelial layers of the liver, spleen and bone marrow comprising the 
RES contain mononuclear macrophages that filter the blood of foreign pathogenic 
particles (8).  Aggregation of foreign particles in the presence of plasma proteins and cell 
adhesion molecules facilitates rapid clearance from the bloodstream (9-12).  To lengthen 
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the circulatory time and decrease macrophage detection, several approaches have been 
attempted.  Liposomes have been one of the most common drug delivery agents used to 
evade RES detection.  Regular liposomes undergo rapid opsonization via the RES cells, 
followed by lysosomal degradation.  Strategies to evade RES detection have included use 
of targeted liposomes (for accumulation in target organs) and or using “stealth” 
liposomes [21].  Long circulating liposomes (stealth) can be prepared by including 
amphiphilic stabilizers (e.g., cholesterol) (13-15), phosphatidylinositol and gangliosides 
(16), or a hydrophilic surface by grafting with polyethylene glycol (PEG) (17).  The 
combination of long-circulating and targeted liposomes has been extremely popular in the 
last decade (such as antibody targeting and PEG) [21].   
 
Cell Membrane Interaction 
Subsequently, therapeutics interact with cell membranes (plasma membranes), 
which are lipid bilayers composed of phospholipids (phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine, and sphingomyelin are common 
phospholipids), cholesterol, glycolipids, and proteins (including proteoglycans, which 
contain a core protein with 1 or more glycosaminoglycans attached) (18).  Proteoglycans 
are important for delivery of drugs via cationic polymers (19, 20).  For example, an ionic 
interaction occurs between cationic polyethyleneimine (PEI), and the cell membrane 
which has negatively charged sulfated proteoglycans on the cell surface (19).   
Conjugation with cell penetrating peptides (CPPs) can also overcome the barrier 
of the cell membrane (21, 22).  In the late 80s and early 90s many groups ((23-25) and 
others) found that a protein transduction domain of 9-16 cationic (polyarginine like) 
 68 
amino acid residues had cell membrane-penetrating capability, including the ability to 
cross the nucleus.  Several other groups (26) showed that peptides and proteins attached 
to CPPs can cross cell membranes (reviewed in (27)).  Many therapeutics have been 
delivered to cells in this manner (28-32).   
Internalization may occur by endocytosis (initiated by electrostatic or 
hydrophobic interactions with the cell membrane, or interaction with a cell surface 
receptor) followed by endosomal escape, or by other means, such as macropinocytosis, or 
combinations of these (33).  After trafficking into the cytosol, the drug may either exert 
its action or traverse to a subcellular compartment (nucleus, mitochondria, peroxisome, 
etc.).  For example, for delivery of genes, the cytoplasmic barrier is only the first step 
before delivery to the nucleus can occur.  Table 2.1 depicts various agents designed to 
target the cytosol and their corresponding cargo (drug).  
Liposomes, cationic lipid DNA and polymer complexes have been used as non-
viral delivery carriers by complexing with DNA (34, 35).  Nanoparticles can encapsulate 
various types of therapeutics including low molecular weight drugs (36, 37), and 
macromolecules (e.g., proteins and DNA).  Liposomes bind to cell membranes and are 
internalized via endocytosis with pH-sensitive liposomes being more efficient (38, 39).  
The formulation of pH-sensitive liposomes with phosphatidylethanolamine (PE) 
increases affinity to adhere to cell membranes due to aggregate formation because of the 
poor hydration of its head-groups (40, 41).  Other liposome examples include 
thermosensitive liposomes, which allow temperature-sensitive release of drug (42-50).  
Development of drug carriers is still in progress to overcome cytosolic barriers, including 
biodegradable polymeric carriers for controlled release (51, 52).   
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Table 2.1.  Cytosolic targeting of drug therapeutics (includes endosomal/lysosomal 
escape, in some cases). 
Class of 
targeting agent 
Targeting agent composition Drug delivered (trade 
name if available) 
References 
Liposomes Liposome composed of lipid 
bilayer neutral lipids, DPPC 
and cholesterol 
 
Amikacin (Arikace™) (53) 
 Liposomal includes soybean 
oil and phospholipids 
Cyclosporin (54) 
 Doxorubicin STEALTH® 
liposome containing MPEG-
DSPE, HSPC and cholesterol 
Doxorubicin (Doxil™) (55) 
pH sensitive 
liposomes 
Liposomes composed of 
CHEMS and DOPE 
Diptheria toxin A chain (38) 





DPPC, HSPC, and cholesterol 

























modified using either levulinic 
acid (LEV) or 4-acetyl benzoic 
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Polyethyleneimine Genes (DNA) (65, 66) 
Virus-mimetic Hydrophobic polymer core 
poly(L-histidine-co-
phenylalanine)(poly(His32-co-
Phe6)and 2 layers of 
hydrophilic shell (one PEG 
end linked to core polymer; 





encoded in a plasmid 
Genes (DNA) (6, 7, 68) 
 NES (ALPPLERLTL) 







Conjugating antibodies to either liposomes or polymers increases internalization 
via a receptor-mediated endocytotic process (70, 71).  Others have targeted ligands to 
their respective cell-surface receptors (folate receptor (72), transferrin receptor (73), LDL 
receptor (74) and many other ligand-receptor mediated methods (75)) for endocytosis and 
eventual release into the cytoplasm. 
It may be desirable to retain a protein or peptide, once inside a cell, in the 
cytoplasm, where it may interact with its target (such as a signal transduction protein or 
receptor).  Proteins smaller than about 45kDa can passively diffuse into the nucleus; 
exclusion from the nucleus (hence cytoplasmic localization) can also be conferred by 
increasing the size of the gene therapy protein to over 60kDa (76).  Such large proteins 
cannot traverse the nuclear pore complex (NPC) passively, and require nuclear 
localization signals for entry into the nucleus via the NPC.  Proteins, peptides and DNA 
may be tagged with amino acid sequences that confer nuclear export (using a nuclear 
export signal, or NES) to achieve this goal, or in the case of a gene, the NES may be 
encoded by plasmid DNA and genetically engineered to the therapeutic gene.  Our 
laboratory uses the latter to confer cytoplasmic localization to engineered proteins (see 
Table 2.1) (5-7, 68).  NESs are composed of sequences that are leucine rich, 
approximately 10-12 amino acids in length.  Proteins with NESs are exported out of the 
nucleus by the classical export receptor, CRM-1 or exportin-1 (76) (Figure 2.2A).  A 
common consensus NES is LX (1-3) LX (2-3) LXJ where L is leucine, X is a spacer 
(numbers in parenthesis indicate number of amino acids in the spacer) and J is leucine, 




Figure 2.2. EGFP fused to different targeting signals and transfected into 1471.1 murine 
adenocarcinoma cells. A) Nuclear export signal (HIV NES) delivers EGFP to cytoplasm. 
B) Nuclear localization signal (MycA8 NLS) delivers EGFP to nucleus. C) Mitochondrial 
targeting signal (ornithine transcarbamylase MTS) delivers EGFP to mitochondria. D) 








Drugs that have entered cells via endocytosis (and need to be delivered to the 
cytosol) are faced with a third obstacle: late endosomal/lysosomal degradation.  The 
process of endocytosis starts at the cell surface.  The material to be internalized gets 
encapsulated by a small portion of the plasma membrane (clathrin coated pit formation), 
followed by a pinching off to form an endocytic vesicle.  In the case of pinocytosis, some 
vesicles may originate at caveolae (instead of clathrin).  Receptor-mediated endocytosis 
is a common mechanism for endocytosis of drugs/drug carriers.  Endocytosed material 
that is not retrieved from endosomes (in the case of recycled receptors, for example) is 
destined for the lysosome (18).  Lysosomes contain hydrolytic enzymes for digestion of 
macromolecules derived intra- or extracellularly; for digestion of phagocytosed materials, 
and even for production of nutrients (18). 
The classic example uses polyethyleneimine (PEI) for endosomal escape (65).  
PEI’s secondary and tertiary amines are protonated in the acidic environment of the 
endosomes.  The “proton sponge effect” causes osmotic swelling and rupture of the 
endosomes (77).  The main drawback of PEI is its toxicity (78, 79), but many 
modifications of PEI have been made to attempt to circumvent this (80-84). 
Many other techniques to escape the endosome (hence bypassing degradation) 
have been investigated.  These include the development of pH-sensitive liposomes and 
polymers, where they switch from a membrane inert (pH 7.4) to a membrane disruptive 
(under acidic condition) conformation (85).  This facilitates a destabilization of the 
endosomal membranes, resulting in release of the encapsulated therapeutic in the 
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cytoplasm (reviewed in (37)).  Further, membrane-disruptive polymers masked by PEG 
via disulfide groups and acid-degradable acetal groups disrupt the endosomal membrane 
when the acidic pH of the endosome degrades the acetal groups unmasking the 
membrane-disruptive backbone (86).  Subsequently, the disulfide groups are reduced in 
the cytoplasm releasing the conjugated drug.  Another strategy is to use membrane 
disruptive peptides mimicking the viral mechanism of endosomal escape.  These peptides 
contain acidic residues that prevent the formation of an α-helix when unprotonated, but 
under slightly acidic pH the peptide forms an α-helix which allows multimerization and 
protein interaction leading to endosomal escape.   
 
Endosomal/Lysosomal Targeting 
A drug may also be targeted to the endosome/lysosome directly for a therapeutic 
effect.  There are over 40 lysosomal storage diseases that occur as a result of lysosomal 
enzyme deficiency which allow various proteins, lipids, and carbohydrates to accumulate 
in the lysosomes.  These diseases manifest usually as neurodegenerative, but can be 
treated with enzyme replacement therapy (reviewed in (87)).  Drug delivery to 
endosomes has been achieved by targeting cell surface receptors (mannose 6-receptor, 
reviewed in (88), the IGF-II/cation-independent mannose 6-phosphate receptor (89)) for 







Transport Through the Nuclear Pore Complex 
Nucleocytoplasmic exchange occurs via pores formed by nuclear pore complexes 
embedded in the nuclear envelope (90).  The 125 MDa nuclear pore complex (NPC) is 
the gatekeeper for nuclear entry, and the central role of this complex is confirmed by the 
high level of conservation among all eukaryotes (91-93).  This complex regulates all 
trafficking into and out of the nucleus, including passive diffusion of molecules smaller 
than 9 nm in diameter (<40 kDa) and active transport of molecules between 9-40 nm in 
diameter (40 kDa to 60 MDa), and has an estimated ability to translocate 1000 molecules 
per second (94-96).  Cytoplasmic filaments, a central channel, and a nuclear basket give 
the NPC complex a tripartite structure constructed from approximately 100 nucleoporins 
(Nups) (97-99) (reviewed in (5)).  The long cytoplasmic filaments project into the 
cytoplasm and interact with karyopherins (family of transport receptors) and deflect non-
shuttling proteins (100-103).  The central channel is a cylindrical intramembrane 
transporter (central aqueous channel) with a 9 nm diameter pore (104-106), and is 
anchored to the nuclear membrane via eight spokes.  The nuclear basket consists of eight 
long filaments projecting into the nucleoplasm, which are connected distally by a ring.   
While molecules that are small enough to fit through the 9 nm pore in the central 
channel can enter the nucleus passively, larger molecules must be escorted through the 
NPC complex by karyopherins.  Karyopherins, such as importin α, recognize and bind 
specific amino acid sequences termed nuclear localization signals (NLS) (76, 107-110).  
Classical NLSs are monopartite with a single stretch of amino acids similar to the NLS 
found in SV-40 large tumor antigen (PKKKRKV; critical residues underlined) (111), or a 
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consensus of K(R/K)X(R/K) (112) (Figure 2.2B).  Bipartite NLSs (two short amino acid 
sequences with a spacer in between) have also been identified in proteins like 
nucleoplasmin (KRPAATKKAGQAKKKKLDK) (113).  Classical NLS sequences are 
recognized by importin α (114, 115), which binds to the HEAT repeats (helical repeats of 
histidine, glutamic acid, alanine, and threonine) of importin β (116) through an importin 
β binding (IBB) domain (117).  Once this ternery complex is formed, importin β mediates 
the translocation of the complex into the nucleus through interactions with FG repeats of 
Nups in the NPC (118).  Inside the nucleus the complex dissociates when RanGTP binds 
to importin β (119), and both importin α and β are escorted separately back to the 
cytoplasm by RanGTP (115, 120, 121).  In the cytoplasm, RanGAP catalyzes the 
conversion of RanGTP to RanGDP, and importin α and importin β are ready for another 
cycle of import.   
 
Challenges of Nuclear Trafficking 
It is not a simple task to diffuse through the highly viscous cytosolic fluid.  DNA 
over 2 kb is almost immobile, and DNA over 250 bp has reduced lateral mobility (122, 
123).  Nevertheless, a mechanism to overcome the challenge of diffusing through the 
cytosol is demonstrated by viruses, which use active transport along the microtubule 
cytoskeleton (124-127).  Another challenge in nuclear targeting is the translocation 
through the nuclear envelope, which has been described as one of the limiting steps for 
non-viral gene delivery (128).  The midplane of the pore in the NPC is the narrowest, and 
is estimated to be approximately 40 nm in diameter (129).  Thus, the largest molecule 
able to fit through this pore and enter the nucleus is roughly 40 nm, an estimate that has 
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been confirmed (39 nm) using gold nanoparticles coated with NLSs (130).  The 36 nm 
capsid from hepatitis B can also transport through the NPC into the nucleus without 
dissociating (130), further demonstrating the capabilities of the NPC and validating the 
40 nm size limitation.  However, plasmid DNA in complex with polylysine crosslinked 
with NLSs, 60 nm in diameter, has been shown to enter the nucleus (131, 132), likely due 
to the increased flexibility of this complex versus the more rigid gold nanoparticles.  
Molecules larger than 40-60 nm in diameter, regardless of containing a NLS, will be 
unable to enter the nucleus (131, 132).   
 
Methods of NLS Incorporation 
Various methods of incorporating the NLS into the therapeutic have been 
attempted (Reviewed in(128, 133)).  For peptide/protein therapeutics, genetic engineering 
provides a facile method of incorporating the NLS as we have recently demonstrated with 
the oncoprotein Bcr-Abl which causes chronic myelogenous leukemia (CML) (4).  
However, for nonpeptide/protein therapeutics, the attachment of the NLS is no trivial 
matter, and can result in drastically different results.  As gene therapy is one of the most 
extensively researched areas in nuclear targeting, Table 2.2 provides examples of various 
methods of linking NLSs to DNA for gene therapy.   
Of these approaches, electrostatic interactions are the simplest, but are not without 
drawbacks.  One potential problem is the dissociation of the complex in the cytosol, 
leaving the DNA without the nuclear targeting signal.  Furthermore, as most electrostatic 
interactions with DNA are nonsequence specific, the interactions may interfere with the 
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Electrostatic NLS in complex with DNA (134-138) 
Electrostatic NLS-PLL in complex with DNA (139) 
Electrostatic M9-ScT in complex with DNA (140) 
Electrostatic NLS-PNA in complex with DNA (141-145) 
Electrostatic Triplex formation between Padlock Oligonucleotide 
with NLS and DNA 
(146) 
Electrostatic NLS-Streptavidin bound to Biotinylated DNA (147) 
Covalent (Random) N3-adenine adduct via cyclopropapyrroloindole 
(CPI)-NLS 
(148) 
Covalent (Random) Photoactivation of p-azido-tetrafluoro-benzyl-NLS (149) 
Covalent (Random) Diazo coupling to increasing lengths of PEG-NLS (150) 
Covalent (Specific) Cross-linked triple helix with psoralen-oligonucleotide  (151) 
Covalent (Specific) Attachment to hairpin of linear DNA (152-154) 
Covalent (Specific) Attachment to PCR primer (154, 155) 
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transcription of the gene after being delivered to the nucleus.  To circumvent this 
problem, peptide nucleic acid (PNA) with a NLS has been used to interact with the DNA 
in a sequence specific manner in a region other than the gene of interest (141), but only 
achieved modest improvements.  Numerous attempts to improve efficiency through 
covalent attachment of the NLS have been attempted, but many have failed to 
demonstrate improved nuclear translocation and gene expression (148-150, 156).  
However, initial attempts to covalently attach the NLS to the DNA did not control where 
on the DNA strand the NLS was attached and may have resulted in the NLS preventing 
the efficient transcription of the gene of interest.   
Further attempts were to then attach the NLS to DNA upstream or downstream 
from the gene of interest so as to avoid interference with transcription.  Nevertheless, in 
spite of various attempts to conjugate the carrier to the DNA away from the gene of 
interest, this approach has not demonstrated the anticipated results.  The triple-helix with 
photoactivation attempted by Neves et al. (151), the conjugation to the hairpin attempted 
by Tanimoto et al. (153), and linear DNA amplified via PCR with NLS-conjugated 
primers (154, 155) all demonstrated a lack of transfection efficiency, and even a lack of 
nuclear tanslocation.  However, one study has shown that covalent attachment of a NLS 
to a hairpin at the 3’-end of linear DNA can enhance transfection anywhere from 10 to 
1000 fold depending on the cell type (152), but similar schemes did not achieve the same 





Therapeutics Targeting the Nucleus 
Pharmacological agents that alter the nuclear translocation (either inhibit or 
induce translocation) also provide a means for therapeutic intervention (157).  Inhibition 
of the NPC through binding FG repeats by antibodies has been used to prevent nuclear 
accumulation (158) but is not specific and inhibits all protein translocation into the 
nucleus.  These antibodies, RL2 and mAb414, are further limited by complications with 
delivery of an antibody inside a cell.  Wheat germ agglutinin (WGA) is a lectin that binds 
to N-acetylglucosamine common to certain Nups and also inhibits general nuclear 
transport through the NPC (159, 160).   Kosugi et al. have also demonstrated that nuclear 
translocation can be inhibited through two peptides, bimax1 and bimax2, that bind to 
importin α (161).  The inhibition of the NPC reduces nuclear transport and results in 
reduced nuclear localization, while the inhibition of nuclear export can increase the 
nuclear accumulation of proteins.  Leptomycin B (LMB) is a general nuclear export 
inhibitor that binds to Crm1 (162-164), a protein that escorts other proteins with nuclear 
export signals (NESs) from the nucleus to the cytoplasm.  Although LMB has antitumor 
properties, it was also found to be highly toxic and cannot be used clinically.  Recently, 
Mutka et al. have identified LMB analogs that retain the potency of LMB, are better 
tolerated, and have shown potential as cancer therapeutics in mouse xenograft models 
(165).  Still, inhibiting the general nuclear import or export of all proteins may be limited 
as a therapeutic approach and methods to target specific proteins would be a better 
alternative. 
 An example of therapeutic intervention through altering the nuclear localization 
of a specific protein is the use of peptides that bind nuclear factor-κB (NF-κB) and 
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prevent its nuclear translocation (166, 167).  The misregulation of the transcription factor 
NF-κB has been associated with cancer and autoimmune diseases, both of which 
potentially could be treated by inhibiting the nuclear accumulation of NF-κB (168).  A 
similar approach of inhibiting nuclear translocation through binding with a peptide has 
been demonstrated for nuclear factor of activated T cells (169).  Moving proteins from 
the cytoplasm into the nucleus has also been demonstrated through the use of protein 
aptamers containing a NLS (170).  We have also developed a sophisticated chimeric 
protein we have termed a protein switch (Figure 2.3), for controlled nuclear transport (6, 
7, 68).  This protein switch (containing both NES and inducible NLS) localizes to the 
cytoplasm, but upon the addition of a ligand is translocated into the nucleus.  This 
controlled nuclear translocation can be used to alter the nuclear localization of 
endogenous proteins, and attempts to do so are currently underway in our laboratory. 
 
Targeting the Nucleolus 
A subcellular compartment such as the nucleolus presents additional challenges in 
identifying specific targeting sequences as it exists in a highly dynamic equilibrium with 
the nucleoplasm and is not enclosed by a membrane.  The nucleolus has been described 
as a machine for ribosome production, and is a dense area composed of nucleolar 
organizer regions (loops of DNA containing genes encoding rRNA), rRNA, ribosomal 
proteins, ribosomal-binding proteins, small ribonucleprotein particles (snRNPs), and 
RNA polymerase I.  The nucleolus typically exhibits fibrillar centers, fibrillar 




Figure 2.3. Protein switch mechanism. The PS, shown schematically (top diagram), 
consists of a NES, NLS, ligand-binding domain and dimerization domain. When PS 
plasmid is transfected into cells, the expressed PS captures a poI in the cytoplasm. Upon 
addition of ligand, the PS-poI complex translocates to the nucleus. 
L: Ligand; NES: Nuclear export signal; NLS: Nuclear localization signal; PoI: Protein of 
interest; PS: Protein switch. 
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transcription is not taking place, where as the fibrillar components are more dense regions 
where transcription is underway, and the granular components are regions where the 
ribosomal precursor particles are undergoing maturation.   
 Various sequences (reviewed in (171)) with as few as seven amino acids (172) 
have been identified that can be used to direct a protein to the nucleolus.  The nucleolus 
localization signals (NoLSs) are very similar to the arginine/lysine rich NLS sequences, 
which is easy to conceive due to the necessity to first be transported into the nucleus 
before targeting the nucleolus.  However, there is a distinction between NLSs and NoLSs 
as demonstrated through deletion analysis of the NoLS in the ORF57 protein (among 
others) resulting in diminished nucleolar localization while retaining nuclear localization 
(173).  Through alignment of various proteins containing NoLSs, Weber et al. (174) 
identified a common NoLS motif (R/K)(R/K)X(R/K).  This highly conserved sequence 
was also noted by Horke et al. after finding it to be important for nucleolar localization in 
the human La protein (175).  Although there is still not a consensus NoLS, and the 
nucleolar targeting is not as well characterized as other signals, the addition of short 
NoLS sequences have been demonstrated to direct proteins to the nucleolus (172, 176), 
validating their use in targeting the nucleolus. 
 Proteins without an identifiable NoLS have been shown to localize to the 
nucleolus via interactions with other molecules at the nucleolus.  One such example is 
nucleolin, a protein which may localize to the nucleolus partially due to RNA binding.  
However, the RNA binding domains are not sufficient to cause nucleolar localization of 
chimeric proteins (177).  Additionally, NoLS-containing proteins, such as NPM (178) 
and NOM1 (179), have been shown to bind and cause a nucleolar localization of proteins 
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that do not contain a NoLS, further expanding the mechanisms for nucleolar localization.  
Emmott and Hiscox (171) have recently proposed that nucleolar hub proteins play an 
essential role in nucleolar localization.  Thus, nucleolar targeting can be achieved through 
NoLSs, by being dragged by a NoLS-containing protein, or potentially by binding to a 
nucleolar hub protein. 
 There are relatively few drugs that target the nucleolus or nucleolar components 
specifically, but actinomycin D has been shown to induce nucleolar segregation due to 
the inhibition of rDNA transcription (180, 181).  Phosphorylation is a critical 
modification in the regulation of nucleolar proteins, and kinase inhibitors have drastic 
effects on the nucleolus (182-184).  One such inhibitor, the casein kinase inhibitor 5,6-
dichloro-1-ribo-furanosylbenzimidazole (DRB), causes the nucleolus to disassemble 
(185).  An example of a more specific interaction involving a potential nucleolar 
targeting therapeutic is the peptide consisting of amino acids 26-46 of the p19ARF protein 
(186).  This peptide, modified with additional arginine residues to increase cellular 
uptake, has been shown to bind Foxm1b and send it to the nucleolus where it is unable to 
function as a transcription factor.  Foxm1b has been shown to have a key role in the 
development of hepatocellular carcinoma (187), and the nucleolar sequestration of 
Foxm1b presents a novel therapeutic intervention. 
 
Mitochondria 
Mitochondria contain a double membrane composed of phospholipid bilayers 
with proteins embedded in them.  This results in two aqueous spaces; the matrix and the 
intermembrane space.  The inner membrane contains the proteins involved in the 
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respiratory chain complex, ATP synthase and protein import machinery.  The human 
mitochondrial matrix encloses a small genome (mtDNA) coding for 13 hydrophobic 
proteins, 22 tRNAs and two rRNAs (188, 189).  The 13 hydrophobic proteins encoded in 
the matrix are all involved in the electron transfer system.  The matrix is also the site for 
the citric acid cycle, urea cycle and fatty acid oxidation.  Therefore, mitochondrial 
dysfunction contributes to a range of human diseases including obesity, diabetes and 
cancer.  Mitochondrial targeting is mainly performed to interrupt mitochondrial function 
including energy production, oxidative stress and the apoptotic pathway.   
 
Mitochondrial Function 
The mitochondria maintain an acidic inner space and an electrochemical potential 
across the inner membrane, which are utilized by the electron transport system to transfer 
electrons to oxygen.  The electron transport chain passes electrons from the reducing 
equivalents to oxygen.  During this process, protons are pumped from the matrix to the 
intermembrane space via NADH dehydrogenase, cytochrome c reductase, and 
cytochrome c oxidase.  As a result, an electrochemical gradient is established, which 
activates ATP synthase to pump protons back in and activates ADP to ATP as the energy 
source for the cell (190).  
In the mitochondrial respiratory chain, oxygen is partially reduced to form 
reactive oxygen species (ROS) activating the proton leak uncoupling proteins, which 
pump protons back into the matrix without forming ATP (191-193).  Superoxides are also 
converted to other ROS such as hydroxyl radicals, which contribute to a number of 
degenerative diseases (194-198).  The oxidative damage, which increases with ageing, 
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also affects lipids, proteins and DNA leading to a decline in the efficiency of oxidative 
phosporylation (195, 199).  Mitochondria destroy the free radicals using antioxidants 
(e.g., vitamin E, ascorbate, ubiquinol), which scavenge ROS, converting them to less 
reactive species or prevent oxidative damage.  Therefore, antioxidants have been used as 
supplements to specifically target the mitochondria (reviewed in (200)).  
Apoptosis is frequently triggered through the mitochondria after collapse of the 
inner transmembrane potential, disruption of electron transport and ATP production, 
oxidative stress, permeability transition pore opening, or mitochondrial swelling with 
outer membrane rupture.  When the outer mitochondrial membrane undergoes 
permeabilization, cytochrome c is released from the intermembranous space into the 
cytosol activating caspase-3 via the Apaf-1 pathway (201-203).  Mitochondrial outer 
membrane permeabilization is commonly disabled in cancer cells and hence its 
pharmacological induction constitutes a therapeutic goal (204).  Bcl-2 and Bcl-XL are 
mitochondrial proteins that inhibit apoptosis by inhibiting Bax and Bak oligomerization 
(205-209).  
 
Mitochondrial Import Machinery 
Drugs targeting mitochondria are necessary to induce apoptosis in cancer cells as 
well as to protect cells from oxidative damage and to repair defects.  The outer membrane 
of the mitochondria allows diffusion of small molecules through pores formed by 
spanning beta barrel protein called porin.  Simple ions with localized charge such as Cl+, 
Na+ or Ca2+ require translocators or energy-dependent transporters to allow them to cross 
into the matrix (reviewed in (210)).  However, ions with delocalized charge and cationic 
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hydrophobic molecules such as triphenylphosphonium (TPP) can diffuse across the 
mitochondrial membrane taking advantage of the hydrophobic nature of the membrane 
(211-213).  Conjugating antioxidants to TPP or a methyl derivative (TPMP) increases 
their accumulation within the mitochondria and selectively blocks mitochondrial 
oxidative damage (Table 2.3).  TPP cation have been covalently attached to antioxidants 
such as ubiquinol (MitoQ) (214-216) and α-tocopherol (MitoE) (217).  The same concept 
has been utilized to target DNA to the mitochondria using dequalinium, a delocalized 
cationic lipid (218).  It crosses the plasma membrane by endocytosis, and then DNA is 
released upon interacting with the mitochondrial membrane (219).  
Large molecules (e.g., proteins) exploit the mitochondrial protein import 
apparatus to cross the outer and inner membrane.  The TOM complex (translocase of the 
outer membrane of mitochondria) is the molecular machine responsible for translocating 
proteins across the mitochondrial outer membrane.  The TOM complex contains receptor 
subunits, Tom70 and Tom20, which recognize proteins destined for import (220, 221).  
Other TOM complex components, Tom40, Tom22, Tom7, Tom6, and Tom5, assist the 
transfer of the protein into the intermembrane space (222-224).  The TIM complex 
(translocase of the inner membrane of mitochondria) binds to proteins destined for 
localization to the inner membrane and the matrix through TIM22 and TIM23, 
respectively (222, 225).  The TIM22 complex translocates proteins depending on the 
electrochemical potential across the inner membrane.  However, the TIM23 complex 
drives the protein trafficking via a motor complex built around a mitochondrial Hsp70 
(221).  Mitochondrial targeting signals (MTSs) are mainly N-terminal cleavable amino 
acids 15-40 residues in length, which are positively charged with a notable absence of 
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Table 2.3. Mitochondria targeting signals/motifs and delivered therapeutic agents. 
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negatively charged residues (234).  These MTSs forming amphipathic α-helices are 
thought to be important for their recognition by the translocation machineries in the 
mitochondrial outer (TOM complex) and inner (TIM complex) membranes (221, 225, 
235-238).  Once the protein is translocated into the matrix, the targeting signal is 
proteolytically removed by mitochondria processing peptidase (MPP) (239, 240).  
Nevertheless, a significant fraction of mitochondrial proteins, especially proteins of the 
outer membrane, the inner membrane space, and the inner membrane, lack typical N-
terminal sequences and are targeted to the mitochondria by means of internal, 
noncleavable signals known as “carrier sequence motifs” (241, 242).  These internal 
signals resemble the N-terminal sequence and are recognized by the TOM machinery 
(243-245).  The internal signals function in combination with a preceding hydrophobic 
region (246).  
Attaching MTSs to essentially any protein, DNA or RNA enables mitochondrial 
targeting (232, 233, 247-249) (Figure 2.2C and D).  MTS has also been fused to 
restriction enzymes such as Sma1 endonuclease to degrade mutant mtDNA in NARP 
disease (250).  Targeting proteins such as p53 to the mitochondria induces apoptosis by 
complexing with Bcl-XL proteins.  The inactivation of Bcl-XL induces conformation 
change and oligomerization of the BH123 effector protein Bak and Bax, which then 
forms a pore in the outer membrane facilitating the release of cytochrome c (251-253).  
We are currently investigating the fusion of a strong NES to small proteins tagged with 
MTS to reduce nuclear localization and increase their availability in the cytoplasm to 
target the mitochondria (unpublished data).  The effect of the different subcellular signals 
in a protein and the outcome of having multiple signals is a largely unexplored area, and 
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warrants attention. Table 2.3 lists examples of chemical (TPP) and biological (MTS) 
means to target therapeutics to the mitochondria.  
 
Endoplasmic Reticulum 
The endoplasmic reticulum (ER) is an organelle found in all eukaryotic cells.  Its 
membrane represents as much as half of the total membrane of an average animal cell.  It 
extends from the nuclear envelop to the cell periphery intertwining with most cellular 
organelles, including the mitochondria, peroxisome and the Golgi apparatus (254).  
Regions of the ER that are coated with ribosomes are called rough ER, where proteins are 
imported into the ER in a co-translational process.  In co-translational transport, one end 
of the protein is translocated into the ER while the rest of the protein is being assembled 
in the ribosome.  Smooth ER is the region that lacks bound ribosomes.  An essential 
function of the ER is the biosynthesis of proteins and lipids that are destined for 
intracellular organelles and the cell surface (255).  It also controls Ca2+ signaling via its 
Ca2+-binding proteins and homeostasis (256).  
 
ER Targeting 
The co-translational targeting of proteins to the ER membrane (transmembrane 
proteins) and lumen (water soluble proteins) is mediated by a cytosolic ribonucleoprotein 
called the signal recognition particles (SRPs) and their cognate membrane-associated 
receptors (SRs) (257-259).  One end of the SRP binds to the ER signal sequence as they 
emerge from ribosomes, while the other end of the SRP blocks the translational 
elongation in the ribosome halting protein synthesis (260-263).  The signal sequence 
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consists of 7-12 large hydrophobic residues that presumably form an α-helix (263-267).  
The SRP-ribosome complex is then directed to the ER membrane by binding to the SRP 
receptor, which is an integral membrane protein complex embedded in the rough ER 
membrane (258, 268-271).  This binding releases the ribosome complex to the integral 
membrane protein Sec61 translocation complex (translocon), allows the translational 
elongation to continue and recycles the SRP back to the cytosol (272, 273).  
The ribosomal exit tunnel is aligned to a water filled pore in the translocon 
through which the protein is translocated and continues being translated.  Subsequently, 
the signal sequence is cleaved via an ER signal peptidase and released into the 
membrane, where they get degraded by other proteases.  The translocon also allows a 
translocating protein lateral access into the hydrophobic core of the membrane for both 
integration of membrane proteins into the bilayers (via either a stop transfer sequence or a 
signal anchored sequence) and the release of the cleaved signal peptide into the 
membrane (for review see (274, 275)).  The ER is not limited to co-translational targeting 
of proteins; some post-translational proteins are imported into the ER in a SRP-
independent mechanism, where they depend on the hydrolysis of ATP and the binding to 
cis-acting molecular chaperones such as heat shock cognate protein 70 (Hsp70) (276-
281).  The signal sequences in this category are no more than 70 amino acid residues in 
length (279, 282).  
The ER signal sequences have substrate-specific differences, which may have 
functional consequences (283, 284).  The signal sequences may differ in their gating of 
the translocation complex (285, 286), dependency on the translocon-associated proteins 
(287, 288), translocation efficiency of proteins (289-291), or sensitivity to translocation 
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inhibitors (292, 293). Table 2.4 lists examples of ER signal sequences fused to 
therapeutic proteins.  
 
ER Function 
Nearly one third of the eukaryotic genome is processed through the ER (294).  
The transferred transmembrane proteins either function in the ER or reside in the 
membrane of other organelles or the plasma membrane.  Similarly, the water-soluble 
proteins are either secreted to the cytosol or transferred into the lumen of other 
organelles.  Transmembrane proteins directed to the ER include plasma and organelle 
membrane receptors and channels that regulate metabolic pathways, regulate cell to cell 
communication and flow of ions and solutes and mediate protein and lipid uptake from 
the surrounding cellular environment.  In addition, secreted proteins and enzymes are 
required for cell communication with its surrounding and to support sorting, metabolic 
and catabolic activities (For review see (295)).  Therefore, a wide range of diseases occur 
due to mistakes in protein handling in the ER such as cystic fibrosis, liver failure, 
Alzheimer, Parkinson and diabetes mellitus (296-304) (For a list of diseases see (295)).  
 
The Golgi Apparatus 
The Golgi apparatus is known typically for posttranslational modifications and 
shipping macromolecules to the plasma membrane, lysosomes, or outside of the cell in 
secretory vesicles.  Thus, the Golgi apparatus ships molecules in the opposite direction of 
drug delivery.  Major players in this process, such as mannose 6-phosphate receptors 
(MPRs), are recycled back to the trans-Golgi network in a retrograde fashion (305-307) 
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Table 2.4. Endoplasmic reticulum targeting signals/motifs and delivered therapeutic 
agents. 




Mammalian prion protein (PrP) (308) 
ALAAALAAAAA G-protein coupled receptors (GPCR) (309) 
MRVLVLLACLAAASNA Recombinant proteins in baculovirus 
expression vector system 
(310) 
MLLPVPLLLGLLGLAAAL 
And KDEL (ER retention) 
Human papilloma virus (HPV-16) E7 
antigen 
(311) 
MRYMILGLLALAAVCSAA Vesicular somatic virus nucleocapsid 
protein and influenza virus 
nucleoprotein 
(312, 313) 










demonstrating the potential for use in therapeutic targeting of the Golgi apparatus.  
However, this recycling pathway involves late endosomes (305, 316, 317) with the 
associated low pH and degradative enzymes that therapeutic delivery systems may want 
to avoid.  However, retrograde delivery to the Golgi apparatus directly from early 
endosomes or recycling endosomes has been characterized with toxic proteins such as 
shiga and cholera toxins (318, 319).  The receptor for these toxins is a glycolipid 
(globotriaosyl ceramide) that uses a pH-independent pathway (319) to target the Golgi 
apparatus that may have therapeutic potential.  While clathrin is critical for efficient 
transport of shiga toxin (320), ricin has been shown to transport to the Golgi apparatus 
independent of clathrin and Rab9-GTPase (321), in a process regulated by cholesterol 
(322).  Other proteins have also been shown to shuttle between the plasma membrane and 
the Golgi apparatus.  One such example is a protein commonly used as a marker for the 
trans-Golgi network named TGN38/41, a receptor for p61 protein complexes and GTP-
binding proteins, important in the formation of exocytic vesicles (323).  Other examples 
are furin (324) and carboxypeptidase D (325). 
 The signaling sequences used by these proteins to target the Golgi apparatus are 
not well characterized and no specific consensus sequence has been proposed.  However, 
tyrosine-containing motifs such as that found in TGN38/41 (SDYQRL) is one signal 
responsible for Golgi apparatus localization.  Attachment of this signal to the LDL 
receptor has resulted in the localization to the Golgi apparatus (326).  It has been shown 
that furin has two specific signals that target the Golgi apparatus:  the acidic sequence 
CPSDSEEDEG, which is sufficient to cause localization to the Golgi apparatus, and the 
tyrosine-containing sequence YKGL, which has been proposed to function as a retrieval 
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signal through targeting of endosomes (327, 328).  The localization of furin to the Golgi 
apparatus, and its shuttling to and from endosomes, is further dependent on 
phosphorylation by casein kinase II (CKII) at serine residues in the acidic cluster motif, 
and dephosphorylation by protein phosphatase 2A (PP2A) (329, 330), highlighting the 
role of posttranslational modifications on localization and not just specific amino acid 
sequences.  A similar mechanism for targeting the Golgi apparatus via a tyrosine motif 
and a phosphorylation site has been demonstrated for the varicella-zoster virus 
glycoprotein I (VZV gpI) (331).  While sequences targeting the Golgi apparatus have 
been studied and identified, little effort has been put forth to harness these signals for 
therapeutic delivery to the Golgi apparatus, leaving much to be explored. 
 Although the Golgi apparatus may not be the target of the therapeutic, delivery of 
therapeutics via the B subunit of Shiga toxin which enters the cell through the retrograde 
pathway involving the Golgi apparatus have been studied for vaccination, targeted killing 
of cancer cells, and imaging of cancer cells.  Although the mechanism has not been 
delineated entirely, the MHC class I pathway involves the retrograde pathway through 
the Golgi apparatus, and Shiga toxin subunit B (STB) or Shiga-like toxin subunit B 
(SLTB) thus has been conjugated to various antigens for tumor protection (332-336).  
The receptor that binds ST/SLT is the globotriaosylceramide (Gb3) found to be 
overexpressed on many tumor cells, allowing the retrograde pathway with ST/SLT or 
STB/SLTB to be used for tumor imaging (337) and targeted delivery of cytotoxic agents 
for colon (338), ovarian (339), and breast cancer (340), as well as lymphoma (340, 341), 
astrocytoma (342), and meningoma (343).  Finally, since the Golgi apparatus has been 
described to exhibit a mechanism for stressed-induced initiation of apoptosis (344), this 
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validates future attempts at targeting therapeutics to the Golgi as a mechanism for 
specific induction of apoptosis in malignant cells.   
 
Peroxisomes 
The peroxisomes are multifunctional, single-membrane enclosed, spherical 
vesicles distributed throughout the cytoplasm (345).  Their numbers vary in different cell 
types and under different stimuli.  The term “peroxisome” was coined due to the fact that 
hydrogen peroxide is formed and degraded in the organelle.  Peroxisomes are responsible 
for a wide variety of biochemical and metabolic pathways, with implications for human 
health.  Aging and several diseases are associated with dysfunction of the peroxisomes, 
which has made it an interesting pharmaceutical target.   
 
Peroxisomal Function 
A major function of the peroxisome is the breakdown of a variety of fatty acids 
via α- and β-oxidation reactions.  Similar to mitochondrial β-oxidation, fatty acids are 
broken down two carbons at a time in the form of acetyl-CoA.  However, fatty acids 
containing a methyl group at the 3-carbon position must be modified before entering the 
peroxisomal β-oxidation pathway (346).  Many of the metabolic pathways in the 
peroxisomes lead to hydrogen peroxide production, which is subsequently metabolized 
by the peroxidase catalase.  Peroxisomes also play a role in the production of bile acids, 




Peroxisomal Import Machinery 
The import machinery to the peroxisomal matrix requires (1) cargo containing 
specific targeting signals, (2) receptors that recognize specific signals, (3) membrane-
associated import via docking and translocating proteins and (4) cargo release (reviewed 
in (347)).  Cytosolic proteins require specific targeting signals recognized by receptors 
for peroxisomal targeting. Two types of peroxisomal targeting signals exist: type I 
(PTS1) and type 2 (PTS2).  PTS1 is the most abundant, which consists of a tripeptide 
(SKL) or a conserved biochemical variant (consensus S/A/C-K/R/H-L/M) at the extreme 
C-terminus of the protein (348-350).  An additional adjacent upstream region to the PTS 
also influences the interaction between receptor and PTS (350-352).  In contrast, PTS2 
consists of less conserved consensus sequence (R/K-L/I/V-X5-Q/H-L/A, where X may be 
any amino acid) and is coded close to the N-terminus (353-355).  For a list of bona fide 
peroxisomal proteins and their PTSs, review (356). 
 Specific proteins called receptor peroxins (Pex5p and Pex7p) bind to the proteins 
harboring PTS in the cytosol, which then target the peroxisomal membrane as a 
receptor/cargo complex.  PTS1 is recognized by Pex5p while Pex7p recognizes PTS2 
(353, 357-359).  Pex5p is retained in the cytosol in the tetramer form.  Upon binding to 
proteins containing PTS1, Pex5p disaggregates into dimers (360).  Each dimer carrying 
two cargo proteins are then transported to the peroxisome.  Subsequently, the 
receptor/cargo complex binds to membrane-associated peroxins (docking proteins), in 
particular Pex8p, Pex13p, Pex14p and Pex17p (361).  The remaining membrane-
associated peroxins (Pex2p, Pex10p and Pex12p) form the RING-finger subcomplex.  
Both the docking proteins and the RING-finger complex form the putative import 
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complex (importomer) which is thought to advance translocation (362).  The precise 
mechanism for the peroxisomal protein import machinery remains ambiguous.  The 
uniqueness in this mechanism is highlighted in its ability to transport folded, co-factor-
bound and oligomeric proteins (363).  There are two proposed models on the receptor’s 
cycle between the cytosol and the peroxisome.  The model of shuttling receptors states 
that the cargo dissociates from the receptor upon binding to the docking proteins (353, 
364).  The cargo is then translocated across the peroxisomal membrane while the receptor 
is released back to the cytosol.  Alternatively, the extended shuttle hypothesis assumes 
that the dissociation between the cargo and receptor takes place in the peroxisomal matrix 
allowing the unloaded receptors to transport back to the cytosol (365-367).   
Targeting the peroxisomal membrane (without translocating to the matrix) 
follows a different import mechanism.  Peroxisomal membrane proteins (PMPs) require 
membrane protein targeting signals (mPTS).  These signals contain a cluster of basic 
amino acids in conjunction with one or more transmembrane region downstream from it 
(368-371).  The mPTS is recognized by Pex19p receptor in the cytosol, which then binds 
to Pex3p on the peroxisomal membrane.  However, the exact mechanism on how PMPs 
are transported to the peroxisomal membrane is still unknown.  There is also a possible 
but controversial involvement of the endoplasmic reticulum in PMP trafficking (347, 
372-374).  The importomer plays an important role for matrix targeting but not for 
membrane protein import.   
 Peroxisomal disorders are due to either mutations in peroxins (peroxisomal 
biogenesis disorder, PBD) or deficiencies in peroxisomal enzymes (reviewed in (375)).  
PBDs are categorized by means of clinical severity into the Zellweger spectrum of 
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disease [Zellweger syndrome, neonatal adrenoleukodystrophy (NALD) and infantile 
Refsum’s disease (IRD)] or rhizomelic chondrodysplasia punctata (RCDP) type I.  For 
example, a defect in the Pex7p disrupts enzymatic pathways for enzymes containing 
PTS2 causing RCDP type I.  In addition to peroxins mutations that affect enzymes 
delivery to the peroxisome, single peroxisomal enzyme deficiencies have been linked to a 
number of human diseases such as adult Refsum’s disease, X-linked 
adrenoleukodystrophy, RCDP type II and III, primary hyperoxaluria type I, acatalasemia, 
etc. (for a full list of diseases, see (375)).   
 
Peroxisomal Targeting 
Specific targeting to the peroxisome is of great clinical value to restore, alter or 
complement peroxisomal function.  It could be used in the treatment of single enzyme 
deficiencies, PBD, as well as diseases associated with altered ROS (375).  Tagging 
protein therapeutics or peroxisomal enzymes to a PTS is required to achieve peroxisomal 
targeting.  The carboxy-terminal PTS1 (SKL or related sequence mentioned above) is 
better characterized and is easily tagged onto a protein of interest using standard 
recombinant molecular cloning techniques.  The adjacent upstream region influences the 
receptor/PTS interaction and can be evaluated using a computer program 
(http://mendel.imp.ac.at/pts1/), which can also predict the relative strength of a PTS1.  To 
be recognized by Pex5p, accessibility of the PTS1 (not buried in the folded protein) is 
also crucial.  Therefore, a spacer between the PTS1 on the carboxy terminal and the 
protein could be introduced.  Table 2.5 lists therapeutic proteins delivered to the 
peroxisome via PTS1.   
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Table 2.5.  Peroxisomal targeting signals and therapeutics delivered. 
Targeting Motif Therapeutic References 







AKL vs.  NKF Catalase (380) 
 
 
Proteasomal Function, Inhibition, and Potential Drug Delivery 
The proteasome is an ATP-dependent protease that functions to remove (degrade) 
abnormal proteins found in the cytosol, nucleus, or ER.  The entire proteasome (26S 
proteasome) consists of the 20S proteasomal core, capped by two 19S regulatory subunits 
on each end.  Polyubiquitination of proteins triggers degradation by the 26S proteasome 
complex (18).  The proteasome has become a popular target for drug therapy, since 
inhibiting the proteasome can be used for treatment of inflammatory diseases and cancer 
(381); on the other hand, activation of the proteasome has therapeutic use in 
neurodegenerative diseases (382).   
Synchronized synthesis and degradation of regulatory proteins is necessary for 
cells to function and progress through the cell cycle.  In the case of tumor development, if 
the degradation of these proteins can be blocked, apoptosis will ensue.  Rapidly dividing 
cancer cells are more susceptible to proteasomal inhibition since they have more 
disruptions in their normal regulatory pathways than noncancerous cells (383).  
Bortezomib is the first small molecule inhibitor of the ubiquitin-protease system to be 
approved for treatment of multiple myeloma (384, 385).  While bortezomib targets the 
20S subunit of the proteasome, many other drugs are being developed to target other 
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components of the proteasome (386, 387) and other components (ubiquitin ligases, 
ubiquitin activating and conjugating enzymes) of the proteasomal degradation pathway 
(388).  In addition, aberrant proteins could be sent to the proteasome for degradation.  
One focus of our laboratory is a gene therapy approach to capture oncogenic proteins and 
send them to the proteasome for degradation. 
 
Future Perspectives 
While unidirectional targeting of a therapeutic agent to single organelles has been 
well-studied and utilized, multi-directional drug targeting, utilizing multiple signals, 
represents a more sophisticated level of targeting which mimics the complexity of nature.  
In nature, many signal transducing proteins are not simply directed to one compartment 
of a cell.  They may interact with other proteins in multiple compartments of a cell.  For 
example, p14/19 ARF protein can bind Mdm2 (a nucleocytoplasmic shuttling protein) to 
inhibit degradation of p53 by Mdm2.  The p14/19 ARF protein also contains a nucleolar 
signal, which can re-direct the p14/19 ARF-Mdm2 complex to the nucleolus (389-391). 
 While we have already demonstrated that unidirectional targeting of an oncogene 
can dramatically alter its function (4), our ultimate goal is to utilize our protein switch 
technology to capture an endogenous protein in one compartment, and move it to another 
compartment (6, 7).  Our laboratory is pursuing this approach for treatment of chronic 
myelogenous leukemia (CML).  Bcr-Abl, the causative agent of CML, is found in the 
cytoplasm of CML cells, where it sends oncogenic signals to other proteins in the 
cytoplasm.  If endogenous Bcr-Abl can be captured and dragged to the nucleus of cells, 
apoptosis will ensue due to loss of oncogenic signaling in the cytoplasm, and gain of 
 102 
apoptotic function in the nucleus.  Like nature, the protein switch was designed to 
regulate cellular proteins by changing their location and hence their function.  The protein 
switch has the advantage of being regulated by an externally added ligand.  The protein 
switch contains a dimerization domain (to capture the endogenous protein of interest), a 
nuclear export signal (conferring cytoplasmic localization), and a ligand-regulated 
nuclear import signal.  Upon addition of ligand, the protein switch is designed to 
translocate from the cytoplasm to the nucleus, and drag its dimerization partner with it. 
 Other groundbreaking studies have included the concept of delivering drugs to 
multiple compartments (across multiple barriers) by mimicking viral delivery.  A review 
by Wagner (392) discusses mimicking viral delivery of DNA to the cytoplasm, and into 
the nucleus.  There are even virus-mimetic nanogels that can deliver drugs to target and 
neighboring cells (67).   
The future of drug delivery to organelles lies in our ability to more closely mimic 
nature, or even improve on nature.  Spatial placement of signaling sequences in a protein, 
balancing the strengths of different signals against each other, and the 
masking/unmasking of signals due to conformational changes in an engineered protein or 
therapeutic have not been fully explored or understood.  The ability to harness genetic 
codes, signal sequences, targeting motifs, or protein-protein interactions will lead to 
enormous complexity and diversity for drug delivery. 
 
Executive Summary 
1. For maximum therapeutic effect and minimal side effects, drugs need to be 
delivered to the appropriate location within the cell. 
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2. The cytoplasm and nucleus are the most widely targeted organelles, and the most 
well-studied. 
3. Cytosolic targeting is crucial before most drugs can reach any organelle within the 
cell. 
4. Drug carriers are still in progress to overcome barriers for cytosolic delivery and 
endosomal escape. 
5. Localization and export of proteins to and from the nucleus can also be blocked 
using molecules that inhibit either the import or export mechanism. 
6. Gene delivery mainly targets the nucleus, while a few studies are targeting DNA 
to the mitochondria. 
7. Targeting other organelles is under investigation, especially the mitochondria due 
to its rule in oxidative stress and apoptosis. 
8. Manipulating current therapeutics with specific targeting signals ensures 
accumulation in certain compartments within the cell. 
9. Capturing and sending oncogenic proteins to the proteasome is a promising 
approach for cancer therapy. 
10. Proteins synthesized at the ER are destined for intracellular organelles and cell 
membrane. 
Newer technologies (protein switch, virus-like delivery systems) mimic nature 
and allow for a more sophisticated approach to drug delivery.  Harnessing different 
methods of targeting multiple organelles in a cell will lead to better drug delivery and 
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REVERSAL OF OXIDATIVE STRESS IN ENDOTHELIAL CELLS 
BY CONTROLLED RELEASE OF ADIPONECTIN 
 
Abstract 
Hyperglycemia causes endothelial dysfunction due to its effect on increasing 
reactive oxygen species (ROS). Adiponectin (Adp) has been reported to suppress 
hyperglycemia-associated ROS-generation. It was hypothesized that administering 
globular adiponectin (gAdp) via injectable biodegradable thermosensitive triblock 
copolymer might effectively reduce ROS generation in endothelial cells. In this study, 
gAdp was incorporated into and released from the polymer gel. The released gAdp was 
further investigated by comparing it with the intact gAdp with regard to the efficiency in 
reducing ROS and activating cAMP. The released gAdp effectively suppressed excess 
ROS-production in the in vitro endothelial cell culture model under high-glucose 
condition via cAMP/PKA pathway.  These data provide a rationale for developing 
controlled release dosage form of gAdp as a therapeutic tool for oxidative stress-related 
pathology in patients with diabetes. 
 
Reprinted by permission from the Journal of Controlled Release 130: 234-7 (2008). 
Mossalam M., Jeong J., Abel E.D., Kim S.W., Kim Y. 
M.M. performed the experiments and wrote the first draft. The rest of authors contributed 
with scientific discussion and feedback. 
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Introduction 
Hyperglycemia is one of the main causes of vascular complications in diabetic 
patients due to its effect on increasing ROS-production, which causes endothelial 
dysfunction (1-3). In blood vessels, ROS have been implicated in the pathogenesis of 
hypertension, vascular lesion formation, atherosclerosis, and diabetic vascular disease (4-
8). Consequently, a novel approach to restore vascular function in diabetes might be to 
reduce mitochondrial ROS-overproduction.  
Adiponectin (Adp) is a circulating hormone secreted by adipose tissue that plays a 
key role in glucose homeostasis and fatty acid metabolism (9). Adp levels are reduced in 
patients with obesity and cardiovascular disease (10, 11). Studies have shown the 
potential role of Adp in coronary artery disease patients with diabetes by suppressing 
ROS generation (12-15). Adp has also been very recently recognized to suppress 
hyperglycemia-associated ROS-generation via a cAMP-dependent protein kinase (PKA) 
pathway (16).  
Adiponectin could be administered using an injectable biodegradable 
thermosensitive triblock copolymer delivery system. The copolymer, which is composed 
of hydrophilic poly (ethylene glycol) (PEG) B-block and hydrophobic poly (lactide-co-
glycolide) (PLGA) A block, allows the delivery of insoluble or unstable substances by 
generating a hydrogel depot at body temperature (17, 18). It has also been used to 
enhance gene delivery efficiency (19). Potentially, these copolymers were proved to be 
valuable components of controlled delivery systems or site-specific administration of 
therapeutics (20, 21). 
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The aim of this study was to develop and characterize a controlled drug delivery 
system containing gAdp, and test the hypothesis that administering gAdp via a polymer 
gel might effectively reduce ROS-generation in endothelial cells and therefore lead to 
recovery of endothelial dysfunction. We investigated the antioxidant effect and 
mechanism of action of released gAdp by the copolymer on reducing ROS in Bovine 
Aortic Endothelial Cells (BAEC). This study investigates a new therapeutical advantage 
in gAdp delivery and also provides the framework for further work involving in vivo 
studies. 
  
Materials and Methods 
BAECs were obtained from Cambrex Bio Science Walkersville, Inc. Cell culture 
materials were from Invitrogen (Carlsbad, CA). The copolymer (ReGel® R40/60) was 
kindly provided by MacroMed, Inc (Salt Lake City, UT), Chen S., et al. has detailed 
synthesis and characterization of the copolymer (22). The mouse recombinant gAdp (16.6 
kDa in E. coli host) and fAdp (35kDa in HEK 293 cells host) were from Kamiya 
Biomedical Company (Seattle, WA). All other chemicals and reagents, unless otherwise 
noted, were obtained from Sigma (St. Louis, MO). 
 
Cell Culture 
BAECs were cultured in Dulbecco’s modified eagle medium (DMEM) containing 
10% fetal bovine serum (FBS), and 1% penicillin-streptomycin. Cells were routinely 




In Vitro ROS Measurements 
BAECs at a density of 2×105 cells/well in 6 well plates were treated under 
different glucose concentrations: 0 mM (as a negative control), 15 mM, and 25 mM (as a 
positive control). The 25 mM glucose treated cells were then treated with 2 µg/ml, 
3µg/ml, 4.5µg/ml, 7 µg/ml and 9µg/ml globular adiponectin (gAdp), and 4.5 µg/ml 
released globular adiponectin from the polymer gel (rAdp) to measure the effect of 
adiponectin on the hyperglycemic-induced ROS. The cells were cultured for 36 hours, 
then treated with 10 µM 5-(and-6)-chloromethyl-2`,7`-dichlorodihydrofluorescein 
diacetate, acetyl ester (CM-H2DCFDA) for 30 minutes. They were then suspended in 
Phosphate-Buffered Saline (PBS). The fluorescence was then measured using flow 
cytometry. The higher the fluorescence, the greater the ROS production (23). 
 
Measurements of Cellular cAMP 
BAECs at a density of 2×105 cells/well were cultured under the same conditions 
as in the in vitro ROS studies. cAMP was then measured by following the manufacturer’s 
instruction using a direct immunoassay kit (BioVision) (24). 
 
In Vitro Release Study of gAdp from the Copolymer 
Firstly, 25 µg gAdp were dissolved in 0.5 ml the copolymer and incubated in a 
37°C water bath. Once gel is formed, 1 ml of PBS was added to and removed from the 
vial containing the polymer gel every 24 hours. The released protein was quantified using 
Adiponectin ELISA kit (B-Bridge International) and then concentrated at different time 
 143 
intervals using centriprep (Amicon) to further investigate its activity. SDS was performed 
on the concentrated protein (25). 
 
Statistical Analyses 
Quantitative data are presented as means ± SD as indicated from the number of 
experiments. Statistical analysis was based on Student’s t-test for comparison of two 
groups. A p value less than 0.05 was used to determine statistical significance. 
  
Results and Discussion 
The method used to measure ROS-overproduction was confirmed by testing the 
effect of gAdp on reducing ROS. BAECs were incubated in different concentrations of 
glucose. There was an increase in the ROS-production with the glucose treated cells in a 
dose dependent manner up to 7.5 fold (P < 0.05) (Figure 3.1). However, when using 
mannitol at the same concentrations, there was no significant difference in the ROS 
ruling out any osmotic effect. Hyperglycemia induces ROS-overproduction through 
several pathways. A major mechanism is through the overproduction of the superoxide 
anion (O-2) by the mitochondrial electron transport chain (26). 
Incubating the cells in 25 mM glucose medium puts the cells in hyperglycemic 
condition. The high-glucose treated cells followed by the incubation with gAdp showed 
reduction in ROS-production in a dose dependent manner with optimum effect at 4.5 
µg/ml concentration (Figure 3.2). It had no effect on the no-glucose treated cells showing 




Figure 3.1. Glucose effect on ROS production. After treatment with glucose, ROS was 
measured via FACSCAN. Mannitol had no effect on ROS. Data are expressed as the 
percent of basal (0mM glucose) and represent the means ± SD of n=3. *P<0.01 and 
**P<0.001 vs. basal. Statistical analysis was corrected after publication. A one-way 
ANOVA was performed with Bonferroni’s multiple comparison test. 
 





Figure 3.2. The gAdp dose response in reducing ROS, induced by high glucose in 
endothelial cells. After treatment, ROS was measured via FACSCAN. The gAdp showed 
no effect on 0 mM treated cells. Data are expressed as the percent of basal (0mM 
glucose) and represent the means ± SD of n=3. *P<0.01 and **P<0.001 vs. glucose 
treated cells. Statistical analysis was corrected after publication. A two-way ANOVA was 




  ** 
      * 
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     The controlled delivery system containing gAdp was developed by solubilizing the 
protein in the polymer gel. In vitro release of gAdp from the polymer gel and its activity 
on ROS and cAMP were tested to characterize and prove the efficacy of the delivery 
model. The release profile showed almost 100% release of the 25 µg gAdp (Figure 3.3) 
over 27 days without initial burst release. The protein was released in a first order manner 
in the first 5 days, then in a zero-order manner in the following 10 days, and then in a 
zero-order manner with a different release rate in the final 12 days. The protein is 
released from the gel upon degradation of the copolymer. The released protein was then 
concentrated using centriprep (Amicon) to further investigate its activity. The SDS PAGE 
performed on the released Adp at different time intervals did not show any degradation or 
aggregation, which shows the stability of the released protein from the polymer gel 
(Figure 3.4).  
The released gAdp (rAdp) from the copolymer was compared to the activity of 
the intact gAdp. It showed that the released gAdp had the same effect as the intact gAdp 
on reducing ROS in endothelial cells with no significant difference (Figure 3.5). These 
results represent the potential of the triblock copolymer as a safe delivery carrier for the 
gAdp. 
cAMP was measured in high glucose induced cells treated with either gAdp or 
rAdp. The gAdp and rAdp showed the same effect on increasing the cellular content of 
cAMP with no significant difference (Figure 3.6) proving the pathway in which gAdp 
reduces ROS and the preservation of the activity of the released gAdp. The rAdp had no 




Figure 3.3. In vitro release study of 25 µg gAdp from injectable, biodegradable, and 
thermosensitive triblock copolymer. The gAdp is fully released over the 27 days. The 





Figure 3.4. SDS PAGE for the released adiponectin compared to the intact adiponectin. It 




Figure 3.5. Effect of the released gAdp (rAdp) from the polymer gel on reducing ROS 
compared to the intact gAdp. Data are expressed as the percent of basal (0mM glucose) 
and represent the means ± SD of n=3. *P<0.05 vs. high glucose. Statistical analysis was 







Figure 3.6. Effect of the released gAdp (rAdp) from the polymer gel on activating cAMP 
compared to the intact gAdp. This confirms the preservation of gAdp activity. The data 
represents means ± SD of n=3. *P<0.05 vs. high glucose. Statistical analysis was 




The polymer gel was not added directly to the cells due to its viscosity. However, 
the protein release could be achieved in animal models. This was performed in our 
laboratory using other proteins. The characterization of the gAdp delivery system raises 
the possibility to be used therapeutically in animal models. 
 
Conclusions 
The gAdp effectively suppressed excess ROS-production in the in vitro BAECs 
under high-glucose condition via cAMP pathway. The controlled release profile of gAdp 
from the polymer gel was achieved showing almost 100% sustained release over 27 days 
with no initial burst release. The released gAdp preserved its activity in reducing ROS 
and activating cAMP. These data raise the possibility that injectable gels containing 
gAdp could be used therapeutically to reduce ROS in the blood vessels of animals with 
diabetes. This released adiponectin might compensate for the reduced adiponectin 
concentrations in the blood stream of diabetic or obese animals. This study provides a 
new direction for developing controlled release dosage form of gAdp as a therapeutic tool 
for oxidative stress related pathology in patients with diabetes. The results provide a 
framework for developing scientific foundation for further work involving in vivo studies.  
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SOLID PHASE SYNTHESIS OF MITOCHONDRIAL  
TRIPHENYLPHOSPHONIUM-VITAMIN E USING  
A LYSINE LINKER FOR REVERSAL  
OF OXIDATIVE STRESS 
 
Abstract 
Mitochondrial targeting of antioxidants has been an area of interest due to the 
mitochondria’s role in producing and metabolizing reactive oxygen species. Antioxidants 
have been conjugated to a lipophilic cation to increase their mitochondrial targeting. This 
paper describes the synthesis of mitochondria targeted vitamin E. We report a faster and a 
more efficient method to conjugate vitamin E to triphenylphosphonium cation via a 
lysine linker using solid phase synthesis. The efficacy of the final product was tested in 
bovine aortic endothelial cells and type 2 diabetic db/db mice to examine reduction in 
oxidative stress and mitochondrial targeting.  
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Introduction 
Metabolic   syndrome,   a   group   of   risk   factors   that   increase   the   risk    of 
cardiovascular disease and diabetes, has become increasingly common in the United 
States (1). Some of the metabolic risk factors associated with metabolic syndrome are 
abdominal obesity, elevated blood pressure, hyperglycemia, insulin resistance, and 
atherogenic dyslipidemia (2, 3). These factors are associated with elevated rates of 
cardiovascular events such as sudden death, acute myocardial infarction, and 
cerebrovascular accidents. Reducing the risk of cardiovascular disease and type 2 
diabetes are the primary goals of clinical management of the metabolic syndrome. 
Diabetic patients have a higher risk of dying of a heart attack or a stroke than non-
diabetic patients (4). Endothelial dysfunction in diabetic patients is mainly caused by 
hyperglycemia, which increases ROS production (5-7). Increased production of systemic 
and vascular ROS leads to reduced endothelial nitric oxide bioactivity, increased 
expression of cell surface adhesion molecules, and inflammatory changes contributing to 
vascular, cellular, and tissue damage (8-12). Various studies have suggested that the 
complex process of endothelial ROS generation may be derived from several cellular 
sources, including NADPH-dependent oxidases, complex III of the electron transport 
chain in mitochondria, and multiple signaling cascades (7, 13-16).  
The mitochondria play roles in cellular energy metabolism, apoptosis, Ca2+ 
homeostasis, and cell signaling (17-20). Because of these roles, the mitochondria have 
been under investigation for therapeutic targeting. Myocardial mitochondria are involved 
in the generation of energy, the regulation of apoptosis, and the generation and 
detoxification of ROS (21-23). Disrupting the mitochondrial Ca2+, ATP, or ROS 
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metabolism plays a role in different diseases such as diabetes, obesity, heart failure, 
stroke, aging, cancer, and neurodegenerative diseases (24).  The mitochondria utilize 
90% of consumed oxygen for ATP synthesis and oxidative phosphorylation (25). This 
process in the electron transfer chain is responsible for ROS production. The cell has its 
own antioxidant defenses such as glutathione, catalase, and superoxide dismutase to 
prevent oxidative stress (26-30). Maintaining ROS/antioxidant ratio is imperative for cell 
signaling (25). Any imbalance between ROS generation and destruction is associated 
with chronic disease (31). Since the mitochondria produces and metabolizes ROS, 
targeting antioxidants to the mitochondria has been a focus of interest. This is achieved 
by conjugating an antioxidant to a lipophilic cation. The positive charge enables 
mitochondrial accumulation 100-1000 times higher due to the high inner mitochondrial 
membrane potential (32-34).  
Conjugating an antioxidant such as vitamin E to a lipophilic cation can be a 
promising approach for reversing oxidative damage. Vitamin E is a fat-soluble 
antioxidant with eight naturally occurring vitamer forms. The most common forms are γ- 
and α-tocopherol. Vitamin E has a positive effect on insulin sensitivity and the prevention 
of type-2 diabetes (35-37) due to its antioxidant capacity (38, 39). Alpha-tocopherol is a 
chain-breaking antioxidant, where it interrupts the formation of lipid-derived oxygen- and 
carbon-centered free radicals (25). These radicals are formed via a chain reaction: 
initiation, propagation, and termination. Clinical trials with antioxidants have failed to 
show any significant clinical benefit. Meanwhile, administering high doses of vitamin E 
may be harmful (40). There is a possibility that this failure is due to the lack of 
antioxidant accumulation in the mitochondria, the proper target for scavenging ROS (25). 
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Targeting vitamin E conjugated to triphenylphosphonium (TPP+) to the mitochondria has 
a better effect in reducing ROS than vitamin E by itself (41, 42). 
The aim of this study was to design a faster and a more efficient method to 
conjugate vitamin E to TPP+ (MitoE) using a lysine linker and solid phase synthesis. We 
also tested the efficacy of the new conjugated MitoE in decreasing ROS in bovine aortic 
endothelial cells (BAEC) and in targeting the mitochondria in type 2 diabetic db/db mice 
(43). 
 
Materials and Methods 
Solid Phase Synthesis of MitoE 
Resin Fmoc Deprotection 
The fluorenylmethoxycarbonyl (Fmoc) group was deprotected on the 4-(2',4'-
Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-MBHA resin (Rink 
Amide MBHA resin, EMD Chemicals, Germany). The resin (25 mg) was dissolved in 6 
ml dimethylformamide (DMF), loaded into a fritted column (Grace Davison Discovery 
Sciences, Deerfield, IL) and washed twice in DMF. It was then incubated with 20% 
piperidine (Sigma-Aldrich, St. Louis, MO) in DMF for 15 minutes at room temperature. 




Three equivalents of Fmoc-N-ε-4-methyltrityl-L-lysine (Fmoc-Lys[Mtt]-OH, 
Anaspec, Fremont, CA) was combined with 5 equivalents of 2-(1H-Benzotriazole-1-yl)-
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1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, EMD Chemicals), 5 
equivalents of HOBt-6-carboxamidomethyl polystyrene (HOBt, EMD Chemicals), and 5 
equivalents of N,N-Diisopropylethylamine (DIPEA, Sigma Aldrich) in DMF. This 
coupling solution was then added to the resin. The mixture was agitated for 5 hours at 
room temperature. 
 
Lysine Fmoc De-protection and TPP Coupling 
The Fmoc on the lysine was deprotected as mentioned above. Subsequently, 5 
equivalents of (3-carboxypropyl)TPP (Sigma Aldrich) was coupled similarly to the 
Fmoc-Lys(Mtt)-OH coupling mentioned above.  
 
Lysine Mtt Deprotecting and Vitamin E Coupling 
The Mtt group on the lysine was de-protected by incubation with 94% 
dichloromethane (DCM, Sigma Aldrich), 5% Triisopropylsilane (Tis, Sigma Aldrich), 
and 1% Trifluoroacetic acid (TFA, Sigma Aldrich) for 15 minutes. The column was then 
drained and washed with DMF. Later, 3 equivalents of 3,4-dihydro-6-hydroxy-2,5,7,8-
tetramethyl-2H-1-benzopyran-2-propanoic acid (α-CEHC, Cayman Chemical, Ann 
Arbor, MI) was coupled as described above.  
 
Resin Cleavage 
The resin was treated with 95% TFA, 2.5% water, and 2.5% Tis and agitated for 2 
hours. The treatment allowed the cleavage of the final product from the resin. The filtrate 
was then collected. 
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Mass Spectroscopy 
A sample of the filtrate was air-dried and then re-dissolved in methanol (Sigma 
Aldrich). The MALDI-TOF mass spectroscopy was performed at the University of Utah 
Core Facility. Full scan spectra were recorded by scanning a m/z range of 500–2000. 
 
Animal Studies and Mitochondria Isolation 
Two hundred µM of the MitoE (8) were given to type 2 diabetic db/db mice (n=4) 
in their drinking water for 2 weeks.(44-46) Another population (n=4) was given plain 
water (no MitoE) as a negative control. The hearts were minced in STE1 buffer (250 
mmol/l sucrose, 5 mmol/l Tris/HCL, 2mmol/l EGTA, pH 7.4) and then incubated in 
STE2 buffer (STE1 containing [wt/vol] 0.5% BSA, 5mmol/l MgCl2, 1 mmol/l ATP, and 
2.5 units/ml protease type VIII from Bacillus licheniformis) for 4 minutes on ice to 
digest.(44) The mixture was then diluted in STE1 buffer and homogenized using a Teflon 
pistil in a Potter- Elvejhem glass homogenizer. The homogenate was centrifuged at 
8000g for 10 minutes at 4°C. Subsequently, the pellet was resuspended in STE1 buffer 
and centrifuged at 700g for 10 minutes at 4°C. The pellet was discarded and the 
supernatant was centrifuged at 8000g for 10 minutes at 4°C. The final mitochondrial 
pellet was diluted in STE1 buffer to a final concentration of 0.1 mg/ml.   All animal 
experiments were conducted and cared for under an IACUC approved protocol from the 
University of Utah. 
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Liquid Chromatograph/Mass Spectrometry (LC/MS) 
The mitochondrial fraction was sonicated (Branson, Danbury, CT) for 5 seconds 
with maximum speed in an ice bath then stirred for 30 seconds. The sonication and 
stirring were repeated six times. The MitoE standard curve was plotted by six-point 
dilutions: 0, 0.5, 1, 2, 4, and 8 µg/ml (47). Samples (mitochondrial fraction and plasma) 
and standard controls were then analyzed on the LC/MS, University of Utah Department 
of Chemistry. The analysis was controlled by MassLynx mass spectrometry software.  
 
Cell Culture and ROS Measurement 
BAECs were grown as monolayers in DMEM (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin-streptomycin 
(Invitrogen). The cells were incubated in a 5% CO2 incubator at 37ºC. A density of 2×105 
cells were seeded in 6-well plates and treated with 5 mM or 25mM glucose (23). The 
cells treated with 25 mM glucose were then incubated with 2 µM Vitamin E (Sigma 
Aldrich) or 2 µM of our MitoE product for 36 hours. The cells were then treated with 10 
µM 5-(and-6)-chlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, 
Invitrogen) for 30 minutes. Cells were then collected and suspended in PBS. 
Subsequently, they were analyzed using flow cytometry at the University of Utah Core 
Facility (48). The experiment was repeated in triplicate (n=3). The data were presented as 
the mean ± standard error. Statistical analysis was performed by using one-way ANOVA 
with Tukey’s posttest. A value p<0.05 was considered significant. 
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Results and Discussion 
We envisaged a method to conjugate vitamin E to TPP. Such conjugation has 
been previously described. The literature precedent for this developed method was 
conducted with a more sophisticated scheme (49). However our goal was to design a 
more faster and efficient method using a lysine linker and solid phase synthesis. This 
method does not require isolation of synthetic intermediates while reagents and by-
products are washed away after each step.  
We used a lysine linker with two protecting groups (Fmoc and Mtt), which 
enabled the conjugation of TPP and vitamin E (Scheme 4.1). The masked lysine was 
coupled onto the Rink Amide MBHA resin. HBTU and HOBt were used to enhance the 
coupling rate (50, 51). The Fmoc was then deprotected to allow for (3-
carboxypropyl)TPP conjugation through its carboxylic acid group forming an amide 
bond. The Mtt protecting group was then removed. The removal of the protecting group 
enabled the carboxylic acid on α-CEHC to form an amide bond with the lysine linker. 
The final product, TPP-Lysine-Vitamin E (MitoE), was then released from the resin via 
treatment with 95% TFA.  
The final product (Figure 4.1) was characterized by MALDI-TOF mass 
spectrometry (Figure 4.2). The molecular weight peak was at 736.39, which corresponds 
to the expected peak for the MitoE generate by ChemDraw software. The mass 
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Scheme 4.1. Solid phase synthesis of MitoE Reagents and conditions: a) 20% piperidine, 
DMF. b) Fmoc-Lys[Mtt]-OH, HBTU, HOBt, DIPEA, DMF. c) 20% piperidine, DMF. d) 
(3-carboxyproppyl)TPP, HBTU, HOBt, DIPEA, DMF. e) 94% DCM, 5% Tis, 1% TFA. 
f) α-CEHC, HBTU, HOBt, DIPEA, DMF. g) 95% TFA, 2.5% water, 2.5% Tis. 
 




Figure 4.1. The structure, nomenclature, and chemical formula of MitoE synthesized. 
Using ChemDraw Ultra software, it also shows the expected molecular weight and mass 
spectrometry analysis.  
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Figure 4.2.  The MALDI-TOF mass spectrometry of sample from resin cleavage (MitoE).  
The 736.39 m/z is the actual mass. 
	   166	  
 
In an effort to investigate if the TPP conjugation to vitamin E via a lysine linker 
would increase mitochondrial targeting, an in vivo experiment was performed. Highly 
insulin resistant db/db mice were provided with 2 µM of the MitoE in their dinking water 
for two weeks. Their plasma was collected and hearts were harvested to isolate 
myocardium mitochondria. The isolated mitochondria were then lysed. The 
concentrations of MitoE in the collected samples were simultaneously measured against a 
concentration standard curve. The retention times for the MitoE standard and samples are 
shown as 13.9 and 13.6 minutes respectively (Figure 4.3). The MitoE amount in the 
isolated mitochondria was 0.775 ± 0.137 µg/0.1g of mitochondria while the plasma 
concentration was 1.78 ± 0.305 µg/ml. The untreated mice showed no traces of MitoE (8) 
in the isolated mitochondria or plasma. 
To further explore the antioxidant activity of the conjugated MitoE, BAECs were 
studied for ROS measurements. The endothelial cells were incubated with low (5 mM) 
and high (25 mM) glucose concentrations. The cells incubated under hyperglycemic 
conditions showed an increase in ROS production. Flow cytometry data also showed 
reduction in ROS production in the hyperglycemic cells treated with MitoE (Figure 4.4). 
Vitamin E conjugated to TPP via a lysine linker (MitoE) showed better effect than 
vitamin E alone. 
In summary, the conjugation of Vitamin E to TPP was achieved in a fast and more 
efficient way using a lysine linker and solid phase synthesis. The conjugated product was 
effective in reducing oxidative stress in BAECs and targeting the mitochondria in type 2 
diabetic db/db mice. This chemistry provides the framework for further products to be 







Figure 4.3. LC/MS data showing the retention time of (A) sample from resin cleavage, 
MitoE and (B) mitochondrial lysate of MitoE treated mice. 




Figure 4.4. Effect of Vitamin E and MitoE on reducing ROS induced by high glucose in 
endothelial cells. ROS was measured via FACSCAN. Data are expressed as the percent 
of basal (5 mM glucose). Statistical analysis was performed by using one-way ANOVA 
with Tukey’s posttest. * p<0.05 compared to 25 mM glucose treated cells. 
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explored. TPP conjugation using this method should be investigated with other 
antioxidants such as co-enzyme Q and quercetin. Different amino acids could also be 
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INDUCTION OF APOPTOSIS THROUGH COMPARTMENT 
SPECIFIC MITOCHONDRIAL TARGETING OF P53 
 
Abstract 
Targeting the tumor suppressor p53 to the mitochondria triggers a rapid apoptotic 
response as efficiently as transcription-dependent p53 (1, 2). p53 forms a complex with 
the anti-apoptotic Bcl-XL, which leads to Bak and Bax oligomerization resulting in 
apoptosis via mitochondrial outer membrane permeabilization (3, 4). Although p53 
performs its main role in the mitochondrial outer membrane it also interacts with 
different proteins in the mitochondrial inner membrane and matrix (5, 6). To further 
investigate mitochondrial activity of p53, we targeted p53 to specific mitochondrial 
compartments. EGFP-p53 was fused to different mitochondrial targeting signals (MTSs) 
directing it to the mitochondrial outer membrane (“XL-MTS” from Bcl-XL; “TOM-
MTS” from TOM20), the inner membrane (“CCO-MTS” from cytochrome c oxidase) or 
matrix (“OTC-MTS” from ornithine transcarbamylase). Fluorescence microscopy and a 	   	  This	  chapter	  has	  been	  submitted	  to	  Molecular	  Pharmaceutics.	  Mossalam	  M.,	  Matissek	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  J.E.,	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  C.S.	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   work	   was	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   both	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   luciferase	   assay	   while	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   helped	   with	   flow	  cytometry	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  image	  analysis. 
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p53 reporter dual luciferase assay demonstrated that fusing MTSs to p53 increased 
mitochondrial localization and nuclear exclusion depending on which MTS was used. To 
examine if the MTSs initiate mitochondrial damage, we fused each individual MTS to 
EGFP (a nontoxic protein) as negative controls. We performed caspase-9, TUNEL, 
Annexin-V, and 7-AAD apoptosis assays on T47D breast cancer cells transfected with 
mitochondrial constructs. Except for EGFP-XL, apoptotic potential was observed in all 
MTS-EGFP-p53 and MTS-EGFP constructs. In addition, EGFP-p53-XL showed the 
greatest significant increase in programmed cell death compared to its non-toxic MTS 
control (EGFP-XL). The apoptotic mechanism for each construct was further investigated 
using pifithrin-α (an inhibitor of p53 transcriptional activity), pifithrin-µ (a small 
molecule that reduces binding of p53 to Bcl-2 and Bcl-XL), and over-expressing the anti-
apoptotic Bcl-XL. Unlike the MTSs from TOM, CCO, and OTC, which showed different 
apoptotic mechanisms, we conclude that p53 fused to the MTS from Bcl-XL performs its 
apoptotic potential exclusively through p53/Bcl-XL specific pathway.  
 
Introduction 
The tumor suppressor p53 stimulates a wide network of signals involved in DNA 
repair, cell cycle arrest, senescence and apoptosis (7-11). Although most of these effects 
can be linked to its role as a transcription factor, recent work has clearly demonstrated 
that p53 can cause apoptosis through its transcription-independent mitochondrial pathway 
(3, 12). A small but highly reproducible fraction of p53 translocates to the mitochondria 
at the onset of p53-dependent apoptosis (12). Translocation of p53 to the mitochondrial 
outer membrane triggers the release of cytochrome c and procaspase-3 activation. The 
	   177	  
DNA binding domain of p53 (DBD, residues 239-248) forms inhibitory complexes with 
anti-apoptotic Bcl-XL and Bcl-2 proteins (Figure 5.1), which are located in the 
mitochondrial outer membrane (13). This induces oligomerization of Bak and Bax 
allowing them to form supramolecular pores (4, 14, 15). In addition, p53 activates, 
directly binds to, and induces oligomerization of Bak and Bax (4, 15, 16). The formation 
of permeability transition pores causes outer membrane rupture and releases cytochrome 
c from the intramembranous space into the cytosol triggering apoptosis via the 
apoptosome formation (Figure 5.1) (17-19). In addition, targeting p53 to the 
mitochondria triggers apoptosis faster than the transcription-dependent nuclear pathway 
(1, 2). In most cancer cells, p53 is not able to bind to Bcl-2 proteins due to missense 
mutations in the DBD of p53, demonstrating the importance of the DBD in mitochondrial 
apoptosis (13).  
In addition to p53’s role in the outer membrane, it also shows activity in the 
mitochondrial inner membrane and matrix. Under stress, p53 forms a complex with 
cyclophilin D, which is found in the mitochondrial inner membrane (20). This complex 
initiates the mitochondrial permeability transition pore, which leads to mitochondrial 
swelling and apoptosis (21). In the mitochondrial matrix, p53 interacts with manganese 
superoxide dismutase and reduces its activity. Due to this interaction, p53 interferes with 
the cellular oxidative defense mechanism resulting in reduced degradation of reactive 
oxygen species. This causes a decrease of mitochondrial potential and results in apoptosis 
(5).  
Despite what is known, the mechanism of mitochondrial p53 activity is still under 
investigation. To elucidate this mechanism, we present data on delivering p53 to different
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Figure 5.1.  The mitochondrial apoptotic pathway of p53.  When p53 is targeted to the 
mitochondria, it interacts with anti-apoptotic Bcl-XL, enables Bax and Bak 
oligomerization, and activates the intrinsic apoptotic pathway.  The apoptosome 
(cytochrome c, APAF-1 and caspase-9) is triggered, leading to apoptosis via activation of 
caspases-3, -6, and -7. The left side of the diagram indicates the different subsections of 
the mitochondria targeted, including the outer membrane (“XL-MTS” from Bcl-XL; 
“TOM-MTS” from TOM20), the inner membrane (“CCO-MTS” from cytochrome c 
oxidase), and the matrix (“OTC-MTS” from ornithine transcarbamylase).   
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 mitochondrial compartments. We fused p53 to different mitochondrial targeting signals 
(MTSs) targeting the mitochondrial outer membrane [MTS from Bcl-XL and MTS from 
the translocase of the outer membrane (TOM 20)], inner membrane (MTS from 
cytochrome c oxidase subunit VIII) and matrix (MTS from ornithine transcarbamylase) 
(Figure 5.1). These MTSs (Table 5.1) are thought to form α-helices, and are important for 
their recognition by translocation machineries in the mitochondrial outer (TOM complex) 
and inner (TIM complex) membranes (22-25). MTSs are mainly found on the amino 
terminus of mitochondrial proteins (22).  
In this project, all MTSs used were cloned on the amino terminus except for XL, 
which is inherently found on the carboxy terminus (26). XL targets the outer surface of 
the mitochondria (26-29) while TOM is inserted into the outer membrane (26). CCO 
translocates the outer membrane and then becomes imbedded into the inner membrane 
(30, 31) while the OTC crosses both membranes and translocates to the matrix (3, 32). 
The purpose of this work was to determine if p53 targeted to different mitochondrial 
compartments exhibit differences in apoptotic potential.  
 
Materials and Methods 
EGFP-p53 plasmid (pEGFP-p53) 
The DNA encoding p53 was amplified through PCR from pCMV-p53 wt (a 
generous gift from Dr. S. J. Baker, Addgene, Cambridge, MA) using the primers 5ʹ′-
GCGCGCGCGCTCCGGAGCCATGGAGGAGCCGCAGT-3ʹ′ and 5ʹ′-GCGCGCGCGC-
GGTACCTCAGTCTGAGTCAGGCCCTTCTGTC-3ʹ′.  This was subcloned into the 
BspEI and KpnI restriction enzyme sites in pEGFP-C1 (Clontech, Mountain View, CA).  
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Table 5.1. A list of the mitochondrial targeting signals used in this paper. TOM and XL 
target the mitochondrial outer membrane, CCO translocates to the mitochondrial inner 
membrane, and the OTC localizes to the mitochondrial matrix. 
Protein Compartment MTS Sequence 
XL Outer Membrane RGPGIQKGPGEIQQMVPDRHDRGRRGAAGQPVQQKX 
TOM Outer Membrane MVGRNSAIAAGVCGALFIGYCIYFDRKRRSDPN 
CCO Inner Membrane MSVLTPLLLRGLTGSARRLPVPRAKIHSL 
OTC Matrix MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQ 
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pOTC-EGFP-p53 plasmid 
An oligonucleotide encoding the mitochondrial targeting signal from OTC 
(including the Kozak region), 5ʹ′-CCGGTCGCCACCATGCTGTTTAATCTGAGG-
ATCCTGTTAAACAATGCAGCTTTTAGAAATGGTCACAACTTCATGGTTCGAAA
TTTTCGGTGTGGACAACCACTACAAAATAAAGTGCAGCGA-3ʹ′ was annealed to 
its complementary strand.  This was then cloned at the amino terminus of EGFP-p53 at 
the AgeI site.  
 
pTOM-EGFP-p53 and pCCO-EGFP-p53 plasmid 
The OTC region from pOTC-EGFP-p53 was replaced with annealed 
oligonucleotides encoding the mitochondrial targeting signal from the TOM20 complex 
(TOM) at the AgeI site, 5ʹ′-GATCCCCGGTCGCCACCATGGTGGGTCGGAACAG-
CGCCATCGCCGCCGGTGTATGCGGGGCCCTTTTCATTGGGTACTGCATCTACT
TCGACCGCAAAAGACGAAGTGACCCCAACCGA-3ʹ′ and its reverse complement, or 
with oligonucleotides encoding the mitochondrial targeting signal from the cytochrome c 
oxidase (CCO) at the AgeI site, 5ʹ′-CCGGTCGCCACCATGTCCGTCCTGACGCCG-
CTGCTGCTGCGGGGCTTGACAGGCTCGGCCCGGCGGCTCCCAGTGCCGCGCG
CCAAGATCCATTCGTTGA-3ʹ′ and its reverse complement. 
 
pEGFP-p53-XL plasmid 
The mitochondrial signal from Bcl-XL was fused to the carboxy terminus of 
EGFP-p53 using the BamHI restriction site as follows. The XL oligonucleotide 5ʹ′-
AGAAAGGGCCAGGAGAGATTCAACAGATGGTTCCTGACCGGCATGACCGTG
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GCCGGCGTGGTGCTGCTGGGCAGCCTGTTCAGCAGAAAGTGA-3ʹ′ was annealed 
to its complimentary strand (with BamHI sticky ends). The p53 stop codon was then 
mutated (TGA to TTA) in pEGFP-p53-XL using the primers 5ʹ′-GAAGGGCCTGACT-
CAGACTTAGGTACCGCGGGCCCGGGAT-3ʹ′ and the reverse complement.  
 
pEGFP constructs with MTSs 
Plasmids encoding OTC-EGFP, TOM-EGFP, CCO-EGFP, and EGFP-Bcl-XL 
were constructed using the same oligonucleotides and restriction sites mentioned above 
but inserted in pEGFP-C1 instead of pEGFP-p53. 
 
MTS-EGFP-p53NLSmut 
Mutations (K319T and K320T) in the nuclear localization signal (NLS) of p53 
were introduced in all mitochondrial p53 constructs via QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent, Santa Clara, CA) using the primers 5ʹ′-CTCTCCCCAGCC-
AACGACGAAACCACTGG-3ʹ′ and its reverse complement. 
 
Cell Lines and Transient Transfections 
1471.1 murine adenocarcinoma cells (gift of G. Hager, NCI, NIH), MCF-7 human 
breast adenocarcinoma cells (ATCC, Manassas, VA), and T47D human ductal breast 
epithelial tumor cell line (ATCC) were grown as monolayers in DMEM (1471.1) or 
RPMI (MCF-7 and T47D) (Invitrogen, Carlsbad, CA), supplemented with 10% fetal 
bovine serum (Invitrogen), 1% penicillin-streptomycin-glutamine (Invitrogen), and 0.1% 
gentamicin (Invitrogen). In addition, T47D and MCF-7 media was supplemented with 4 
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mg/L insulin (Sigma, St. Louis, MO). The cells were maintained in a 5% CO2 incubator 
at 37ºC. 7.5 × 104 cells for 1471.1 and 3.0 × 105 cells for MCF-7 and T47D were seeded 
in 6-well plates (Greiner Bio-One, Monroe, NC) or 2-well live cell chambers (Nalgene 
Nunc, Rochester, NY). Transfections were carried out 24 hours after seeding using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s recommendations. 1 pmol 
DNA was transfected per well for all assays unless otherwise indicated. 
 
Mitochondrial Staining, Microscopy, and Image Analysis 
Prior to live-cell imaging and mitochondrial staining, media in live cell chambers 
was replaced with phenol red-free DMEM (Invitrogen) for 1471.1 cells or phenol red-
free RPMI (Invitrogen) for T47D and MCF-7 cells containing 10% charcoal-stripped 
fetal bovine serum (CS-FBS, Invitrogen). Cells were incubated with 250nM MitoTracker 
Red FM (Invitrogen) for 15 min at 37˚C and protected from light. Images were acquired 
as previously (33), using an Olympus IX71F fluorescence microscope (Scientific 
Instrument Company, Aurora, CO) with high-quality narrow band GFP filter (ex: 
HQ480/20 nm, em: HQ510/20 nm) and HQ:TRITC filter (ex: HQ545/30, em: HQ620/60) 
from Chroma Technology (Brattleboro, VT) with a 40X PlanApo oil immersion objective 
(NA 1.00) on an F-View Monochrome CCD camera. Images were analyzed for 
mitochondrial stain overlap with EGFP fusion constructs using ImageJ software and the 
JACoP plugin (34). JACoP was used to generate the colocalization statistic [i.e., 
Pearson’s correlation coefficient (PCC) post Costes’ automatic threshold algorithm (35, 
36)]. PCC evaluates correlation between pairs of individual pixels from EGFP and 
MitoTracker stained cells. The higher the PCC value the higher the correlation. For 
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increased visual clarity of mitochondrial localization of the EGFP-fused constructs, 
spatial representations of pixel intensity correlation have been generated using 
Colocalization Colormap (ImageJ) (37). 
 
Luciferase Assay 
All constructs (3.5 µg of DNA) were co-transfected with 3.5 µg of p53-Luc Cis-
Reporter (encoding for firefly luciferase, Agilent) in T47D and MCF-7 cells. To 
normalize for transfection efficiency, 0.35 µg of pRL-SV40 plasmid (encoding for renilla 
luciferase, gift from Dr. Philip Moos, University of Utah) was co-transfected. The Dual-
Glo Luciferase Assay System (Promega, Madison, WI) was used to determine firefly 
luciferase activity and renilla luciferase per manufacturer's instructions. Luciferase 
activity was detected 24 hours after transfection using PlateLumino (Stratec Biomedical 
Systems, Birkenfeld, Germany). Firefly luciferase values were normalized for renilla 
luciferase. EGFP-p53 served as a positive control and EGFP as a negative control. The 
Dual-Glo Luciferase Assay was run three times independently, each in triplicate. 
 
Caspase-9 Assay 
T47D cells were probed 19 hours after transfection using CaspaLux®9-M2D2 kit 
(OncoImmunin, Inc., Gaithersburg, MD) per manufacturer’s recommendations. The cells 
were then suspended in flow cytometry buffer (OncoImmunin, Inc.) and analyzed via the 
FACSAria-II (BD-BioSciences, University of Utah Core Facility) utilizing 488 nm (for 
EGFP) and 563 nm (for cleaved caspase 9 substrate) lasers. FACSDiva software was 
used as an evaluation tool. Only EGFP transfected cells at 507 nm emission were 
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analyzed. The samples were detected in the PE (phycoerythrin) channel with the 580 nm 
emission peak. Each construct was assayed three times (n=3).  
 
TUNEL Assay 
T47D cells were prepared 48 hours after transfection using In Situ Death 
Detection Kit, TMR red (Roche, Mannheim, Germany) per the company’s protocol. The 
FACSAria-II was used to analyze the cells suspended in PBS (Invitrogen). The same 
FACS settings mentioned above with the caspase-9 assay were used. Only EGFP positive 




At 48 hours post transfection, T47D cells were assayed for Annexin-V binding. 
The cells were suspended in 100 µl Annexin binding buffer (Invitrogen) and incubated 
with 5 µl Annexin-APC (Annexin-V conjugated to allophycocyanin, Invitrogen) for 15 
minutes. The incubated cells were then diluted in 400 µl Annexin binding buffer and 
analyzed using the FACSCanto-II (BD-BioSciences, University of Utah Core Facility) 
with FACSDiva software. EGFP was excited at 488 nm wavelength and detected at 507 
nm. APC was excited with 635 nm laser and detected at 660 nm. Analysis was based on 
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7-AAD Assay 
T47D and MCF-7 cells were stained with 7-aminoactinomycin D (7-AAD, 
Invitrogen) according to manufacturer’s instructions 48 hours after transfection. The 
samples were analyzed using the FACSCanto-II (BD-BioSciences). Analyzed cells were 
gated for EGFP (as mentioned in Annexin-V assay). In addition, EGFP and 7-AAD were 
excited with the 488 nm laser.  EGFP and 7-AAD were detected at 507 nm and 660 nm, 
respectively. Each construct was assayed three times (n=3). 
 
Rescue Experiment Using Pifithrin-α 
Six hours after transfection, T47D cells were incubated with 40 µM pifithrin-α 
(Cayman Chemical, Ann Arbor, MI) for 42 hours and compared to transfected cells 
without pifithrin-α. At the 48 hour time point, the 7-AAD assay was performed as above.  
 
Rescue Experiment Using Pifithrin-µ 
Six hours after transfection, T47D cells were incubated with 5 nM pifithrin-µ 
(Tocris Bioscience, Ellisville, MO) for 42 hours and compared to transfected cells 
without pifithrin-µ. At the 48 hour time point, the 7-AAD assay was performed as 
detailed above.  
 
Rescue Experiment Using Bcl-XL 
T47D cells were co-transfected with 1 pmol of MTS constructs and 1 pmol of 
pBcl-XL (Addgene). After 48 hours, cells were pelleted and assayed with 7-AAD as 
described above. 
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Statistical Analysis 
All experiments were repeated in triplicate (n=3). The data were presented as the 
mean ± standard error. Statistical differences between each MTS-EGFP-p53 and its 
MTS-EGFP were resolved via unpaired t-test using GraphPad Prism software. The MTS-
EGFP controls were compared to EGFP by one-way ANOVA with Tukey’s posttest. A p 
value <0.05 was considered significant. 
 
Results 
Mitochondrial Localization of MTS-EGFP-p53 
Mitochondrial targeting of all constructs was verified using fluorescence 
microscopy. Figure 5.2A shows 1471.1 cells, which are larger in size, spread well, and 
are generally easier to visualize versus T47D or MCF-7 cells. However, irrespective of 
the cell line, similar microscopy results were observed in T47D and MCF-7 cells (data 
not shown). PCC values range from +1 to -1; perfect correlation is represented by +1, 
anti-correlation by -1, and a PCC value of zero denotes random distribution (34). 
Following the example of Bolte and Cordelières, a PCC of 0.6 or greater will define 
colocalization, or co-compartmentalization (Figure 5.2B) (34). Fusing different MTSs to 
EGFP and p53 showed a high degree of colocalization with the mitochondria. EGFP-C1 
served as negative control for colocalization analysis and as expected, there was no 
colocalization between EGFP alone and the mitochondria. EGFP and p53 tagged to TOM 
and XL targeted the mitochondria better than CCO-EGFP-p53 and OTC-EGFP-p53. 
CCO and OTC were the “weakest” MTSs since there was some nuclear targeting of both 
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A. 
 
Figure 5.2. Colocalization of MTS constructs and MitoTracker Red mitochondrial stain 
in 1471.1 cells. A) Representative images of MTS-EGFP-p53, MTS-EGFP-p53 NLS 
mutation, MTS-EGFP and EGFP-C1 are shown in the left column with images of 
MitoTracker Red distribution in the middle column. The ‘EGFP’ and ‘MitoTracker’ 
columns have been false colored green and red, respectively. Enhanced visualization of 
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B. 
 
Figure 5.2 Cont. colocalized pixels is rendered in the ‘Color Map’ column. Warm colors 
depict pixels with highly correlated intensity and spatial overlap while cool colors are 
indicative of anti- or random correlation (colorbar for interpretation is shown below 
column). Corresponding PCC values are shown in the right column. White scale bars are 
all 10 µm. B) The degree of colocalization is represented by PCC following Costes’ 
approach. All constructs with values higher than 0.6 are considered highly colocalized 
with mitochondrial stain MitoTracker Red. Statistical analysis was performed by using 
odds ratio. The adjusted odds ratio for PCC value of 0.6 were compared with each 
sample. *p<0.05, and **p<0.01 comparing odds ratio of lowest value for samples with 
odds ratio of 1 for PCC of 0.6. 
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CCO-EGFP-p53 and OTC-EGFP-p53. Therefore we mutated K319T and K320T in the 
nuclear localization signal (NLS) of p53 (38) which resulted in increased mitochondrial 
targeting for CCO-EGFP-p53 and OTC-EGFP-p53. For easier visualization of 
colocalization among constructs, a spatial depiction of pixel overlap and intensity 
correlation are provided in the ‘Color Map’ column (Figure 5.2A). The Color Map 
spectrum moves from cold to warm colors as pixel correlation increases (37).   
 
Testing the Transcriptional Activity of MTS-EGFP-p53 
To demonstrate the lack of transcriptional activity of these p53 constructs, a p53 reporter 
dual luciferase assay was performed in T47D (Figure 5.3A) and MCF-7 cells (Figure 
5.3B). T47D cells contain a mutation in p53 (in the DBD which renders it inactive) that is 
also localized in the cytoplasm (39, 40) while MCF-7 cells express wild-type p53 
mislocalized to the cytoplasm (41). TOM and XL fused to EGFP-p53 showed no nuclear 
activity in either cell lines. CCO-EGFP-p53 expressed similar transcriptional activity to 
EGFP-p53 (positive control) in T47D (Figure 5.3A) and significant activity in MCF-7 
(Figure 5.3B) compared to the EGFP negative control. Introducing NLS mutations 
(K3319T and K320T) in CCO-EGFP-p53 resulted in major reduction of nuclear activity 
in both cell lines. OTC-EGFP-p53 showed low transcriptional activity in MCF-7 (Figure 
5.3B) and a significant activation in T47D cells (Figure 5.3A). Surprisingly, introduction 
of NLS mutations into OTC-EGFP-p53 did not result in any changes in nuclear activity 
in either cell line (Figures 5.3A and B).  
 




Figure 5.3. Luciferase assay: All MTS-EGFP-p53 and MTS-EGFP-p53 NLS mutation 
constructs were tested for their ability to activate a p53 reporter in A) T47D cells and B) 
MCF-7 cells. EGFP-p53 serves as a positive control and EGFP as a negative control. All 
constructs were corrected to EGFP-p53 control, which is set at 100%. Statistical analysis 
was performed by using one-way ANOVA with Tukey’s posttest. **p<0.005 and 
***p<0.0005 compared to EGFP-p53. 
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Figure 5.3 Cont. 
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The Effect of MTS-EGFP-p53 on Early Apoptosis 
In this paper we focused on T47D cell line because MCF-7 cells initiate apoptosis 
more rapidly than T47D (42). The apoptotic potential of p53 fused to different MTSs 
targeting the mitochondrial matrix, outer, and inner membranes was evaluated via 
caspase-9 assay, TUNEL assay, Annexin-V and 7-AAD. Caspases are a group of 
proteolytic enzymes that are directly involved in apoptosis by cleaving proteins such as 
lamin and PARP. Its inactive form procaspase-9 is activated through cytochrome c 
release and APAF-1 which occurs after mitochondrial outer membrane disruption (known 
as the intrinsic apoptotic pathway) (43). Caspase-9 itself cleaves the peptide sequence 
LEHD, which was used in the caspase-9 assay to measure the intrinsic apoptotic pathway 
(44). All MTS-EGFP-p53 constructs showed caspase-9 activity. However, only EGFP-
p53-XL (p<0.05) and OTC-EGFP-p53 (p<0.05) were significantly different from their 
corresponding MTS-EGFP controls as shown in Figure 5.4. 
 
The Effect of MTS-EGFP-p53 on DNA Fragmentation 
Mid-stage apoptosis was then measured by terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL), which detects DNA fragmentation by labeling the 
terminal end of nucleic acids. DNA fragmentation is a hallmark of apoptosis and is 
generated by caspase cleavage (45). Figure 5.5 illustrates that EGFP-p53-XL and CCO-
EGFP-p53 are the only constructs that were statistically significant from their control 
MTS-EGFP. Constructs with mutations in the NLS of p53 did not differ from constructs 
without mutation (data not shown). Staurosporine, which activates caspase3/7 and leads 
to DNA fragmentation (46), served as a positive control. 




Figure 5.4. The activation of caspase-9 was analyzed 19 hours following transfection of 
T47D cells. All constructs were corrected to untreated control, which is set at 100%. 
Statistical analysis was performed by using unpaired t-test. * p<0.05 for MTS-EGFP-p53 
compared to its MTS-EGFP negative control. 
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Figure 5.5. T47D cells were tested 48 hours following transfection. DNA fragmentation 
was analyzed with the TUNEL assay. All constructs were corrected to staurosporine 
positive control, which is set at 100%. Statistical analysis was performed by unpaired t-
test. * p<0.05 for MTS-EGFP-p53 compared to its MTS-EGFP.  
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The Effect of MTS-EGFP-p53 on Plasma Membrane 
The effects of the mitochondrial constructs were further explored by analyzing the 
induction of late apoptosis (Figure 5.6). Annexin-V was used to detect the externalization 
of phosphatidylserine on the cell surface of apoptotic cells via flow cytometry (47, 48). In 
the majority of healthy cells, the plasma membrane expresses phosphatidylserine on the 
cytosolic surface while in apoptotic cells, the phosphatidylserine is transported to the 
outer surface, which allows labeled Annexin-V to bind (49). All MTS-EGFP-p53 showed 
a significant effect on inducing late apoptosis than their corresponding MTS-EGFP 
controls in T47D cells (Figure 5.6). In addition, EGFP-XL was the only construct that 
showed similar activity to EGFP alone (Figure 5.6). 
To further validate the effect of mitochondrial p53 on late apoptosis, the 7-AAD assay 
was performed via flow cytometry (Figure 5.7). The 7-AAD fluorescent marker cannot 
stain the DNA in healthy cells due to inability to penetrate an intact cell membrane (50). 
However, it is able to stain the DNA in apoptotic and necrotic cells because of their 
disrupted membrane (51). Similar to Annexin-V results, all mitochondrial p53 constructs 
showed significant 7-AAD intercalation with DNA compared to their MTS-EGFP 
controls (Figure 5.7A). In addition, EGFP-XL was the only construct that showed similar 
activity to EGFP alone (Figure 5.7A). In a cell line that is less resistant to apoptosis such 
as MCF-7 (42), EGFP-p53-XL is the only construct that was significant than its MTS-
EGFP control (Figure 5.7B). In MCF-7, there was no statistical difference between p53 
fused to TOM, CCO or OTC and their respective MTS- 




Figure 5.6. Annexin-V assay was conducted in T47D cells 48 hours after transfection. 
Statistical analysis was performed by one-way ANOVA with Tukey’s posttest. 
**p<0.005 and ***p<0.0005 comparing MTS-EGFP-p53 to their MTS-EGFP controls. 
The negative controls (MTS-EGFP) were compared to EGFP-C1 using one-way ANOVA 
with Tukey’s posttest ##p<0.005. 
	   198	  
A. 
 
Figure 5.7. The 7-AAD assay was accomplished in (A) T47D and (B) MCF-7 cells 48 
hours after transfection. Statistical analysis was performed by one-way ANOVA with 
Tukey’s posttest. * p<0.05, **p<0.005 comparing MTS-EGFP-p53 to their MTS-EGFP 
controls. The controls (MTS-EGFP) were compared to EGFP-C1 using one-way 
ANOVA with Tukey’s posttest #p<0.05, ###p<0.0005. 
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Figure 5.7 Cont. 
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EGFP controls (Figure 5.7B). Mutating the NLS of p53 in MTS-EGFP-p53 had no effect 
on 7-AAD permeation in both cell lines (data not shown). In addition, EGFP-XL showed 
the least significance from EGFP alone in MCF-7 (Figure 5.7B). Similar to Annexin V, 
EGFP-XL was also the only construct that did not show difference in activity to EGFP 
alone in T47D (Figure 5.7A). 
 
Investigating the Apoptotic Mechanism of 
Mitochondrial p53 in T47D Cells 
Apoptosis resulting from p53 transcriptional activity of our mitochondrial p53 constructs 
was examined via a pifithrin-α rescue experiment. Pifithrin-α is a small molecule, which 
inhibits p53-mediated transcriptional activity (52, 53). The effect of pifithrin-α was 
measured in 7-AAD assay (Figure 5.8A). The apoptotic effect of EGFP-p53 fused to 
either CCO or OTC was reduced significantly after pifithrin-α treatment. In addition, 
there was no impact on the apoptotic potential of EGFP-p53 fused to either XL or TOM 
(Figure 5.8A). 
In order to investigate p53’s apoptotic mechanism in the mitochondria, pifithrin-µ 
was used in a rescue experiment in the 7-AAD assay. Pifithrin-µ is a small molecule that 
reduces the binding affinity of p53 to the anti-apoptotic proteins, Bcl-2 and Bcl-XL (54, 
55). Pifithrin-µ had a significant impact on the apoptotic potential of p53 fused to both 
XL and OTC (Figure 5.8B). However, apoptosis caused by p53 fused to either TOM or 
CCO was not rescued by pifithrin-µ. In addition, all the MTS-EGFP controls were not 
altered in this rescue experiment (data not shown).  
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Figure 5.8. Rescue experiments using (A) pifithrin-α, (B) pifithrin-µ, or (C) Bcl-XL. 7-
AAD assay was performed 48 hours after transfection in T47D cells. All constructs were 
fused to EGFP. Statistical analysis was performed by unpaired t-test. *p<0.05, and 
**p<0.005 comparing treated (with pifithrin-α, pifithrin-µ, or Bcl-XL) to untreated (no 
drug or Bcl-XL added). 
 




Figure 5.8 Cont. 
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The apoptotic mechanism was further explored by over-expression of the anti-
apoptotic protein, Bcl-XL. The cells were then analyzed in the 7-AAD assay via flow 
cytometry. Bcl-XL had a significant effect on reducing 7-AAD positive cells treated with 
EGFP-p53 fused to TOM, XL, and OTC (Figure 5.8C). Cells treated with EGFP-p53-XL 
showed the most significant reduction in 7-AAD when co-transfected with Bcl-XL. 
Meanwhile, Bcl-XL had no effect on cells transfected with CCO-EGFP-p53. 
 
Discussion 
The tumor suppressor p53 was delivered to different mitochondrial sub-
compartments in order to investigate its mitochondrial mechanism of apoptosis. We 
hypothesized that it might be possible that sending any protein (even EGFP) to 
mitochondria could be “toxic” to cells by disruption of mitochondrial function. Fusing 
p53 to MTSs targeting the mitochondrial outer membrane, inner membrane, and matrix 
did indeed result in apoptosis. However, we discovered that sending even EGFP to the 
mitochondrial matrix (OTC), the inner membrane (CCO), or the TOM complex (TOM) 
disturbed mitochondrial internal stability.  Only p53-XL was capable of inducing 
mitochondrial apoptosis exclusively via mitochondrial p53 pathway. 
Directing EGFP to the matrix and inner membrane via OTC and CCO, respectively, 
resulted in late stage apoptosis (7-AAD). This shows that fusing EGFP to OTC or CCO 
has a toxic effect on the mitochondria. We speculate that sending EGFP to the 
mitochondrial matrix and inner membrane could cause an imbalance in the sensitive 
mitochondrial system due to import through mitochondrial membranes. On the other 
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hand, targeting EGFP to the mitochondrial outer membrane using TOM and XL shows 
minimal toxicity with XL but significant toxicity with TOM. Since EGFP-XL is directed 
towards Bcl-XL (56) on the surface of the outer membrane (26-28), it is not expected to 
become imbedded into the mitochondrial membrane. On the other hand, the TOM-EGFP 
may interfere with TOM20 involved in mitochondrial import machinery (57, 58). The 
TOM complex is responsible for importing proteins across the mitochondrial outer 
membrane. TOM20 is one of the receptor subunits in the TOM complex (59, 60). It could 
be concluded that fusing any protein to the MTS from TOM20 might affect the sensitive 
import mechanism.   
As p53 is a nuclear protein, the MTS fused to it will compete with the protein’s 
nuclear localization signals (NLSs). p53 contains three NLSs; the most active of them is 
located at residues 305-322 (38). The nuclear import of large proteins is dependent on the 
availability of a NLS (61-63). To prevent the nuclear targeting of our constructs, we 
introduced mutations (K319T and K320T) in the strongest NLS of p53 (38). 
Colocalization data and p53 transcriptional activity assay showed an increase in 
mitochondrial targeting and a decrease in p53 nuclear activity after the introduction of the 
NLS mutations in CCO-EGFP-p53. According to our colocalization data, CCO-EGFP 
showed the lowest mitochondrial targeting compared to the other MTS-EGFP (Figure 
5.2). The weak CCO signal explains the high transcriptional activity when fused to p53 
without NLS mutations (Figure 5.3). The strong NLS in p53 competes with the relatively 
weak MTS from CCO and shifts the distribution to the nucleus. After mutating the strong 
NLS, the CCO MTS was also in competition with the other weak NLSs in p53 (38), 
which may explain why the CCO-EGFP-p53 NLS mutation still showed transcriptional 
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activity (Figure 5.3). However, the mutations did not have any effect on the 
mitochondrial targeting or nuclear activity of the TOM, XL, and OTC constructs. EGFP-
p53 fused to TOM and XL showed minimal nuclear p53 activity presumably due to their 
strong mitochondrial signals. Introducing NLS mutations to p53 fused to TOM or XL did 
not show any reduction on the already low transcriptional activity (Figure 5.3). On the 
other hand, OTC-EGFP-p53 showed significant p53 nuclear activity but was not reduced 
upon NLS mutation (Figure 5.3). 
In addition, the nuclear activity of MTS-EGFP-p53 differed between MCF-7 and 
T47D. These differences might be due to variability in proteins involved with p53 
transcriptional activity, mitochondrial shuttling, or number of mitochondria in each cell 
line. In MCF-7, all MTS-EGFP-p53 constructs (with or without NLS mutations) showed 
minimum transcriptional activity except for the CCO-EGFP-p53, which had half the 
activity of wild type EGFP-p53 (Figure 5.3B). However, in T47D cells all MTS-EGFP-
p53 constructs showed generally higher nuclear activity than in MCF-7, especially CCO-
EGFP-p53, which showed the same nuclear activity as wild type EGFP-p53. CCO-
EGFP-p53 NLS mutation and OTC-EGFP-p53 (with and without NLS mutation) showed 
fifty percent transcriptional activity in T47D (Figures 5.3A).  
Even though the NLS mutations increased mitochondrial targeting of the CCO-
EGFP-p53 construct, it did not have any effect on increasing the apoptotic potential. This 
was also the case for NLS mutations in all other constructs (data not shown). CCO-
EGFP-p53 was significant compared to its CCO-EGFP control in TUNEL, Annexin-V 
and 7-AAD assays. Since CCO-EGFP showed cytotoxicity, the increase in apoptosis 
when attached to p53 was likely due to nuclear p53 activity. This is reflected in our 
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luciferase assay (Figure 5.3) and the rescue experiments with pifithrin-α, pifithrin-µ and 
Bcl-XL (Figure 5.8). The apoptotic activity of CCO-EGFP-p53 was reduced in the 
pifithrin-α (an inhibitor of p53 transcriptional activity) rescue experiment. However it 
was not rescued by either over-expression with the anti-apoptotic Bcl-XL or incubation 
with pifithrin-µ (an inhibitor of p53 binding to Bcl-2 and Bcl-XL) (54, 55). This 
demonstrates that CCO-EGFP-p53 does not initiate p53-mitochondrial-specific apoptosis 
(Figure 5.9).  
OTC-EGFP-p53 also showed transcriptional activity. In addition, OTC-EGFP-
p53 exhibited significant caspase-9 induction, and late stage apoptosis compared to its 
cytotoxic OTC-EGFP control. To examine if the increase of activity was due to nuclear 
or mitochondrial p53, the rescue experiments mentioned above were conducted and 
showed reduction in programmed cell death (Figure 5.8). This indicates that apoptosis 
was likely initiated through p53 binding to Bcl-XL and Bcl-2. In addition to the 
transcriptional activity data, this demonstrates that OTC-EGFP-p53 has activity in both 
the nucleus (rescued by pifithrin-α) and the mitochondria (rescued by pifithrin-µ and Bcl-
XL) (Figure 5.9). Even though OTC directs p53 to the mitochondrial matrix, p53 is still 
able to interact with Bcl-XL and Bcl-2 proteins on the outer membrane. This could be 
due to cleavage of the MTS by endopeptidase, which enables p53 to target the outer 
membrane (3, 12). 
Instead of targeting the protein to the matrix then translocating it to the outer 
membrane, as was the case for OTC, we fused EGFP-p53 to TOM to directly target the 
outer membrane. Direct targeting of the outer membrane with TOM-EGFP-p53 was able 
to initiate late stage apoptosis robustly compared to its TOM-EGFP control. Interestingly 




Figure 5.9. Speculated MTS-p53 apoptotic mechanism. p53-XL binds to Bcl-XL. TOM-
p53 binds to Bak. OTC-p53 binds to Bcl-XL and shows transcriptional activity. CCO-p53 
induces transcriptional activity. Pifithrin-α reduces the activity of both CCO-p53 and 
OTC-p53, while pifithrin-µ reduces the activity of OTC-p53 and p53-XL. In addition, 
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this increase in apoptosis was only rescued when Bcl-XL was co-transfected but not 
when pifithrin-α or pifithrin-µ was added (Figure 5.8). The pifithrin-α rescue experiment 
indicates that TOM-EGFP-p53 has no transcriptional activity. We speculate that TOM-
EGFP-p53 is binding to pro-apoptotic Bak (Figure 5.9) and enhancing its 
oligomerization, which disrupts the mitochondrial outer membrane (15, 16). Bcl-XL 
forms a heterodimer with Bak and prevents Bak homodimerization (16, 64, 65). 
Therefore, when Bcl-XL is over-expressed, it competes with TOM-EGFP-p53 in binding 
with Bak and hence reduces apoptosis. Since pifithrin-µ reduces the binding of p53 to 
anti-apoptotic Bcl-XL and Bcl-2 and has no effect on binding to Bak, there was no 
reduction in programmed cell death. 
In an effort to directly target the p53/Bcl-XL pathway, we fused XL to EGFP-
p53. Directing p53 to the mitochondria via XL showed significant caspase-9, TUNEL, 7-
AAD and Annexin-V activity compared to its EGFP-XL control. This apoptotic response 
was not due to transcriptional activity of p53 as shown in the luciferase assay data 
(Figure 5.3) and the pifithrin-α rescue experiment (Figure 5.8A). However, the apoptotic 
response was due to p53 direct interaction with anti-apoptotic Bcl-XL. To confirm this 
interaction, rescue experiments using pifithrin-µ and Bcl-XL were conducted and showed 
reduction in apoptosis (Figure 5.8B and C). In addition, the EGFP-XL control showed 
low toxicity compared to the other MTS-EGFP controls especially in MCF-7 cells 
(Figure 5.6 and 5.7). This data demonstrates that sending p53 to a specific protein (Bcl-
XL) in the mitochondrial outer membrane causes p53 specific apoptosis. Table 5.2 is a 
summary of the results and speculation from this work.  
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Table 5.2. A summary of collected data and speculated mechanism. The table compares 
the four MTSs in localization, strength (*based on colocalization), mito-toxicity of MTS-
EGFP, apoptotic response of MTS-EGFP-p53 compared to MTS-EGFP, and speculated 
apoptotic mechanism.  








Inner membrane Matrix 
Relative MTS 
Strength* 
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In summary, efficiency in targeting the mitochondria depends on the strength of 
the MTS. In the case of targeting proteins containing relatively strong NLSs such as the 
one found in p53 (residues 305-322) (38), mitochondrial targeting can only be achieved 
by using strong MTSs to counter the NLS. In our studies, relatively weaker MTSs are not 
efficient enough to compete with the strong NLS in p53. In addition, protein targeting to 
the mitochondria disrupts the sensitive balance in the mitochondria, which initiates 
intrinsic apoptosis. Except for EGFP-XL, all mitochondrial constructs had apoptotic 
effects. We conclude that EGFP-p53-XL was the most specific to p53/Bcl-XL 
mitochondrial pathway. Our data shows that not all mitochondrial targeting signals are 
optimal for mitochondrial induction of apoptosis with p53. In conclusion, specific 
binding of p53 to mitochondrial Bcl-XL (and hence apoptotic activity) is best achieved 
by directly targeting p53 to Bcl-XL via the XL MTS. This work therefore provides a 
mechanistic understanding of mitochondrial p53 apoptosis. Ultimately, p53-XL gene 
therapy is expected to be beneficial for other types of progressive cancers that currently 
have no effective therapy. 
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Proteasomal degradation of proteins is necessary especially in neurodegenerative 
diseases and cancer. The tumor suppressor p53 is one of the proteins that is constantly 
degraded in unstressed and some cancer cells. The degradation of p53 is due to binding to 
the ubiquitin ligase, MDM2, which is overexpressed in a variety of human cancers. In 
this work, a proteasomal protein switch was constructed taking advantage of p53 
degradation. p53 was fused to EGFP, a nuclear localization signal, a nuclear export 
signal, and a ligand binding domain. We provide indirect evidence that the resulted fused 
protein translocated from the cytoplasm to the proteasome upon the addition of a ligand. 
This approach could be used to capture and degrade cytoplasmic oncogenic proteins via 
fusing a binding domain. It also gives an alternative method for p53/MDM2 inhibitor 
screening using fluorescence microscopy. 
 
Introduction 
Proteins are targeted to the proteasome for degradation, when marked with a 
death signal (polyubiquitin chain) (1). Proteasomal targeting of proteins could be utilized 
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for neurodegenerative diseases and cancer (2, 3). Knowledge of the ubiquitin-proteasome 
system is pivotal for understanding the degradation of proteins via the proteasome (4). A 
protein that is destined for degradation goes through a post-translational modification 
called ubiquitylation. Ubiquitylation is a process that covalently modifies proteins with 
ubiquitin via the enzymatic activity of an E1, an E2, and an E3 protein (Figure 6.1). 
Ubiquitin is first activated and transferred to the E1 active cysteine residue via a thioester 
linkage in a process requiring ATP. Ubiquitin is then transferred to the active cysteine 
residue of an ubiquitin-conjugating enzyme, E2, via a trans(thio)esterification reaction. 
Ubiquitin ligase, E3, interacts with both E2 and the targeted protein. In general, E3 is 
important for mediating substrate specificity (241). Subsequently, ubiquitin is ligated to 
the ε-amino group of a lysine of the target protein through a more stable isopeptide 
linkage. Since ubiquitin itself contains seven lysine residues, it allows the synthesis of 
polyubiquitin chains though isopeptide linkages. The process is then repeated giving rise 
to a polyubiquitin chain, which is recognized by the 19S regulatory caps of the 
proteasome. In the case of p53 degradation, MDM2 acts as the ubiquitin ligase (E3) while 
Ubc5 is the ubiquitin conjugating enzyme (E2) (5). There are six lysine residues in p53 
that get ubiquitinated by MDM2: K370, K372, K373, K381, K381, and K386 (6). 
The tumor suppressor p53 is a transcription factor that is found at low levels in 
normal unstressed cells through ubiquitylation and proteasomal degradation (7, 8). The 
half-life of p53 is 6-20 minutes in healthy cells. However the concentration of p53 is 
increased 3- to10-fold and the half-life is improved to hours in response to a variety of 
stresses including DNA damage, hyperproliferation, and hypoxia (9, 10). When p53 is 
induced, certain genes are up-regulated promoting growth arrest, apoptosis, and DNA 




Figure 6.1. The enzymes and reactions of the ubiquitin-proteasome system. Ubiquitin is 
transferred to E1 enzyme in an ATP-dependent manner. Ubiquitin is then transferred to 
E2 enzyme, which carries the ubiquitin to E3 enzyme. The substrate (targeted protein) is 
ubiquitinated upon E3 binding. The ubiquitination of the substrate is repeated, which 
leads to the formation of polyubiquitin. The proteasome recognizes the polyubiquitin and 
initiates the degradation of the substrate. 
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repair (11). Loss of p53 activity predisposes cells to cancer, while errant p53 activation 
can lead to premature senescence and apoptosis. MDM2, which is also known as HDM2 
in human, is one of the negative regulators of p53 (12). In addition, p53 regulates and 
induces the expression of MDM2 creating a negative feedback loop (13). 
MDM2 contains a p53 binding domain, nuclear localization signal, nuclear export 
signal, and a RING finger domain. When p53 is activated, MDM2 binds to p53 to inhibit 
its transcriptional activity, and to mark it for proteasomal degradation (14, 15). 
Degradation of p53 is dependent on the nuclear exclusion of p53 by MDM2 (16). 
However, some nuclear proteasomal degradation of p53 can be induced by MDM2 (17). 
In addition, MDM2 is capable of regulating its own levels through auto-ubiquitination. 
There is an overexpression of MDM2 in a variety of human cancers such as breast 
cancer, melanoma, esophageal cancer, leukemia, sarcoma, non-small cell lung cancer, 
and non-Hodgkin’s lymphoma (18). Overexpression of MDM2 is correlated with poor 
diagnosis in glioma, leukemia, and sarcoma (19). Preclinical studies have focused on 
inhibiting MDM2 to restore p53 activity in cancer cells (20-22). Since the MDM2-p53 
interaction has been well characterized, small molecule inhibitors of MDM2 has been 
developed (23, 24). Nutlin-3 is one the most commonly used inhibitor, which targets 
MDM2 by interacting with the p53-binding pocket of MDM2, prevent its binding to p53, 
and hence increase the transcriptional activity of p53 (25, 26).  
In this work, we took advantage of our nuclear protein switch (PS), which 
contains a ligand inducible nuclear import (27) and an export signal to control the 
localization to the nucleus (28). The localization is controlled by a dexamethasone-
specific ligand-binding domain (LBD), which was cloned from a nuclear receptor, the 
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glucocorticoid receptor (GR). When expressed, the protein is localized to the cytoplasm 
but is targeted to the nucleus upon ligand induction (29-31).  
In an effort to create a proteasomal protein switch, we fused p53 to the nuclear 
protein switch. Upon ligand addition, the p53 is localized to the nucleus where it binds to 
MDM2. This binding allows the ubiquitination of p53 and further proteasomal targeting.  
 
Materials and Methods 
Construction of EGFP-PS-p53 
The DNA encoding p53 was amplified through PCR from pCMV-p53 wt (a 
generous gift from Dr. S. J. Baker, Addgene, Cambridge, MA) using the primers 5ʹ′- 
GCGCGCGGATCCGCCATGGAGGAGCCGCAGT-3ʹ′ and 5ʹ′-GCGCGCGGATCCT-
CAGTCTGAGTCAGGCCCTTCTGTC-3ʹ′. This was subcloned into the BamHI 
restriction enzyme site in the EGFP-HIV-MycA8-GRLBD (EGFP-PS) plasmid 
constructed previously (30). The EGFP-PS contains a nuclear export signal (NES) from 
HIV-rev protein (29), a nuclear localization signal (NLS) from MycA8 protein (30) and a 
ligand binding domain from glucocorticoid receptor (GRLBD) with a point mutation 
(C656G) that makes it 10 times more sensitive to the agonist dexamethasone (dex) (32). 
 
Construction of E-PS-p53 ΔMBD 
p53 was amplified without its MDM2 binding domain (MBD) through PCR using 
5ʹ′-GCGCGCGCGCGGTACCGCTCCCAGAATGCCAGAGGC-ʹ′3 and 5ʹ′-GCGCGCG-
GATCCTCAGTCTGAGTCAGGCCCTTCTGTC-3ʹ′. This was subcloned into the KpnI 
and BamHI restriction enzyme sites in EGFP-PS (32). 
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Cell Lines and Transient Transfections 
1471.1 murine adenocarcinoma cells (gift of G. Hager, NCI, NIH) were grown as 
monolayers in DMEM (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine 
serum (Invitrogen), 1% penicillin-streptomycin-glutamine (Invitrogen), and 0.1% 
gentamicin (Invitrogen). The cells were maintained in a 5% CO2 incubator at 37ºC. 7.5 × 
104 cells were seeded in 2-well live cell chambers (Nalgene Nunc, Rochester, NY). 
Transfections were carried out 24 hours after seeding using 1 pmol DNA and 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s recommendations. 




Approximately 24 hours after transfection, protein localization was viewed by 
fluorescence microscopy. Prior to live-cell imaging, media in live cell chambers was 
replaced with phenol red-free DMEM (Invitrogen) containing 10% charcoal-stripped 
fetal bovine serum (CS-FBS, Invitrogen). Images were acquired as previously (33), using 
an Olympus IX71F fluorescence microscope (Scientific Instrument Company, Aurora, 
CO) with high-quality narrow band GFP filter (ex: HQ480/20 nm, em: HQ510/20 nm) 
from Chroma Technology (Brattleboro, VT) with a 40X PlanApo oil immersion objective 
(NA 1.00) on an F-View Monochrome CCD camera. The microscope stage was 
maintained at 37°C with an air stream incubator (Nevtek ASI 400, Burnsville, VA). All 
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experiments were repeated in triplicates (n=3) and 10 cells were analyzed for each time-
point in each experiment. 
 
Treatment with LMB and Nutlin-3 
Cells were incubated with 10 nM leptomycin B (LMB, an inhibitor of nuclear 
export) 10 hours after transfection and 14 hours before ligand induction with dex 
followed by microscopy. Another population of transfected cells was incubated with 10 
µM nutlin-3 one hour before ligand induction (Sigma, St. Louis, MO). 
 
Results and Discussion 
Our previous studies have shown that the localization of exogenous proteins can 
be controlled by fusing a protein switch (PS) containing a nuclear localization signal 
(NLS), a nuclear export signal (NLS), and a ligand binding domain (LBD) (29, 30, 34, 
35). The fused protein is initially concentrated in the cytoplasm followed by localization 
to the nucleus upon ligand addition (Figure 6.2a). In this study, we aimed to rationally 
design a proteasomal PS, which is cytoplasmic in the absence of ligand and proteasomal 
in the presence of ligand. We took advantage of the p53/MDM2 ubiquitin proteasome 
system when designing the PS.  
The tumor suppressor p53 was fused to EGFP-PS forming a construct whose 
localization is controlled by a ligand, dex. In the absence of ligand, the protein localized 
to the cytoplasm. But unlike EGFP-PS alone, EGFP-PS-p53 localized to the proteasome 
(which has a characteristic punctate dot formation (36)) upon ligand induction (Figure 
6.2b). The proteasomal targeting occurred within 30 minutes after the addition of dex.  
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Figure 6.2. Change in protein localization on ligand induction. Change in localization of 
a) EGFP-PS and b) EGFP-PS-p53 are observed after induction with 100 nM dex for 1 
hour. White scale bars are all 10 µm. 
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Cells were captured using live cell fluorescence microscopy every 5 minutes for 1 
hour. A representative set of pictures over 30 minutes at 100 nM dex dose for EGFP-PS-
p53 is shown in Figure 6.3. We speculate that fusing EGFP and PS to p53 makes it harder 
for p53 to form a tetramer. When the p53 is in the monomer or dimer form, it is easier for 
MDM2 to bind and export it from the nucleus (37). This might explain why EGFP-p53 
was localized into the nucleus without proteasomal degradation (data not shown).  
The proposed mechanism of our construct is still dependent on nuclear 
localization. We propose that EGFP-PS-p53 is localized to the nucleus upon ligand 
addition. However, the MDM2 protein binds to the construct causing its ubiquitination, 
nuclear export, and ultimately proteasomal targeting (Figure 6.4). To examine if this 
process is initiated because of the MDM2 pathway, we cloned a p53 deficient of the 
MDM2 binding domain (ΔMBD) to the EGFP-PS. This construct was initially 
concentrated in the cytoplasm and mainly localized to the nucleus upon addition of dex 
(Figure 6.5). To further explore the MDM2 pathway, cells were incubated with nutlin-3, 
which is a small molecule that interacts with MDM2 at the binding pocket of p53 
preventing p53 binding (25, 26). Cells transfected with EGFP-PS-p53 and treated with 
both nutlin-3 and dex showed similar results to EGFP-PS-p53 ΔMBD (Figure 6.6). 
To investigate the ability of MDM2 to export our construct from the nucleus to 
the cytoplasm, cells were incubated with leptomycin B (LMB). LMB is an inhibitor of 
CRM1 (chromosome region maintenance/exportin 1), which is a protein required for the 
nuclear export of proteins such as MDM2 and ubiquitinated p53 (38, 39). Cells 
transfected with EGFP-PS-p53 and treated with both LMB and dex showed nuclear




Figure 6.3. The proteasomal switch mechanism. p53-PS is expressed in the cytoplasm 
and is targeted to the nucleus upon ligand induction. MDM2 binds to p53 in the nucleus 
causing ubiquitination of p53. A small percentage of the ubiquitinated p53 is sent to 
nuclear proteasome for degradation. The majority of the ubiquitinated p53 is exported 
back to the cytoplasm and targeted to the cytoplasmic proteasome for degradation.  






Figure 6.4. Representative time-dependent targeting for protein constructs. The figure 
shows representative time-dependent targeting for EGFP-PS-p53 with 100 nM dex. The 
movement of the protein could be observed from the cytoplasm to the proteasome over 
time upon ligand induction. White scale bars are all 10 µm. 





Figure 6.5. Change in EGFP-PS-p53 ΔMBD localization on ligand induction. Change in 
localization of protein is observed after induction with 100 nM dex for 1 hour. White 
scale bars are all 10 µm. 




Figure 6.6. The effect of nutlin-3. Change in localization of protein is observed after 
induction with 100 nM dex for 1 hour preceded with 1 hour of incubation with 10 µM 
nutlin-3. White scale bars are all 10 µm. 
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localization of the constructs with some targeting to nuclear proteasome and no targeting 
to cytoplasmic proteasome (Figure 6.7). While LMB was able to prevent nuclear 
exclusion, it was not able to prevent targeting the limited nuclear proteasome (17, 40).  
Like nature, the protein switch was designed to regulate cellular proteins by 
changing their location and hence their function (41-43).  The protein switch has the 
advantage of being regulated by externally added ligand (29, 30, 34). The proteasomal 
protein switch can be engineered with a dimerization domain of a protein of interest, 
which will allow it to “capture” a cytoplasmic endogenous protein and send it for 
proteasomal degradation upon ligand induction. Since the ubiquitin ligase (E3) is what 
mediates substrate specificity (2), we envision the use of the constructed proteasomal 
protein switch as a therapeutic to target oncogenic proteins. Depleting cytoplasmic 
oncogenic proteins such as Bcr-Abl, survivin, p27, and Raf-1 (33, 44-46) would be a 
specific treatment for cancer cells. This might prove useful in cancer with elevated levels 
of MDM2 such as breast cancer, melanoma, esophageal cancer, leukemia, sarcoma, non-
small cell lung cancer, and non-hodgkin’s lymphoma (18). In addition, the EGFP-PS-p53 
construct could also be used as a p53-MDM2 binding assay using fluorescence 
microscopy to screen for inhibitors that could disrupt the p53-MDM2 interaction. Nutlin-
3, a MDM2 inhibitor was used to confirm the feasibility of the assay. 
 
Conclusion 
A proteasomal protein switch was constructed taking advantage of the 
degradation pathway of p53. A protein switch containing EGFP, a NLS, a NES, a 
GRLBD, and p53 was cloned. We provided indirect evidence that the expressed protein 
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Figure 6.7. The effect of LMB. Change in localization of protein is observed after 
induction with 100 nM dex for 1 hour preceded with 14 hours of incubation with 10 nM 
LMB. White scale bars are all 10 µm. 
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 is localized to the cytoplasm and is moved to the proteasome upon the addition of dex. 
The proteasomal targeting was achieved via binding to and nuclear exclusion via the 
ubiquitin ligase, MDM2. Preliminary studies shown here indicate that this mechanism is 
feasible by using LMB, nutlin-3, and p53 ΔMBD. Indirect immunefluorescence and 
western blotting will be performed to prove proteasomal targeting and protein 
degradation. Further studies are expected to investigate the application of this switch to 
capture cytoplasmic oncogenic proteins and send them for degradation upon ligand 
induction. The proteasomal switch could also be used as an alternative microscopy-based 
screening for inhibitors of the p53/MDM2 interaction.  
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CONCLUSIONS AND FUTURE WORK 
 
Conclusions 
This thesis described the delivery of therapeutics (small molecules or biologics) to 
achieve a certain effect at a specific subcellular compartment (1). The main theme of this 
research is to use subcellular targeting to elicit or enhance a therapeutic effect, which 
leads to the hypothesis that targeting specific organelles in a cell will lead to better drug 
delivery and improvements in disease therapy. The delivery of the adiponectin protein 
was optimized to affect the oxidative stress mechanism in the mitochondria. Vitamin E 
was also conjugated to a cation to enhance its mitochondrial targeting where it acts as an 
antioxidant. Mitochondrial targeting was further investigated to deliver proteins such as 
p53 to induce apoptosis in cancer cells. In addition, proteasomal targeting was explored 
to create a ligand inducible protein switch to the proteasome.  
 
Adiponectin Released from the Triblock Copolymer 
Maintained Its Antioxidant Effect 
The concept of using a biodegradable polymer for constant release of a 
therapeutic protein offers novel treatment therapies for cardiovascular disease and 
diabetes (2). The triblock copolymer used contains a hydrophilic polyethylene glycol 
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(PEG) block and two hydrophobic poly(lactide-co-glycolide) (PLGA) blocks (3, 4). The 
copolymer is arranged as PLGA-PEG-PLGA, which allows the delivery of insoluble or 
unstable therapeutics. The polymer is in the liquid form at low temperature but becomes a 
hydrogel at body temperature. The goal of using the biodegradable polymer is to maintain 
a controlled delivery of a therapeutic at a specific site such as the heart (5, 6). The 
globular form of adiponectin (gAdp) was solubilized in the polymer gel and was 
completely released over 27 days without an initial burst.  The protein was not degraded 
or aggregated after being released from the polymer gel. The released gAdp from the 
triblock copolymer maintained its activity in reducing reactive oxygen species (ROS) in 
endothelial cells via cAMP/PKA pathway. The ability of reducing oxidative stress was 
measured in hyperglycemic cells, which overproduce ROS via the mitochondrial electron 
transport chain (7). This indicates that injectable gels containing gAdp could be used as a 
formulation to reduce oxidative stress if injected locally to the heart. The hydrogel depot 
containing gAdp could also be injected subcutaneously to compensate the reduction of 
adiponectin in the plasma of diabetic patients.  
 
A Faster Synthesis of Mitochondrially Targeted 
Vitamin E for Reversal of Oxidative Stress 
A faster and a more efficient method to conjugate vitamin E to 
triphenylphosphonium (TPP) was designed. The conjugation was carried out using a 
lysine linker and solid phase synthesis. Targeting the mitochondria for reducing oxidative 
stress has been under investigation because of the mitochondria’s role in producing and 
metabolizing ROS. Targeting antioxidants to the mitochondria can be amplified by 
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conjugating a cation taking advantage of the mitochondrial transmembrane potential (1, 
8-10). Conjugating antioxidants to TPP has been previously conducted but with a more 
complicated scheme (11). Solid phase synthesis does not require isolation of synthetic 
intermediates. In addition, all reagents and byproducts are easily washed out after each 
step. A lysine linker with two protecting groups enabled the conjugation of vitamin E and 
TPP. The resultant MitoE was able to localize and concentrate into the myocardial 
mitochondria of treated mice. MitoE also showed better reduction of oxidative stress in 
hyperglycemic endothelial cells than vitamin E alone. This method of conjugating TPP to 
vitamin E should be further investigated with other antioxidants.  
 
Mitochondrial p53 Activity Depends on 
the Mitochondrial Signal Used 
Mitochondrial targeting of p53 triggers a rapid apoptotic response by releasing 
cytochrome c (12, 13). p53 induces the oligomerization of the pro-apoptotic Bak and Bax 
(14-16) by directly binding to them (17) or binding to the anti-apoptotic Bcl-XL (18). 
Since subcellular targeting is crucial for protein activity, we explored targeting 
mitochondrial subcompartments. p53 was targeted to the outer surface of the 
mitochondria via fusing to the mitochondrial signal (MTS) from Bcl-XL (XL) (19-22). It 
was also inserted into the outer membrane and the inner membrane by fusing the MTSs 
from TOM20 (TOM) (19) and cytochrome c oxidase (CCO) (23, 24), respectively. The 
mitochondrial matrix was also targeted by fusing p53 to the MTS from ornithine 
transcarbamylase (OTC) (25, 26). In addition, EGFP was also fused to all MTSs to 
examine their innate toxicity. EGFP fused to XL showed minimum toxicity, while EGFP 
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fused to the other three MTSs initiated apoptosis. This concludes that fusing EGFP to 
TOM, CCO, or OTC has a toxic effect on the mitochondria. From our microscopy and 
luciferase assay data, it was discovered that efficiency in targeting the mitochondria 
depends on the strength of the MTS especially when fusing a protein that contains 
nuclear localization signals (NLSs) such as p53 (27). XL and TOM showed maximum 
strength in targeting the mitochondria followed by OTC and then CCO being the weakest 
signal. Because of their weak signal strength, OTC-p53 and CCO-p53 showed nuclear 
activity in addition to their mitochondrial activity. On the other hand, TOM-p53 and p53-
XL had no nuclear activity. Based on our apoptotic assays (caspase-9, TUNEL, Annexin-
V, and 7AAD) and rescue experiments (Bcl-XL, pifithrin-α, and pifithrin-µ), TOM-p53 is 
speculated to initiate apoptosis through direct binding to Bak. The p53-XL construct was 
the most promising and specific to p53/Bcl-XL mitochondrial pathway. Further 
experiments will be carried out to explore the p53 binding to Bcl-XL using smaller 
domains of p53 and introducing p53 mutations to increase the binding.  
 
Proteasomal Localization Controllable Construct 
The concept of using a protein switch for changing intracellular localization of 
proteins from cytoplasm to proteasome offers novel treatment therapies for diseases 
caused by cytoplasmic oncogenic/aberrant proteins. A proteasomal protein switch was 
constructed containing EGFP, a NLS, a nuclear export signal (NES), a ligand binding 
domain from the glucocorticoid receptors (GRLBD), and p53. The protein switch without 
p53 localizes to the cytoplasm and then is targeted to the nucleus upon the addition of 
ligand (28-30). However, the expressed protein switch, containing p53, localized 
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predominately in the cytoplasm in the absence of ligand and translocated to the 
proteasome on ligand induction. Our initial studies (using leptomycin B, nutlin-3, and 
p53 ΔMDM2 binding domain), while not complete, indicate indirect evidence that the 
proteasomal targeting was achieved via binding to and nuclear exclusion by MDM2. We 
speculate that p53 cloned into our protein switch binds to MDM2 in the nucleus upon 
ligand addition. MDM2, an ubiquitin ligase (E3), helps the transfer of ubiquitin from E2 
to the lysine residues on the carboxy terminus of p53 (31-33).  Subsequently, the 
proteasome recognizes the poly-ubiquitinated protein for degradation.  
 
Future Work 
The long term objective of this research is to exploit different mechanisms of 
targeting the various cellular compartments to enhance drug delivery and disease therapy. 
The tested hydrogel formulation containing adiponectin should be further examined in 
vivo by either subcutaneous injection or local delivery to the heart. The chemistry used to 
conjugate TPP to vitamin E should be taken advantage of to conjugate other antioxidants 
and test their mitochondrial activity.  In addition, the mitochondrial p53 will be further 
explored by identifying the p53 domain that binds best to Bcl-XL. The p53 binding to 
Bcl-XL will also be enhanced by introducing point mutations in p53 to increase the 
hydrophobic and electrostatic interactions. Moreover, p53 will be modified to bind to Bak 
on the outer surface of the mitochondria. The transcriptional activity of p53 will also be 
explored by controlling nuclear localization and increasing tetramerization and nuclear 
accumulation. Finally, the proteasomal protein switch will be tested in leukemia cell lines 
to deplete the cytoplasmic Bcr-Abl, oncogenic protein.  
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Antioxidant Potential of Controlled 
Released Adiponectin In Vivo 
The ability of adiponectin to reduce oxidative stress in type 2 diabetes (db/db 
mice) using a triblock copolymer formulation should be assessed. Other studies have 
shown promising results in vivo using other proteins such as interleukin-2 (IL-2), porcine 
growth hormone (pGH), and PEGylated camptothecin (34-36). IL-2 loaded hydrogel 
showed an enhanced anti-tumor effect when injected subcutaneously to H22 tumor 
bearing mice (34). The formulation containing pGH and PEGylated camptothecin were 
also delivered subcutaneously in rabbits and S-180 sarcoma-bearing Kunming mice, 
respectively (35, 36). In addition, type 2 diabetic rats were also used as a model for 
subcutaneous delivery of incretin hormone glucagon-like peptide-1 (GLP-1) and insulin 
in a hydrogel formulation to increase plasma insulin levels (37, 38). 
After db/db mice are subcutaneously injected with the hydrogel formulation 
containing gAdp, blood plasma will be collected over a period of 10 days to note 
elevation of adiponectin in the blood stream. Echocardiogram will also be obtained 
before and after treatment. After the 10 days, mice will be sacrificed and their hearts will 
be harvested. Myocardial mitochondria will be isolated to determine rates of 
mitochondrial oxygen consumption, ATP generation (to analyze mitochondrial 
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Conjugation of Antioxidants to TPP Using 
Solid Phase Synthesis 
TPP conjugation via solid phase synthesis should be explored with other 
antioxidants such as co-enzyme Q and quercetin. Mitochondrially targeted co-enzyme Q 
(MitoQ) shows promising results in preventing loss of spatial memory retention and early 
neuropathology in transgenic mice with Alzheimer's disease by reducing ROS (39). In 
addition, quercetin conjugated to TPP accumulates in the mitochondria and inhibits 
mitochondrial ATPase activity (40). The TPP conjugation to the different antioxidants 
should be investigated using different amino acid linkers (such as lysine versus glycine). 
The effect of the length, hydrophobicity, and charge of the amino acid on the activity of 
the final product should be explored. The activity of the conjugated amino acid will be 
tested first in vitro in endothelial cells measuring their ability to reduce ROS as was 
performed in our previous study (2).  
The conjugated antioxidants should be further investigated in vivo. Diabetic mice 
will be given the antioxidant in their drinking water for two week. The mice will be 
sacrificed and their hearts harvested. After the isolation of mitochondria, the amount of 
Mitochondrially targeted antioxidants will be measured with the rates of mitochondrial 
oxygen consumption, ATP generation, and mitochondrial hydrogen peroxide generation. 
If the triblock copolymer mentioned above is proven successful in vivo with adiponectin, 
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Targeting Small Domains of p53 to 
Mitochondrial Bcl-XL 
This study shows that fusing p53 to XL expressed optimal mitochondrial 
targeting, highest specificity to the p53/Bcl-XL apoptotic pathway, and lowest MTS 
toxicity when fused to EGFP. Truncated domains of p53 will be fused to XL to better 
understand p53/Bcl-XL binding and to create the smallest mitochondrial p53 version that 
will maintain its activity. There are conflicting reports on how p53 binds to Bcl-XL. 
There are multiple studies claiming that p53 binds to Bcl-XL through its DNA binding 
domain (DBD, amino acids 102-292) (Figure 1.5) (26, 41, 42). Other reports affirm that 
the amino terminus domain (NTD, amino acids 1-101) is sufficient in binding to Bcl-XL 
(15, 43, 44). The NTD contains the transactivation domain (TAD, amino acids 1-62) and 
the proline rich domain (PRD, amino acids 63-101). There is also a study that shows 
efficient induction of intrinsic apoptosis when sending p53 ΔC-terminus (amino acids 1-
305) to the mitochondria. Another study explains the effective binding of MDM2 binding 
domain (MBD, amino acids 15-29) of p53 to Bcl-XL (45).  
Future studies will fuse different domains of p53 to XL and examine their 
apoptotic activities. The following seven domains of p53 fused to XL will be compared 
to the wild type p53 (amino acids 1-393) fused to XL: DBD (amino acids 102-292), NTD 
(amino acids 1-101), MBD (amino acids 15-29), PRD (amino acids 63-101), PRD-DBD 
(amino acids 63-292), p53 ΔC-terminus (amino acids1-305), and p53 ΔMBD (amino 
acids 63-393). The following apoptotic assays will be performed: capase-9, TUNEL, 
Annexin-V, and 7-AAD. Rescue experiments using pifithrin-µ and over-expression of 
Bcl-XL will be carried out to confirm p53/Bcl-XL pathway as in Chapter 5. Mammalian 
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two-hybrid assay will also be performed to verify interaction of p53 domains with Bcl-
XL. The construct with the highest apoptotic potential (similar to wild type p53) will give 
us a better insight on which domain of p53 is efficient to induce apoptosis by binding to 
Bcl-XL. The minimal domains necessary to induce apoptosis at the mitochondria will 
decrease the overall size of the final plasmid allowing better transfection efficiency in 
cell lines (46). This study will be performed on T47D, and MCF-7 cell lines as in Chapter 
5. This work is currently in progress by Karina Matissek in the Lim lab. 
 
Creating “Super” Mitochondrial p53 
To further investigate the interaction of p53 with Bcl-XL, certain mutations will 
be introduced to p53-XL. The point mutations will be introduced to the amino acids that 
have been reported to bind to Bcl-XL. Mutations will be introduced to the DBD in the 
following amino acids: G117, S121, V173, C176, H178, C182, C238, N239, S241, 
M243, R248, C277, G279, and R280 (18, 42, 47). We will explore the hydrophobic and 
electrostatic interactions among residues. We will start with N239 and C176 since they 
are involved in binding to both Bcl-XL and Bcl2 (42). The proposed mutations for these 
two amino acids are N239Q, N239Y, C176V, C176M, C176F, and C176I. Since 
asparagine (N) forms a hydrogen bond with Bcl-XL, introducing glutamine (Q) or 
tyrosine (Y) might show a better interaction. The longer chain on Q will shorten the 
distance for better hydrogen bonding. On the other hand, the hydroxyl group on Y might 
give a better alternative for hydrogen bonding instead of the amino group on N. In 
addition, the hydrophobic interaction from cysteine (C) will be further explored by 
replacing it with more hydrophobic amino acids: valine (V), methionine (M), 
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phenylalanine (F), or isoleucine (I). Moreover, mutations to the MBD will also be 
introduced to p53-XL. The following amino acids have been reported to bind to Bcl-XL: 
Q16, F19, S20, L22, W23, L25, L26, and P27 (45). We will start with W23 and L26. The 
proposed mutations for these two amino acids are W23F, L26F, and L26I. The 
hydrophobic interaction from tryptophan (W) and leucine (L) will be enhanced by 
replacing them with more hydrophobic amino acids: F and I. All constructs will be tested 
on the following apoptotic assays: capase-9, TUNEL, Annexin-V, and 7-AAD. 
Mammalian two-hybrid assay will also be performed to verify interaction of p53 domains 
with Bcl-XL. This work is currently in progress by Karina Matissek in the Lim lab. 
 
Enhanced Dimerization of p53 to 
Target Mitochondrial Bak 
In addition to binding p53 to Bcl-XL, targeting Bak in the mitochondria will be 
explored. p53 can bind directly to Bak to induce its oligomerization causing 
mitochondrial outer membrane permeabilization (16, 17). Bak is a member of the Bcl2 
family protein and is found on the outer surface of the mitochondria (48). We plan on 
fusing the MTS from Bak or Bax to p53 to ensure its Bak targeting. It is important to note 
that the tetramerization domain (TD) is crucial for p53 binding to Bak (17). Any mutation 
or deletion of TD weakens the ability of p53 to interact with Bak. p53 has to either be in 
the dimer or tetramer form to ensure binding (17). Therefore we plan to only use full 
length p53 in this project. We will also investigate increasing the 
tetramerization/dimerization of p53 to enhance binding to Bak. This will be performed by 
replacing the TD from p53 with a coiled coil (CC) from Bcr protein (49) forming p53-
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CC. More information on using CC will be discussed in the following section. Our 
constructs (p53 and p53-CC) fused to the MTSs from Bak or Bax will be tested in 
apoptotic assays as described above. The p53 and p53-CC interaction with Bak will be 
studied using the mammalian two-hybrid assay. We expect to see an increase in apoptotic 
activity with p53-CC-Bak. This work is currently in progress by both Abood Okal and 
Karina Matissek in the Lim lab. 
 
Substituting Tetramerization Domain of 
p53 with Bcr Coiled Coil 
A major barrier to using p53 for gene therapy stems from a “dominant negative” 
effect in certain cancers. In these cancers, p53 is mutated or mislocalized.  Any 
exogenous wild type p53 forms a dimer/tetramer with the endogenous mutated p53, 
causing the inactivation of the added p53. To circumvent this problem, the TD of p53 
will be replaced by the coiled-coil from Bcr. This p53-CC construct will only 
dimerize/tetramerize with itself, and not to the mutated p53 in cancer cells. As a result, 
there will be no dominant negative effect. The CC behaves similarly to TD in forming an 
antiparallel dimer of dimers (49). In addition, the removal of the carboxy terminus (Δ 
amino acids 323-293) will also eliminate the lysine residues that are ubiquitinated by 
MDM2. We expect the p53-CC to show elevation in transcriptional activity due to the 
stronger binding motif and the prevention of proteasomal degradation. The p53-CC 
should have a better impact on cells containing mutant p53 because of the inability to 
form hetero-tetramers. Our preliminary data using a transcription activity assay (Dual-
Glo luciferase assay) suggests elevation in transcription activity of p53-CC compared to 
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wild type p53 (data not shown). The following apoptotic assays will be performed: 
capase-3/7, TUNEL, Annexin-V, and 7-AAD. Rescue experiments using pifithrin-α will 
be carried out to confirm DNA binding. Cell cycle arrest will also be assayed using 
DyeCycleTM Ruby stain. The gene expression profile of p53-CC will also be investigated 
using a Signaling Pathway PCR Array. This work is currently in progress by Abood Okal 
in the Lim lab. 
 
Fusing 4 NLSs to p53 
Increased nuclear accumulation of exogenous p53 will be explored to increase its 
transcriptional activity. The accumulation of p53 in the nucleus is necessary to bind to 
DNA (50, 51). Proteins containing NLSs are recognized by the nuclear import receptors 
and are translocated to the nucleus. p53 already contains a medium strength NLS (amino 
acids 305-322) and two weak NLSs (amino acids 369-375 and 379-384). Mutating the 
medium strength NLS is sufficient to decrease nuclear targeting dramatically (27). We 
hypothesize that fusing a stronger NLS to p53 will increase its nuclear accumulation and 
hence its transcription activity. It might also decrease proteasomal degradation since 
having a stronger NLS might prevent MDM2 from dragging p53 out of the nucleus. Our 
preliminary data using a transcription activity assay (Dual-Glo luciferase assay) suggests 
that fusing one NLS from MycA8 protein to p53 increases its transcriptional activity 
compared to wild type p53 (data not shown). Our lab has also proved that fusing 4 NLSs 
from SV40 Large T-antigen to Bcr-Abl was able to translocate the protein into the 
nucleus better than 1 NLS (52). Therefore, we will use the same approach by fusing 4 
NLSs from SV40 to p53. Moreover, multiple NLSs will also be fused to p53-CC to 
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increase its nuclear accumulation. Similar apoptotic and cell cycle arrest assays will be 
performed as described above. This work is currently in progress by Abood Okal in the 
Lim lab. 
 
Controlled Nuclear Targeting of p53-CC 
A p53 nuclear protein switch will be developed to control the localization and 
hence the activity of p53. When p53 was fused to our nuclear protein switch, it was 
targeted to the proteasome instead and was used as a proteasomal protein switch. To 
restore the nuclear p53 protein switch, the p53 proteasomal degradation will be blocked 
by removing the carboxy terminus, where the ubiquitinated lysine residues reside, and 
replacing it with a CC from Bcr as discussed above. The new construct (EGFP-PS-p53-
CC) will be expressed in the cytoplasm. However we expect that it will localize to the 
nucleus upon ligand induction. The transcriptional activity of p53-CC should be activated 
upon the addition of ligand. The localization of the construct will be monitored using 
fluorescence microscopy. The apoptotic potential of the protein switch will be tested 
before and after ligand. The transcriptional activity will also be observed using a Dual-
Glo luciferase assay. This work is currently in progress by Abood Okal in the Lim lab. 
 
Application of the Protein Switch: Depleting Cytoplasmic  
Bcr-Abl in Chronic Myelogenous Leukemia 
Bcr-Abl is an oncoprotein that is found in the cytoplasm of Chronic Myelogenous 
Leukemia (CML) (53, 54). Bcr-Abl interacts with multiple signal transduction pathways 
transmitting anti-apoptotic signals (55). Small molecules such as imatinib targeting Bcr-
	   250	  
Abl are usually the treatment of choice for CML (56-58). However some patients have 
developed resistance to imatinib due to mutations in the kinase domain of Bcr-Abl (59-
61). Our lab has shown that nuclear p53 has apoptotic potential (52). In addition, the Lim 
lab has developed mutations in the CC domain of Bcr to enhance binding to Bcr-Abl 
(62). The CC domain with certain mutations was efficient in binding to Bcr-Abl and 
disrupting some of its activity (62). We plan to use the third generation of CC mutations 
(CC3) as a binding domain for Bcr-Abl. The mutations introduced increased hetero-
oligomerization with Bcr-Abl and decreases homo-oligomerization of CC3. CC3 will be 
fused to our proteasomal protein switch (EGFP-PS-p53). We expect the construct to 
localize to the cytoplasm of k562 cells (CML cells) allowing oligomerization with 
endogenous Bcr-Abl. Upon ligand induction, we predict the localization of our protein 
switch along with Bcr-Abl to the proteasome causing its degradation. The feasibility of 
dragging Bcr-Abl to the proteasome will be confirmed using fluorescence microscopy 
and indirect immunofluorescence. Apoptotic assays will also be performed to investigate 
its apoptotic potential. This work is currently in progress by James R. Davis in the Lim 
lab.  
 
Validating Our Therapy In Vivo Using an  
Adenovirus Vector 
The optimized p53 plasmids (targeting the mitochondria and the nucleus) will be 
constructed into an adenoviral vector using Adeno-X Expression System 2 (Clontech). 
Adenovirus is the most efficient in terms of delivering their genetic cargo to the nucleus 
(63-67). Adenovirus containing p53 has been widely used in gene therapy clinical trials 
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(73). In addition, the immunogenicity of adenovirus has improved recently enhancing its 
prospects for long-term gene transfer in a wide range of different tissues (68). Although 
not without issues, adenovirus will be used in our lab’s future studies as a means to 
validate our model as a high efficiency vector. The cancer specific surviving promoter 
(69) will also be used in the viral vector delivery system since we will be using breast 
cancer animal model. The therapeutic effect of nuclear and mitochondrial p53 and p53-
CC will be tested in a human breast cancer xenograft model using female athymic nude 
mice (Balb/c nude; immunocompromised) subjected to right dorsa subcutaneous injection 
of MCF-7 cells (70).  The adenoviral vector will be injected into the tumor. Tumor 
elimination or size reduction will be measured as an indicator of therapeutic efficacy. 
Toxicity/immunogenicity of adenoviral constructs will be tested as well.  This work will 
be carried out by Karina Matissek, Abood Okal, and Shams Reaz in the Lim lab. 
This dissertation and future work will offer a better understanding on subcellular 
delivery. The aim is to apply subcellular targeting to elicit or enhance therapeutic effect. 
By focusing on the targeting of subcellular organelles, we are taking therapeutic delivery 
to the next level. Controlled compartmentalization of proteins is already used by cells as 
a mechanism to regulate protein activity. This thesis and future work exploit these 
cellular mechanisms to alter the way gene therapy is approached, and could be applied to 
many other diseases besides the breast cancer and CML systems discussed here. The 
concept of controlled compartmentalization is particularly useful for gene therapy with 
p53, which is apoptotic in the nucleus and the mitochondria. It also represents a new era 
in drug design for therapy for cancers, where subcellular location alters function. 
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